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Abstract 
Effective vaccine design and public vaccination programs have led to the 
eradication of several diseases and protected millions of people from deadly infections. 
However, neutralizing antibodies induced by most vaccine technologies cannot address 
intracellular infections, which require the activation of cytolytic mechanisms.  CD8+ T 
cells promote effector mechanisms for infected cell killing subsequent to their priming 
by antigen-presenting cells. Their activation occurs upon detection of intracellular 
antigen presented in the context of major histocompatibility complex (MHC) class I, a 
pathway that many current subunit vaccine technologies are trying to approach by 
cross-presentation. Advances in CD8+ T cell-inducing subunit vaccines include direct 
targeting of antigens to cross-presenting cells and are studied in this thesis. 
 
Antigen delivery to the appropriate cell type for cross-presentation to CD8+ T 
cells can occur with fusion antibodies. Our laboratory has previously demonstrated that 
intravenously injected antigens bearing an erythrocyte-binding antibody domain 
(TER119) target the liver and are cross-presented to CD8+ T cells. We used this 
technology to fuse TER119 and ovalbumin (OVA) antigen with the BBOX domain of 
the high mobility group box 1 (HMGB1) danger signal and co-administer it with CpG-
B adjuvant in a hepatic vaccine context. In liver vaccines, activation of local cytotoxic 
responses with long-lasting memory represents an important challenge. Erythrocyte-
mediated OVA delivery with adjuvants resulted in cytotoxic CD8+ T lymphocyte 
(CTL) activation with memory formation in the liver. Furthermore, protection was 
provided after infection with Listeria monocytogenes in mice immunized with 
immunogenic TER119 constructs. 
 
An alternative method for antigen targeting is through a dendritic cell (DC) 
subset known to cross-prime CD8+ T cells, called CD8+ DCs. Recent studies in mice 
showed successful vaccination against OVA fused to XCL1 ligand, which uniquely 
binds CD8+ DCs. In order to attract CD8+ DCs to the site of injection for increased 
antigen uptake, we co-injected XCL1-OVA with a fusion protein consisting of XCL1 
and the extracellular matrix (ECM) binding domain of placenta growth factor-2 (PlGF-
2123-144), called XCL1-PlGF. XCL1-PlGF binds extracellular matrix at the injection site 
and attracts CD8+ DCs locally. In the context of prophylactic and therapeutic 
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vaccination, the combination of two fusion proteins (XCL1-OVA and XCL1-PlGF) 
enhanced cytotoxicity and prolonged survival against B16-OVA melanoma. 
 
In a similar context, PlGF-2123-144 was fused to OVA as a method to trap 
antigen at the injection site and form a depot effect that would promote slow antigen 
release and result in enhanced uptake by DCs. OVA-PlGF was evaluated in a prime-
boost vaccine both for humoral and cellular responses and was compared to the free 
OVA vaccine formulation. Contrary to the hypothesis of our design, no striking 
differences were observed between fused OVA-PlGF and free OVA groups when 
cellular activation and antibody production were considered.    
 
Finally, antigen transport via biomaterial delivery platforms was evaluated as 
an alternative method to deliver antigens to immunologically relevant sites. Our 
laboratory and others have shown that nanoscale carriers promote CTL responses in 
vaccination. However, the fabrication of polymer-based nanoparticle vaccines 
commonly requires relatively complicated procedures for covalent attachment of 
components to the carrier surface. Here we present a cationic micelle vaccination 
platform in which OVA and adjuvant (CpG-B and/or MPLA) loading is mediated by 
non-covalent molecular encapsulation and adsorption. Following a prime and double 
boost vaccination, CTL responses were raised in the spleen and lymph nodes of 
vaccinated mice, along with antigen-specific antibody production. These findings 
highlight the advantages of the micelle carrier platform in vaccine applications.  
 
Overall, this thesis presents novel techniques to target antigens to the 
appropriate cell compartments, facilitating CTL activation in vaccination either by 
direct targeting of antigen fused to antibodies and chemokines, or antigen delivery with 
polymeric vehicles. These platforms for optimized delivery seek to improve current 
approaches and impact the design of new strategies in CD8+ T cell inductive 
vaccination.  
Keywords: subunit vaccine, CD8+ T cells, CTL, cross-presentation, hepatic targeting, 
TER119, XCL1, PlGF-2, micelles, Listeria monocytogenes, B16-OVA, tumor vaccine 
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Résumé 
Le design de vaccins efficaces a permis d’éradiquer de nombreuses maladies et 
de protéger des millions de personnes contre des infections mortelles. Les anticorps 
neutralisant induits par la plupart des vaccins ne peuvent pas lutter contre des 
infections intracellulaires, qui requièrent une action cytolytique des lymphocytes T 
(LT) CD8+. Ceux-ci possèdent des mécanismes effecteurs permettant de tuer les 
cellules infectées suite à la reconnaissance d’un antigène intracellulaire, présenté par le 
Complexe Majeur d’Histocompatibilité I des cellules présentatrices d’antigènes (CPA). 
La voie de « présentation croisée » de l’antigène par les CPA est actuellement la cible 
de nombreux vaccins sous-unités. Cette thèse se focalise sur le développement de 
plateformes de vaccination CD8 et sur l’étude du ciblage spécifique des antigènes sur 
les CPA utilisant la présentation croisée.  
 
Notre laboratoire a précédemment démontré que des antigènes fusionnés à un 
domaine d’anticorps liant les globules rouges (TER119) sont efficacement présentés 
aux LT CD8+ dans le foie. Nous utilisons ici cette technologie pour le développement 
de vaccins hépatiques, et avons créé une protéine de fusion contenant TER119, 
l’antigène ovalbumine (OVA) et le domaine BBOX d’HMGB1 servant d’adjuvant. La 
co-administration de cette protéine tripartite avec du CpG-B induit l’activation des LT 
CD8+ cytotoxiques (LTc) et la formation d’une mémoire immunitaire à long-terme 
dans le foie, résolvant ainsi une limitation importante des vaccins hépatiques actuels. 
De plus, cette technologie a engendré une protection immunitaire efficace dans un 
modèle murin d’infection par la Listeria monocytogenes. 
 
Les cellules dendritiques (CD) CD8+ sont connues pour leur capacité à 
présenter efficacement de façon croisée les antigènes aux LT CD8+. De récentes études 
ont montré que la fusion entre OVA et la chimiokine XCL1 permettait d’attirer et de 
lier les CD CD8+, fournissant ainsi une vaccination adéquate contre OVA. Afin de 
promouvoir un effet localisé de XCL1, nous l’avons fusionné à un domaine (PlGF) 
ayant une forte affinité pour les matrices extracellulaires. Nous avons ensuite co-
injecté XCL1-OVA et XCL1-PlGF dans le but de recruter les CD CD8+ au site 
d’injection et d’accroître l’internalisation de l’antigène. La combinaison de ces deux 
protéines de fusion a augmenté la cytotoxicité de la réponse immunitaire contre OVA 
et a prolongé la survie de souris ayant un mélanome B16F10-OVA. 
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Dans un contexte similaire, la protéine de fusion OVA-PlGF a été développée 
afin de séquestrer l’antigène au site d’injection et de former un dépôt qui permettrait la 
libération ralentie de l’antigène et une meilleure assimilation par les CD. Les groupes 
OVA-PlGF et OVA ont été comparés dans un modèle de vaccination à un rappel. 
Contre toute attente, aucune différence n’a pu être observée entre les deux groupes au 
niveau de l’activation des cellules immunitaires et de la production d’anticorps. 
 
Finalement, l’utilisation de biomatériaux peut également permettre de libérer 
des antigènes dans les compartiments appropriés des cellules immunitaires. Il a été 
montré que des vaccins basés sur des nanoparticules de polymères améliorent les 
réponses des LTc. Cependant, la fabrication de ces vaccins requiert une conjugaison 
covalente de l’antigène au nanoparticules, une procédure relativement complexe. Nous 
avons donc développé des micelles cationiques dans lesquelles l’antigène OVA et 
l’adjuvant (CpG-B et/ou MPLA) peuvent être encapsulés de façon non-covalente et 
complexés par des interactions électrostatiques. Dans un modèle de vaccination à deux 
rappels, cette plateforme micellaire entraîne une augmentation de la réponse des LTc 
dans la rate et les ganglions lymphatiques, ainsi que la production d’anticorps 
spécifiques contre OVA. Ces résultats mettent en évidence les avantages de ce 
nanomatériau pour la formulation de vaccins. 
 
Ainsi, cette thèse présente de nouvelles technologies de vaccination permettant 
l’administration des antigènes à des compartiments cellulaires spécifiques afin de 
faciliter l’activation des LTc, soit 1) par le ciblage spécifique de l’antigène sur les 
CPAs, grâce à sa fusion avec des anticorps ou des chimiokines, ou 2) par une 
administration médiée par des nanomatériaux polymériques. Ces technologies 
démontrent le potentiel de stratégies d’optimisation d’administration des antigènes 
pour le développement de nouveaux vaccins CD8 plus performants.  
 
Mots clés : Vaccins sous-unités, cellules T CD8+, présentation croisée, ciblage 
hépatique, TER119, XCL1, PlGF-2, micelles, Listeria monocytogenes, B16F10-OVA, 
tumeur?
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Chapter 1 : 
 
Overview of the Thesis  
 2 
1.1 Motivation 
?
Vaccination is the most cost effective medical intervention to prevent infectious 
diseases. The first documented observation of immunological memory was made by 
Thucydides in 430 B.C., during the Peloponnesian War, when he reported that the 
deadly plaque of Athens never attacked the same man twice [1]. Many years later, the 
first vaccine was developed by Edward Jenner, against smallpox, and this was 
considered the foundation of immunology and the origin of the vaccination era [2]. 
Since then, profound reduction or elimination of many diseases has been achieved 
through vaccination and life expectancy in the developed world has increased [3-5]. 
The first vaccines, and the most successful to date, were live attenuated vaccines 
consisting of viable pathogens that have been altered to reduce their virulence. 
Although live vaccines have been very efficient in protecting against several diseases 
and have been used for many years, concerns about the safety of these complex 
mixtures have motivated the development of a new generation of vaccines called 
subunit vaccines. 
 
This new generation of vaccines is based on proteins/peptides or carbohydrate 
antigens purified from a pathogen or produced by recombinant techniques. Subunit 
vaccines are safer than live attenuated vaccines, but they are not as immunogenic. 
Nowadays, a new field in immunology has emerged for technologies that focus on 
enhancing the immunogenicity of subunit vaccines and supporting a more efficient 
administration of the antigen. Immunostimulatory compounds, called adjuvants, are 
incorporated into subunit vaccine formulations to boost their immunogenicity. 
Moreover, novel delivery systems facilitate the targeting of the antigen to the proper 
cell types and trigger potent immune responses. Various adjuvants have been 
developed for subunit vaccination [6], with the most commonly used being alum [7]. 
Vaccines incorporating this adjuvant are very efficient in the induction of humoral 
responses and can, in particular, trigger the production of neutralizing antibodies. 
However, they generally fail to stimulate the T cell compartments of the immune 
system that are mandatory for dealing with chronic infectious agents, viruses and 
tumors. 
 
The eradication of tumors and intracellular pathogens like human 
papillomavirus (HPV), human immunodeficiency virus (HIV), Mycobacterium 
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tuberculosis, hepatitis B and C and malaria requires robust cytotoxic T lymphocyte 
responses, which makes development of effective subunit vaccines for these diseases 
challenging. For some challenging pathogens, cellular vaccines have been developed, 
but their efficacy is sub-optimal and/or short-lived. Examples include the Bacillus 
Calmette-Guérin (BCG) vaccine against tuberculosis, which is effective in preventing 
severe tuberculosis in children but does not prevent infection or re-activation of latent 
disease [8] and hepatits B, where patients with chronic situations fail to initiate 
responses against the virus [9]. Moreover, prophylactic subunit vaccines for HPV, 
which can prevent the development of cervical cancer (Gardasil), and therapeutic 
vaccines against prostate cancer (Sipuleucel-T (Provenge®)) and melanoma [10, 11] 
are available on the market. However, subunit vaccines against many chronic 
infections, such as HIV, malaria and hepatitis C, as well as tumors caused by viral 
infections, like liver cancers, remain unmet needs. Effective vaccines for these diseases 
must activate CD8+ T cells to exert cytotoxic effects against the infected or mutant 
cells. Activation of this cell type can occur by presenting the antigen to the MHC class 
I molecule that will facilitate the engagement to CD8+ T cells. Enhancing the response 
of these cells and eliciting long-lasting cytotoxic immune responses against specific 
pathogens is the task of current CD8+ T cell-inducing vaccine design efforts.  
 
Among the strategies pursued to enhance the efficacy of CD8+ T cell subunit 
vaccines in recent years, direct targeting of the antigen to the appropriate cell type with 
the use of surface ligands or delivery vehicles has been explored. The most widely 
studied approach involves delivery of molecules to dendritic cells (DCs), which are the 
most potent antigen presenting cells (APCs) and the most common targets in T cell 
vaccines [12]. Examples of DC surface molecule linkers include antibodies towards 
specific markers or chemokine ligands that bind to receptors on DCs, reviewed later in 
this Introduction. Moreover, among many other delivery systems developed, a novel 
nanoparticle-antigen carrier was established in our laboratory that elicited potent T cell 
responses in vaccinations [13]. The aim of this thesis is to explore alternative ways for 
efficient delivery of antigens in immune cell compartments or organs where previous 
vaccination has failed, such as the liver. Moreover, we also aimed to provide new 
platforms for targeting antigens to DCs in a chemokine-ligand fusion manner and a 
delivery vehicle with the overall goal to enhance long-lasting cytotoxic CD8+ T cell 
responses.   
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1.2 Background 
1.2.1 The innate and adaptive immune responses 
?
During the course of evolution, living organisms developed an immune system 
designed to protect them from invasion by pathogenic species. Immune systems vary in 
complexity from bacteria to vertebrates, but in essence, these systems have evolved to 
enable the detection and elimination of opportunistic microbes and other pathogens, by 
eliciting immune responses to protect the host. An immune response refers to the 
sequence of the reactions orchestrated by the different components of the immune 
system − which includes nucleic acids, proteins and cells − working in concert to clear 
an infection from within the host. The immune system is composed by two arms, the 
innate and adaptive. The innate immune system is the most prevalent form of 
immunity in living organisms, as it exists in both vertebrate and invertebrate species, 
while only vertebrates possess an adaptive immune system. Even though each immune 
system has its distinct role and function, innate and adaptive immunity are tightly 
connected arms of the overall immune system that interact to provide robust responses 
against pathogens. In vertebrates, early mechanisms of innate immunity elicit 
appropriate signals that eventually activate the adaptive immune system, to provide 
target-specific immune responses.  
 
Innate immunity provides the first line of defense against pathogens. It is not 
antigen specific, but acts rapidly to recognize non-self species within the host, and this 
triggers pro-inflammatory responses against such species [14, 15]. The innate immune 
system in humans consists of the following types of cells: 
• epithelial cells that form a physical barrier, such as the skin, to prevent the 
entry of pathogens,  
• neutrophils, which are often the first to respond to an infection by releasing 
chemokines to attract more cells,  
• macrophages. which are the most efficient migratory phagocytic cells, capable 
of engulfing microbes and inducing inflammation by secretion of chemokines, 
• natural killer (NK) cells that recognize and kill virus-infected cells or tumor 
cells,  
• mast cells that are associated with cytokine release in response to pathogens, 
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but are also responsible for responses in allergies and anaphylaxis,  
• neutrophils, eosinophils and basophils known as granulocytes that upon 
activation they release a range of toxins to deal with bacteria and other 
infections, and finally,  
• dendritic cells (DCs) that are phagocytic cells involved in the processing and 
presentation of antigen, and are the major link between the innate and adaptive 
immune systems.  
 
The innate immune system functions by recognizing and responding to highly 
conserved structures in microbes called pathogen-associated molecular patterns 
(PAMPs), using receptors present on the innate immune cells. These receptors are 
known as pattern recognition receptors (PRRs) [16]. The best-known examples of 
PAMPs are bacterial lipopolysaccharides, peptidoglycans, lipoteichoic acids, mannan, 
bacterial DNA, double-stranded RNA, and glucans. These PAMPs all share unique 
structural motifs, and are recognized by PRRs present on professional antigen-
presenting cells (APCs) of the innate immune system (i.e. macrophages, dendritic cells 
and B cells). Binding of PAMPs by PRRs immediately activates intracellular signal 
transduction pathways, leading to the secretion of pro-inflammatory cytokines and the 
upregulation of costimulatory molecules on APCs [17]. The Toll-like receptor family 
(TLRs) is a very well-characterized class of PRRs. TLRs can be divided into 2 
subfamilies: cell surface TLRs (TLR-1, -2, -4, -5, -6 and -10) that mainly recognize 
bacteria, and intracellular TLRs (TLR-3, -7, -8 and -9) specialized in the recognition of 
foreign nucleic acids, as seen in Fig. 1. Engagement of TLRs by microbial components 
leads to induction of genes responsible for antimicrobial host defense [18].  
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Figure 1: TLR molecules and activation pathways (adapted from Clinical Microbiology 
Reviews [17]). TLR-1,-2,-4,-5,-6, are displayed on the cell surface and TLR-3, -7, -8, -9 are 
located in the endosome. Most TLRs utilize MyD88 as the adaptor for signal transduction with 
the exception of TLR-3, which is dependent on TRIF for signaling, and TLR-4, where both are 
involved. 
The two main molecules responsible for activation of distinct pathways for the 
production of inflammatory cytokines and type I interferon (IFN) are MyD88 and 
TRIF (Toll receptor-associated activator of interferon), respectively. These molecules 
bind to the cytoplasmic domain of TLRs [19, 20], as described in Fig. 1. Upon 
activation, a signal is transmitted through cytoplasmic molecules to the nucleus, where 
three signaling pathways are responsible for mediating TLR-induced responses, 
namely: the Nf-κB pathway, the mitogen-activated protein kinases (MAPKs) pathways 
and IFN regulatory factors (IRFs) pathway [21, 22]. The result is release of pro-
inflammatory cytokines such as IL-1, IL-6, TNFα and IFNγ production, which 
promotes the maturation of DCs.  
As stated above, DCs are the bridge between innate and adaptive immunity. The 
adaptive immune system mounts more sophisticated immune responses than the innate 
system that are highly specific to a particular antigen. These responses are carried out 
by a subset of white blood cells called lymphocytes, divided in two main classes called 
B cells and T cells. B cells trigger antibody production whereas T cells role is to react 
against a foreign antigen either by cytokine release or direct killing of infected cells. 
There are two subclasses of T cells, CD4+ and CD8+ T cells, with distinct functions 
described below in details.  
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Following the uptake of antigen, DCs become activated and upregulate their 
costimulatory molecules (CD80, CD86, CD40) and antigen-presenting MHC 
molecules. Activation and maturation of DCs is a prerequisite for optimal interaction 
with CD4+ and CD8+ T cells of the adaptive immune system. In particular, after 
maturing, DCs migrate to the regional lymph nodes to present the antigenic peptides in 
the context of relevant MHC molecules. MHC class I molecules report intracellular 
events such as viral infection to CD8+ T cells. Protein fragments of cytosolic and 
nuclear origin generated by proteolysis, are loaded on MHC class I molecules in the 
endoplasmic reticulum (ER) and the complex is transported to the APC surface (Fig. 
2a). In contrast, endocytosed extracellular proteins generate peptides by lysosomal 
proteolysis of phagocytosed material, and these peptides are loaded on MHC class II 
molecules (Fig. 2b) [23, 24]. A representation of these two distinctive functions is seen 
in Fig. 2. 
 
Presentation of peptide via the MHC class I pathway facilitates the engagement of 
cytotoxic CD8+ T cells (CTLs), through a process called direct presentation. CTLs play 
a major role in the control of viral infection and killing of tumor cells. Upon activation, 
CTLs carry out the lysis of infected cells by the perforin granule exocytosis pathway or 
by the activation of the Fas ligand (FasL), which leads to programmed cell death [25]. 
Furthermore, CD8+ T cells also secrete cytokines such as IFNγ and TNFα to recruit 
and activate other effector cells [26]. CTL responses can also be elicited against 
antigens derived from an exogenous source. In this case, antigens are loaded onto the 
MHC class I molecule and the complex primes CD8+ T cells in a process called ‘cross-
presentation’, first described by Bevan et.al. [27]. On the other hand, presentation via 
the MHC class II pathway stimulates activation and differentiation of CD4+ T 
lymphocytes into different T helper (Th) subsets, namely: Th1, Th2 and Th17 [24]. 
Th1 responses are mainly characterized by secretion of the IFNγ cytokine, and are 
important for protection against viruses and intracellular bacteria. Th2 responses 
involve the secretion of IL-4, IL-5 and IL-13 cytokines against extracellular protozoa 
at mucosal surfaces, and are involved in allergic responses. Finally, Th17 is a recently 
discovered subset with important functions against certain bacterial infections, and a 
possible role in autoimmunity. 
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Figure 2: The MHC class I and MHC class II antigen-presentation pathways. 
(adopted from Nature immunology reviews [28]) a. Intracellular antigens such as viruses and 
tumor antigens are transported to the ER and loaded onto MHC class I molecules. MHC class I 
complexes traffic to the cell surface where they present the antigen to CD8+ T cells. b. 
Antigens from extracellular sources are phagocytosed and processed by endolysosomal 
enzymes into peptide fragments. The peptides are then loaded onto the MHC class II groove 
and presented to CD4+ T cells.  
 
Another role of the adaptive immune system is the induction of humoral responses. 
Maturation of B cells into plasma cells, following help from CD4+ T cells, results in 
the production of antibodies with high affinity through the induction of somatic 
hypermutation [29]. Antibodies are glycoproteins that belong to the immunoglobulin 
family and exist in five isotypes: IgG, IgM, IgA, IgD and IgE. The isotypes differ in 
the constant regions of the antibody protein sequence, conferring the different effector 
functions observed with each isotype. IgG immunoglobulins are the most abundant, 
and are further divided to IgG1, IgG2, IgG3 and IgG4 subclasses [30]. Antibodies 
protect the host by three main ways:  
 
• binding to pathogens and inhibiting their toxic effects (neutralization), 
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• coating pathogens so that phagocytes can phagocytose or engulf and kill them 
(opsonization), and  
• activating the complement cascade.  
Responses mediated by antibody production (humoral responses) and CD4+ and 
CD8+ T lymphocytes (cellular responses) are both necessary for the clearance of 
pathogens, and thus are the targets of immune induction in vaccination.  
1.2.2. Immune responses in vaccination 
?
Vaccines are designed to elicit strong and durable antigen-specific immune 
responses with long-lasting memory. Vaccination relies on the effective administration 
of non-pathogenic forms (i.e. live, attenuated or subunit forms) of an infectious agent 
to induce a sustained immune response. Various elements of the innate and the 
adaptive immune systems affect the efficacy with which antigen is processed and 
presented, and also the nature of the overall immune response. Early vaccination 
approaches with “B cell vaccines” triggered the development of long-lived plasma 
cells that induced antibody-mediated immunity to neutralize or block infection. More 
recent approaches are directed towards activation of the cellular compartment of the 
adaptive immune system, to enable recognition and killing of pathogen-infected cells, 
using “T cell vaccines”. The immunological foundations for B cell and T cell vaccines 
are not mutually exclusive, and novel vaccines ought to prime both humoral and 
cellular responses. The objective of this thesis is to establish new strategies for the 
design of T cell vaccines and, as such, the following paragraphs focus on describing 
the T cell activation events in vaccination.   
The kinetics of an immune response in vaccination can be divided into three 
different phases [31]. First, T lymphocytes must encounter the antigen presented by 
APCs within few hours after infection. Next, the CD4+ and CD8+ T cell compartments 
are activated and proliferation occurs rapidly, generating > 1000-fold increase in the 
number of clones, which are needed to elicit antigen-specific responses and to clear the 
infection from the host. This lasts for a few days, and when the infection is eradicated, 
> 90% of the newly generated T lymphocytes are cleared by apoptosis to return to 
homeostastis and prevent the development of autoimmunity. Eventually, memory T 
cells are raised from the once activated effector cells and these remain in circulation 
and/or in tissues ready to respond to re-infection. These memory cells express distinct 
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activation markers and intracellular proteins that distinguish them from naive and 
effector T cells, and they also express distinct chemokine and adhesion receptors that 
allow them to home to and to traffic through infected tissues and organs throughout the 
body [32].  
 
Following a classical immunization pathway in vaccination, CD4+ T cells, and in 
particular follicular helper (TFH) cells [33], provide help to B cells to promote isotype-
switching and the generation of high affinity antigen-specific antibodies. In addition, 
CD4+ T cells can also promote cytotoxicity in Th1 type responses by the release of 
granzyme and perforin as well as other antimicrobial cytokines such as IFNγ and 
TNFα [34].  Finally, CD4+ T cells can provide help in the activation of CD8+ T cells. 
However, activation of CD8+ T cells can also occur via cross-presentation as described 
earlier. The cross-priming of CD8+ T cell with vaccines is an area of particular interest, 
as these cells can deal with chronic infections and intracellular pathogens. The direct 
contact of CTLs with a target cell for periods ranging from several minutes to an hour 
can kill the infected cells while the CD8+ T cell remains intact for additional killing. 
Also, activated CD8+ T cells elicit inflammatory responses against a pathogen through 
the secretion of cytokines and chemokines that interfere with replication and spreading 
of the pathogen [35]. A schematic representation of the main functions of CD4+ and 
CD8+ T cells are summarized in Fig. 3, adapted from [36]. 
The hallmark of a successful T cell-mediated immunization is the generation of 
long-lived memory cells capable of recognizing and expanding to fight against a re-
infection. At least two types of memory T cells exist in mice and human, namely: 
effector memory (TEM) and central memory (TCM) T cells. TEM and TCM are mainly 
distinguished by the expression of surface markers, their location in the body and their 
profiles of cytokine secretion [37]. In particular, TCM cells reside within lymphoid 
organs where upon restimulation they expand to resupply the effector T cells at 
peripheral sites; a process that takes a few days. At their surface, these express the 
CD62L and CCR7 markers, which distinguishes them from TEM that express neither 
and reside in the peripheral tissues [38, 39]. TEM’s role is to provide immediate 
protection at the sites of infection by cytokine secretion and perforin-mediated killing, 
without requiring re-differentiation. However, these cells have a limited proliferation 
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capacity when compared to TCM. CD4+ and CD8+ memory T cells can persist for 
decades and it is believed that CD4+ T cells play a role in their maintenance [40]. 
 
Figure 3. The main roles of activated cells in vaccination (adapted from Haes et. al.[36]). 
Antigen is taken up by APCs and used to activate CD4+ T cells which provide help to B cells 
for antibody production, elicit TH1 type responses and provide help to CD8+ T cell activation. 
The latter are also directly cross-primed by the antigen in a process called cross-presentation  
1.2.3. CD8+ T cell-inducing vaccines 
The important role of T cells, specifically CD8+ T cells, in the elimination of 
intracellular infections and tumors has given rise to the study and development of 
CD8+ T cell-inducing vaccines (referred to here simply as CD8+ T cell vaccines), 
designed to elicit potent CTLs in the context of both prophylactic and therapeutic 
vaccination. For this reason, there has been growing interest in understanding the key 
determinants of CD8+ T cell activation and how to take advantage of these 
determinants in vaccines. Current CD8+ T cell vaccines primarily activate CTLs 
through the use of endogenously produced proteins (i.e. DNA vaccines or viral 
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vectors) or by cross-presentation of exogenously administered antigens (peptide-based 
vaccines) to CD8+ T cells. The maintenance of these activated CD8+ T cells, however, 
and their conversion to memory cells remain challenges in vaccine design. Several 
factors affect the quality of the induced CTLs, the first of these being the nature of the 
stimulation. CD8+ T cells can be cross-primed by the cross-presentation of antigen on 
MHC class I molecules of DCs, while maturation of DCs can be achieved through TLR 
signaling along with the induction of soluble factors such as IL-12 and type I IFN [41-
43] that promote the proliferation of activated CD8+ T cells [44, 45]. Cross-
presentation of antigen by DCs is of the utmost importance for activating CTLs in 
vaccination, but it requires the induction of co-stimulatory signals to sustain the 
interactions of DCs with CD8+ T cells. Furthermore, a number of studies suggest that 
these vaccines also rely heavily on help from CD4+ T cells for maintenance of the 
response and the generation of memory cells [35, 46]. Other factors that impact the 
quality of induced CTLs include the dose of antigen, the route of administration and 
the kind of delivery systems used [47]. How these factors affect the development of 
CTLs is still unclear, and their resolution is critical for the design of better CD8+ T cell 
vaccines. 
 
1.2.4. Rational vaccine design 
 
 Three elements are considered key in the design of effective subunit vaccines 
which, when combined, can potentially lead to induction of an optimal immune 
response and outcome.  
 
1. Antigen selection  
 The antigen against which an immune response is raised is the most important 
element for raising specific immunity. The antigen in subunit vaccination is a purified 
or a recombinant protein that retains the immunogenic epitopes of the microbe or 
pathogen. Regarding the relevance of an antigen for use in a vaccine, two 
recommended selection criteria are: sequence conservation across the different strains 
of the pathogen and the levels of protein expression during the normal course of an 
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infection, especially when considering gene-based vaccination. Choosing the right 
antigen can be challenging, as most viruses, for example, have multiple epitopes, and 
more importantly, these epitopes tend to mutate, allowing escape from the immune 
response. Another significant consideration when designing an effective subunit 
vaccine is the amount of antigen that will be presented to T cells, as this can have a 
negative effect on immune activation. Studies have shown, for instance, that low dose 
vaccination resulted in preferential generation of protective T cells [48, 49]. Finally, 
susceptibility of the antigen to lysosomal proteolysis should also be taken into 
consideration when selecting antigens for vaccination, as it has been reported that 
exacerbated degradation of an antigen after uptake by APCs destroys potential peptides 
for T cell recognition [50]. Therefore, protection of the antigen against proteolysis can 
improve the outcome of a vaccination.   
 
2. Adjuvant selection 
 In subunit vaccination the antigen alone is typically poorly immunogenic and 
thus, inclusion of immune potentiators, termed adjuvants, in the vaccine formulation is 
necessary to enhance the immunogenicity of the antigen. Adjuvants act as PAMPs that 
bind to the PRRs on APCs and trigger early innate immune responses that aid the 
generation of robust adaptive immune responses. Co-stimulation provided by adjuvants 
results in the upregulation of surface molecules on DCs such as CD40, CD80 and 
CD86, and accelerates the generation of robust T cell responses [51]. Moreover, 
adjuvants can create a depot effect that allows sustained release of the antigen and 
increases the duration of the immune response, even in low-inducers [52]. With 
sustained release, the amount of antigen required for vaccination can be reduced, 
which also limits the costs of the therapy. In subunit vaccination the most commonly 
used adjuvants are the TLR agonists. Currently licensed adjuvants include bacterial by-
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products, toxins, lipids, nucleic acids, peptidoglycans, cytokines and other small 
molecules [53]. The most commonly used adjuvant in human vaccines is alum, which 
mainly induces humoral responses [54], however, many other adjuvants have been 
licensed for use and are recommended for CD8+ T cell activation [52, 55] . Of 
particular interest for the purpose of this thesis are 3 adjuvants: Monophosphoryl lipid-
A (MPLA), CpG and poly(I:C). MPLA is a synthetic LPS-derivative, and as such, it is 
a TLR4 activator that induces Th1 responses and has been approved for use in human 
vaccines in Europe (AS03 adjuvant by GlaxoSmithKline) [56]. Another adjuvant that 
is of particular interest is the TLR9 agonist CpG, consisting of nonmethylated 
cytosine-phosphate-guanosine domains of DNA. CpG is under clinical investigation, as 
it is a potent in Th1 activator that also triggers antibody production [57]. Finally, 
poly(I:C) is a TLR3 agonist made of double stranded RNA, which mimics replicating 
viruses. It is a potent IFN inducer and its nontoxic analog has been used in clinical 
trials of HIV vaccination [58]. 
 
3. Delivery system for direct targeting of the antigen  
 In subunit vaccines, direct targeting of the antigen to the appropriate cell type 
in vivo is critical for the induction of an immune response. DCs are usually the target in 
T cell vaccines, and an increasing number of delivery systems have been developed 
throughout the years to facilitate the transportation of antigen to the proper type of DC 
for uptake in the lymphoid organs, without prior manipulation ex vivo. There are two 
means of antigen delivery in vaccination that can facilitate the initiation of an immune 
response:  
• direct targeting of APCs with antigen fused to antibodies or chemokines, and  
• incorporation of the antigen into a vehicle formulation.  
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 The simplest approach for delivering antigen is to vaccinate with peptides that 
can bind directly to MHC class I molecules, but this has resulted in limited 
immunogenicity to the CD8+ T cell compartments and is dependent upon the specific 
MHC I allele of the host. Combination of soluble antigen with adjuvants and direct 
targeting to DCs and/or other APCs has also been a common approach in 
protein/adjuvant vaccine formulations. DCs express unique surface markers and, as 
such, fusion of an antigen to an antibody or ligands that can bind these markers is a 
common vaccination strategy [12, 59, 60]. Examples where CTL responses have been 
generated by DC-targeted antigens include vaccination with molecules targeting DEC-
205 [61], DCIR2 [62, 63], mannose receptor [64], Dectin-1 [65] and Clec9A [66]. 
Robust CD8+ T cell responses have also been achieved with the use of dead cells. 
Studies have shown that DCs and other APCs can collect and process antigens from 
dead cells [67-69], which suggests that the idea of first targeting antigens to other cell 
types that will eventually result in the activation of CD8+ T cells, may be feasible.   
 
 For antigen delivery by vehicles, there is an extensive list of tools available, 
which include the use of DNA vaccines, liposomes, virosomes, water-in-oil-emulsions 
and micelles [70]. In DNA or viral particles the antigen (protein) is synthesized inside 
the cell; this is probably the most direct method for loading antigen onto a MHC class I 
molecule for presentation to CD8+ T cells. DNA and viral vaccines have been used 
against cancer, tuberculosis, HIV, influenza virus and other [71, 72]. Other vehicle-
based platforms attempt to encapsulate the antigen and deliver the contents to the 
appropriate cell compartments. Liposomes, for example, can carry viruses, proteins, 
glycoproteins, nucleic acids, carbohydrates, and lipids, and facilitate their delivery to 
immune cells [73]. Similarly, virosomes − small spherical vesicles, embedded with 
viral proteins that can fuse to immune cells − can be used to transport and deliver 
antigenic cargo [74]. Of particular interest for the purpose of this thesis are micelles 
that are self-aggregated clusters of amphiphilic surfactant molecules, which can trap 
antigens and promote their delivery to relevant immunological sites in the body [75]. 
 
?
?
?
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1.3. Accomplishments 
 
In this thesis, we present new methods for T cell activation in subunit 
vaccination. To target compartments of the innate immune system eligible for raising 
robust T cell responses in the adaptive immune system, two approaches were 
undertaken : (1) novel nanoscale vehicles for vaccine delivery were developed, and (2) 
and recombinant cloning techniques for protein fusion to antibodies and chemical 
ligands were explored.  
 
In Chapter 2, a novel technology for liver vaccine with direct antigen targeting is 
presented. We used an antibody technology established in our laboratory for antigen 
binding to erythrocytes, promoting their cross-presentation to CD8+ T cells in a 
tolerogenic context. Using recombinant protein techniques, we inserted an 
immunogenic signal onto the erythrocyte binding antibody to reverse the tolerogenic 
outcome, and delivered the antigen to hepatic APCs together with potent adjuvant in a 
prime-boost vaccine. Direct antigen targeting to liver elicited potent CTL responses for 
local clearance of pathogen-infected cells. Most importantly, CTLs displayed a long-
lasting memory phenotype, currently a significant challenge in hepatic vaccination.   
 
In Chapter 3, a DC vaccine for direct antigen cross-presentation was developed 
with a novel design to improve cytotoxicity of a currently available technology. In 
particular, we targeted a subset of DCs known to excel in cross-presentation : CD8+ 
DCs. The model antigen OVA was fused with recombinant techniques to the XCL1 
ligand, which is uniquely expressed on the surface of this DC subtype. To enhance 
antigen uptake by CD8+ DCs, we co-administred XCL1-OVA and a fusion protein of 
XCL1 with a domain of the extracellular matrix binding protein PlGF-2, produced with 
recombinat technology. Co-immunization with XCL1-PlGF attracted cross-presenting 
DCs to the injection site and increased XCL1-OVA uptake efficiency, leading to 
improved immunogenicity in vaccination. The technology was evaluated in 
prophylactic and therapeutic tumor models, in which XCL1-OVA mixed with XCL1-
PlGF significantly prolonged survival of tumor-bearing mice.   
 
The concept of extracellular matrix binding protein fusion was also tested in 
Chapter 4, with the fusion protein OVA-PlGF.  In this study, we explored whether 
retaining the fusion protein at the injection site and creating a depot effect would result 
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in improved immune responses in vaccinations. Our initial hypothesis was not 
confirmed by the vaccination results, as soluble OVA elicited similar humoral and 
cellular responses as the OVA-PlGF formulation.  
 
Finally, in Chapter 5, the immunogenicity of a micelle-based vaccine platform, 
kindly produced by Dr. Carrie Brubaker, was evaluated in a vaccine model. 
Encapsulation or complexation of different adjuvants and mixtures of adjuvants were 
used in antigen- bearing micelle formulations to vaccinate animals in a prime-boost-
boost study. OVA- and CpG-B-presenting micelles resulted in significant activation of 
both humoral and cellular responses, suggesting potential for this novel platform in 
other further studies exploring tumor vaccination or clinically-relevant antigen.  
 
In conclusion, we have developed new technologies for enhancing the CD8+ T 
cell response to prophylactic and therapeutic vaccines. Hepatic antigen targeting as 
well as tumor vaccines remain a challenge in current vaccine technologies and as such, 
we believe that this work has potential impact in the development of a new generation 
of rationally designed vaccines with strong CTL activation and long lasting memory.  
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2.1 Abstract 
 
A challenge in liver-targeted subunit vaccines is the activation of local cytotoxic 
responses with long-lasting memory. Previously we demonstrated that intravenous 
injected antigens bearing the TER119 erythrocyte-binding domain target the liver and 
crosspresent very efficiently to CD8+ T cells. Here, we present a tri-domain fusion 
protein of TER119, OVA as a model antigen, and the BBOX domain of high mobility 
group box-1 (HMGB1) as an adjuvant (TER119-BBOX-OVA), which, when co-
administered with CpG-B, we show elicits robust cytotoxic T lymphocyte (CTL) 
responses with a memory phenotype intrahepatically. Following a prime-boost 
immunization, we found that TER119-BBOX-OVA + CpG resulted in 6-fold higher 
IFN-γ secretion in the liver of vaccinated mice compared with OVA + CpG 
vaccinations. Mice immunized with TER119-BBOX-OVA + CpG overcame the 
tolerogenic fate of activated CD8+ T cells in the liver and developed memory cells that 
responded to a recall 5 weeks after the vaccination. Also, immunizations with 
TER119-BBOX-OVA + CpG resulted in clearance of the Listeria monocytogenes 
infected cells in the liver within 72 hr after infection. Overall, we designed a novel 
vaccine platform that efficiently cross-primes CD8+ T cells and, when combined with 
adjuvants, activates CD8+ T cells intrahepatically. Considering the simplicity of 
recombinant production of practically any fusion antigen, this strategy has potential to 
treat hepatic diseases where a strong, local cytotoxic response is required and the 
infected cells are difficult to approach by standard vaccination.  
 
 
 
 
 
 
 
 
 
 
 
 
 25 
2.2. Introduction  
?
Effective vaccines against viruses and tumors must induce the activation and 
expansion of antigen-specific CD8+ T cells [1]. Accordingly, many efforts in vaccine 
design have focused on the induction of robust cellular responses.  The ability to 
generate such immune responses in the disease-relevant organs is likewise essential to 
the efficacy of vaccines. However, organ-specific targeting has largely eluded vaccine 
designs to date. Common examples of infections where traditional vaccines are unable 
to raise sufficient CD8+ T cell responses include liver infections [2]. In hepatitis B, a 
prophylactic vaccine has been available for years but adult infections or 
perinatal/postnatal mother-to-child infections still occur, emphasizing the need for 
improved vaccines from the standpoint of inducing cellular responses for therapeutic 
treatments [3]. Also, chronic hepatitis B patients with exhausted immune cells fail to 
initiate responses against the virus, a situation that can lead to hepatocellular 
carcinomas. Finally in malaria, the sporozites released in the blood harness the 
tolerogenic environment of the liver and escape immune surveillance. Thus, strong 
CD8+ T cells raised in the liver are required to achieve protection with vaccination [4]. 
Efforts in liver vaccination focus on the induction of effective CD8+ T cells with long 
lasting memory [5-7]. Recent studies have shown that the liver plays a major role in 
local immune responses and, more specifically, that induction of high numbers of 
memory CD8+ T cells in the liver is a prerequisite for virus protection [8]. 
 
Raising effective CD8+ T cell responses in the liver is challenging due to its 
role in promoting T cell tolerance [9-11]. Intrahepatic activated CD8+ T cells can soon 
become defective in the liver after immunization and are cleared by apoptotic 
mechanisms [12]. However, contradictory studies support that the liver plays an 
important role in the defense against blood-borne pathogens, suggesting that generating 
and supporting strong intrahepatic CD8+ T cell responses is possible [13-15]. The main 
challenge for liver immunity is to prevent the exhaustion of activated CD8+ T cells, 
expand their number locally and directly target and kill the infected cells. Current 
vaccine approaches targeting liver focus on the induction of CD8+ T cell responses 
with a memory phenotype that can be used as a preventive or therapeutic approach in 
liver infections and the treatment of chronic infections.  
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Traditional vaccination approaches include immunization with live or 
attenuated viruses, the preparation of which is difficult and requires the maintenance of 
the viability of the virus throughout the whole procces. Such technical limitations have 
opened the field to the development of subunit vaccines with synthetic peptides or 
whole protein antigens. The successful design and development of liver subunit CD8+ 
vaccines would require effective activation of CD8+ T cells with a memory phenotype 
[16]. Prolonged antigen presentation and thus enhanced uptake by antigen presenting 
cells (APCs) is mandatory for such activation. Another prerequisite for effector CD8+ 
T cells is the efficient cross-presentation of the antigen by loading on to MHC class I 
molecules on the surface of the appropriate APC. In addition to antigen cross-
presentation, a potent TLR agonist that can activate costimulatory molecules and 
engage the T cells is necessary for the APCs to provide the appropriate signal that will 
prevent tolerogenic outcomes, which can exist in the absence of costimulation. Direct 
and prolonged targeting of the antigen to the liver, crosspresentation to CD8+ T cells 
and sufficient costimulation would raise robust immune responses that would further 
initiate local immunity.  
 
The purpose of this study was to design a vaccine platform that can induce 
antigen specific CD8+ T cell responses inside the liver and overcome the tolerogenic 
fate of CD8+ T cell activation that is frequently associated with the liver. Our 
laboratory has previously engineered antigens bearing antibody fragments that upon 
intravenous injection bind to erythrocytes [17]. Targeting antigens to erythrocytes 
improves the circulation half-life of the antigen and, more importantly, dramatically 
increases the (tolerogenic) cross-presentation of the antigen to CD8+ T cells in the 
spleen and liver [18]. We hypothesized that coupling the enhanced antigen cross-
presentation of our erythrocyte binding technology with a powerful danger signal 
would activate immunity and induce robust CD8+ T cell responses. To examine the 
potential benefits of our approach in the context of vaccination, we engineered a fusion 
protein consisting of an erythrocyte binding, glycophorin A-specific scFv called 
TER119 [19], the danger signal domain BBOX from the endogenous adjuvant high 
mobility group box 1 (HMGB-1) [20] and the model antigen ovalbumin (OVA). The 
HMGB-1 protein is released by necrotic cells and activates dendritic cells via its 
BBOX domain only when a critical cystein in the 193 position is present [21, 22]. In 
our experiments, the fusion protein TER119-BBOX-OVA was mixed with the strong 
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CpG-B adjuvant to further enchance the cytotoxic responses. Moreover, we took 
advantage of the intravenous route of administration to directly target the antigen to the 
liver and raise local responses.  
 
We found that TER119-BBOX-OVA, when administered i.v. with CpG, 
induces strong Th1 cytotoxic responses in the liver that led to the clearance of 
pathogen-infected cells and generation of long-lasting CD8+ T cell memory. 
 
2.3. Materials and Methods 
?
Animals. Female C57BL/6J mice were purchased from Harlan, and female Ly5.1 
(CD45.1) mice were purchased from Charles River Laboratories. All mice were aged 
between 8-12 weeks and kept under pathogen free conditions at the animal facility of 
Ecole Polytechnique Fédéral Lausanne (EPFL). Female C57BL/6-Tg(TcraTcrb) 
1100Mjb (OTI) mice between 8-15 weeks that were used for isolation of splenocytes 
were bred under specific pathogen-free (SPF). The Veterinary Authority of the Canton 
de Vaud has approved all procedures and experiments. 
 
Recombinant production of proteins. Design and cloning of TER119-BBOX-OVA. 
The altered pSecTag plasmid carrying the DNA sequence coding for theTER119 scFv 
antibody fragment fused with the OVA antigen at the 3’ end, was previously developed 
in our laboratory [18]. The HMGB1 vector was purchased from HMGBiotech; the 
forward primer “accggtgacttcaaggaccccaatgcacccaagaggcctcc” and the reverse primer 
“gatattgctgcctacagagctaaaggtggcggttctggtggcggttctggatcc” were used to amplify the 
BBOX sequence of HMGB1. A GGSGGS linker was added upstream and downstream 
of the BBOX sequence to allow proper folding of the protein after translation. A 6 
Histidine tag sequence was further added to the 3’ end to facilitate purification. HEK 
cells were transfected with the TER119-BBOX-OVA construct under serum free 
conditions with 3.75 mM valproic acid (Sigma-Aldrich) [23], and after 7 days the 
protein in suspension was purified with immobilized metal affinity chromatography 
using a HiTrap HP His-tag column (GE Healthcare). The purified protein was analyzed 
for purity using SDS/PAGE, endotoxin levels were assessed in THP-1 x Blue cells 
(InvivoGen), and concentration was measured using bicinchoninic acid assays 
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(Thermo Scientific). The final product was sterile-filtered, and stored at −80 °C in 
working aliquots. 
 
Pharmacokinetic and pharmacodynamic studies. To measure the TER119-BBOX-
OVA dissociation constant kd with the erythrocyte surface TER119-BBOX-OVA was 
diluted in a range of concentrations varying from 0.1 nM to 5000 nM in a total of 10 μl 
PBS with 10 mg/ml BSA, whereas 20 μl of diluted erythrocytes (1 μl of blood in 100 
μl PBS mixed with 10 mg/ml BSA) were added in a total volume of 180 μl PBS mixed 
with 10 mg/ml BSA. After incubation for 1 hr at 37oC, the cells were washed, 
centrifuged and labeled with 100 μl of OVA-FITC antibody (Abcam) in a dilution of 
1:100 for 20 min on ice. The geometric mean fluorescence intensity of the antibody 
binding was measured by flow cytometry and analyzed by Prism (One site-total 
binding).   
 
For in vivo binding measurements, 34 μg TER119-BBOX-OVA mixed with 20 
μg OVA were injected i.v. into the tail vein of C57BL/6 mice. At predetermined time 
points, 1 μL of blood obtained by tail incision was diluted 100-fold into PBS mixed 
with 10 mg/ml BSA, washed 3 times and incubated with 100 μl of OVA-FITC 
antibody (dilution 1:100) for 20 min on ice. The OVA content of the samples was 
analyzed by flow cytometry and calculations of the t1/2 were done in Prism (One phase 
decay).  
 
Labeling of proteins. The TER119-OVA, TER119-BBOX-OVA and OVA proteins 
were labeled with the Alexa 647 fluorophore (Dyomics). All proteins were mixed with 
the fluorophore in a protein:dye molar ratio of 1:10, and incubated for 1 hr at room 
temperature. The free dye was removed by centrifugation with Zeba columns (Thermo 
Scientific). All reactions were performed under sterile conditions to protect from 
endotoxin contamination.  
 
Biodistribution studies and liver processing for uptake. The fluorescently 
conjugated proteins TER119-OVA A647, TER119-BBOX-OVA A647 and OVA A647 
were injected i.v. in equimolar amounts of 0.45 nmoles with or without 5 μg CpG, and 
were allowed to circulated in vivo for 17 hr. Female C57BL/6L mice 8 weeks old were 
used for this experiment. The mice were euthanized by cervical dislocation, and the 
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liver was perfused with 10 ml Hanks’ Balanced Salt Solution media (Gibco) mixed 
with 0.5mg/ml Collagenase D (Roche) through the inferior vena cava with a 25 Ga 
needle. The portal vein was cut to release the pressure in the liver and allow the blood 
to exit. Subsequently, it was cut and homogenized to single cell suspension. The 
hepatocytes were removed first via centrifugation at 20xg, and stained with antibodies 
against CD45 (1:200), MHCII (1:800) and CD1d (1:200) for flow cytometry. The 
remaining homogenate was mixed in a 70% Percoll (VWR) layer, overlayed by a 20% 
layer of PBS, and centrifuged for 20 min. The hepatic stellate cells (HSCs) were 
removed from the 20-PBS surface, whereas the liver dendritic cells (DCs), Kupffer 
cells (KCs), and liver sinusoidal endothelial cells (LSECs) from the 20-70 layer, 
washed and stained with the following antibodies: HSCs: CD45, MHCII, CD1d and 
CD146 (1:200); liver DCs: CD45 and CD11c (1:200); KCs: CD45 and F4/80 (1:200); 
LSECs: CD45, CD146 and CD31 (1:200). All the aforementioned antibodies were 
purchased from eBiosciences.  
 
Adoptive transfer of OTI T cells. Female CD45.2+ cells were isolated from 
splenocytes of OTI mice, between 12-16 weeks old, using a CD8 magnetic bead 
negative selection kit (Miltenyi Biotec). The isolated CD8+ OTI cells were incubated 
with 1 μM CFSE (Invitrogen) for 6 min at room temperature, and the reaction was 
quenched with an equal volume of Iscove’s modified Dulbecco’s medium (IMDM) 
with 10% (vol/vol) FBS (Gibco). Before injection, cells were resuspended in pure 
IMDM to a final concentration of 107 cells/ml. A total of 100 μl were injected i.v. into 
the tail vein of recipient female Ly5/ CD45.1+ mice, 8 weeks old. The following day 
the mice received an i.v. injection of equimolar (0.45 nmoles) amounts of TER119-
OVA, TER119-BBOX-OVA or OVA with or without 10 μg CpG, and they were 
sacrificed 4 days later. The liver and spleen were collected and processed and stained 
for flow cytometry as described previously. 
 
Immunizations, and memory recall experiments. Female C57BL/6 mice, 8 weeks 
old, were immunized under isofluorane anesthesia on day 0 (i.v. injection of 100 μl 
total mixture) and on day 14 (s.c. injection of 200 μl total mixture volume) with 32 μg 
TER119-OVA, 32 μg TER119-OVA + 5 μg CpG, 34 μg TER119-BBOX-OVA, 34 μg 
TER119-BBOX-OVA + 5 μg CpG, 20 μg OVA (endotoxin free, Hyglos), 20 μg OVA 
+ 5 μg CpG or just saline. 5 days later the mice were euthanized, and the liver and 
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spleen were collected for ex vivo restimulation. For the memory recall, the mice were 
immunized as described above, and 5 weeks after the boost injection they all received a 
s.c. injection of 10 μg OVA + 20 μg CpG. A control group of mice that was not 
originally vaccinated also received the recall boost. All mice were euthanized, and 
their organs (spleen, liver and the axillary, branchial and inguinal lymph nodes) were 
processed and restimulated as described previously. 
 
Listeria monocytogenes infection. Listeria monocytogenes bacteria expressing OVA 
(Listeria strain 10403; modified by the Dietmar Lab (UNIL, Lausanne) to express 
OVA as described here [24]) were grown at 37oC in Brain Heart Infusion (Fulka) 
media without antibiotics until the OD reached 0.3. The cells were subsequently 
diluted with PBS to a final concentration of 105 CFU/ml, and C57BL/6 mice were 
injected with 100 μl of the bacterial cell suspension via i.v. injection in the tail vein. 3 
days after the infection the mice were euthanized, and their organs were processed as 
described elsewhere [25]. Briefly, the liver and spleen were homogenized through a 
100-μm cell sieve and a 70-μm cell sieve correspondingly, and PBS was added to a 
final volume of 40 ml. 100 μl of the homogenate were plated in brain heart infusion 
agar plates (Fulka) prepared 1 day before, and the number of bacteria colonies was 
assessed after overnight incubation at 37oC.  
 
Tissue and cell preparation for ex vivo restimulation of lymphocytes. The liver was 
perfused with 10 ml HBSS through the inferior vena cava, and gently homogenized 
through a 100 μm cell sieve. Hepatocytes were removed by centrifuge for 5 min at 
20xg, and lymphocytes were separated from other hepatic cells with a 30% Percoll 
(VWR) gradient. Remaining red blood cells were lysed for 5 min with 0.155M NH4Cl. 
Splenocytes were obtained by disruption of the spleen through a 70-μm cell sieve, and 
subsequent red blood cell lysis with 0.155M NH4Cl. The lymph nodes were digested 
for 30 min with 2 mg/mL Collagenase D (Roche) in IMDM, and passed through a 70-
μm cell sieve to obtain single cell suspensions. All organs were kept in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% FBS and 1% 
penicillin, streptomycin (Invitrogen). For CD8+ T-cell–specific restimulation and 
intracellular cytokine staining, cells were first cultured for 3 hr at 37 °C in the presence 
of 1 μg/mL SIINFEKL, 104 U/ml IL2, and 0.5 μg anti-CD28 (eBioscience), and 
subsequently for 3 hr with the addition of 250 μg/mL brefeldin A (SigmaAldrich). For 
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CD4+ T-cell restimulation, 104 U/ml IL2, 0.5 μg anti-CD28 and 100 μg/mL of ????
?????? ??? ??????????????? were added to the cells for 3 hr, followed by incubation 
with 50 μg/mL brefeldin A for another 12 hr. Alternatively, cells were restimulated for 
4 days in the presence of 100 μg/mL OVA or 1 μg/mL SIINFEKL for the analysis of 
cytokine production in the supernatant.  
 
Flow cytometry and ELISA. For the detection of live cells, cells were suspended at a 
concentration of 1 mio cells in 200 μl, washed with PBS, and labeled with live/dead 
fixable cell viability reagent (Invitrogen). Subsequently, the cells were incubated for 20 
min on ice with PBS/2% FBS solutions of the surface markers CD3 (1:100) and CD8 
(1:200) or CD4 (1:200). For intracellular cytokine staining, cells were fixed in 2% 
paraformaldehyde solution, washed with 0.5% saponin (SigmaAldrich) in PBS/2% 
FBS, and incubated with the IFNγ (1:200) antibody diluted in saponin solution for 30 
min on ice. Finally, the cells were resuspended in PBS/2% FBS for analysis. Samples 
were processed on CyAn ADP Analyzer (Beckman Coulter), and data were analyzed 
with FlowJo software (Tree Star). The antibodies against mouse CD3, CD4, CD8, 
IFNγ and TNFα were purchased from eBioscience.   
For the detection of cytokines in the supernatant of incubated cells, Ready-SET-go! 
ELISA kits were purchased from eBioscience, and the manufacturer’s instructions 
were followed for a sandwich ELISA.  
 
Data Analysis. All flow cytometry data were analyzed using FlowJo (v8.8.6). Graphs 
and statistical analyses of worked-up data were performed using Prism (v5, GraphPad). 
The statistical significance was determined by one way ANOVA – Bonferoni test or t-
test with Welch correction. The asterisks indicate the significance as follows: *p<0.05, 
**p < 0.01, ***p < 0.001. 
 
2.4. Results and Figures 
?
2.4.1. Production and characterization of erythrocyte-binding antigens.  
Engineering proteins to bind to erythrocytes improves their pharmacokinetic 
properties and increases the circulation half life [17]. We generated a tri-domain fusion 
protein consisting of an erythrocyte-binding antibody fragment, an adjuvant domain, 
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and an antigen domain. In particular we used the TER119 antibody that binds to 
glycophorin-A on the surface of erythrocytes in mice [19], the BBOX active domain of 
the endogenous necrotic signal HMGB1 [20], and the model antigen OVA, and we 
cloned the TER119-BBOX-OVA fusion protein. We evaluated the pharmacokinetic 
properties of the protein compared to the non-erythrocyte binding OVA-only protein 
and found that the former binds to red blood cells and circulates in vivo longer than 
OVA only. The binding affinity of TER119-BBOX-OVA to red blood cells was 
validated in vitro by equilibrium binding measurements using varying concentrations 
of the protein. TER119-BBOX-OVA binds to red blood cells with high affinity and an 
equilibrium dissociation constant (kd) of 740 nM (Fig. 1A), whereas OVA-only does 
not bind (data not shown). We also performed pharmacokinetic measurements to 
characterize the in vivo circulation time of TER119-BBOX-OVA. Following a single 
i.v. injection of 32 μg TER119-BBOX-OVA, we sampled the blood frequently and 
used flow cytometry to determine the amount of TER119-BBOX-OVA bound to the 
surface of erythrocytes as a function of time.  TER119-BBOX-OVA exhibits a cell 
surface half life (t1/2) of 6 h and remains in circulation for a few days after the injection 
as opposed to OVA that is cleared immediately from the body (Fig. 1B). The above 
results confirm the binding of TER119-BBOX-OVA to red blood cells and show the 
improved pharmacokinetic parameters of the molecule compared to OVA-only. 
?
Figure 1: TER119-BBOX-OVA binds to erythrocytes and circulates in vivo for a few 
hours. A) The equilibrium dissociation constant of TER119-BBOX-OVA to erythrocytes was 
determined by flow cytometry, using an anti-HIStag PEantibody (Analysis with Prism 5: One 
site- total, R2=0.9827). B) The half life (t1/2) of equimolar amounts (0.45 nmoles) of TER119-
BBOX-OVA and OVA administered i.v. with a single dose were measured by flow cytometry 
using an anti-OVA FITC antibody (Analysis with Prism 5: One phase decay, R2=0.9844).   
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2.4.2. TER119-BBOX-OVA bears a danger signal.  
Erythrocytes undergo physiological death associated with immune suppressive 
and tolerogenic signals, whereas cells dying under stress release damage-associated 
molecular patterns (DAMPs) that can activate the immune system [26]. We aimed to 
force an artificial danger signal on dying erythrocytes by introducing BBOX within the 
tri-domain fusion protein and activating DCs to uptake the erythrocyte debris and 
initiate further immune responses. To confirm that the BBOX retains its adjuvant 
properties within the TER119-BBOX-OVA protein, we injected C57BL/6 mice with 
TER119-BBOX-OVA or BBOX-only and compared the upregulation of costimulatory 
molecules on CD11c+ DCs, in their spleens. We found that the BBOX within TER119-
BBOX-OVA retains the adjuvant properties of free BBOX. In particular, we looked for 
upregulation of common costimulatory molecules on DCs such as CD40, CD80 and 
CD86. All 3 molecules were equally upregulated both with TER119-BBOX-OVA and 
BBOX compared to naïve untreated mice (Fig. 2A, B and C correspondingly). In 
addition, we searched for the proinflammatory cytokines IL12 and TNFα by 
intracellular staining. The secretion of IL12 by TER119-BBOX-OVA was higher than 
BBOX or naïve mice; 1.77% of IL12 positive cells in TER119-BBOX-OVA group 
compared to 1.11% and 1.2% for BBOX and naïve groups correspondingly (Fig. 2D 
and 2E). The secretion of TNFα was similar in all groups (data not shown). Even 
though the secretion levels are not very high, these findings confirm the presence of a 
danger signal inside the tri-domain fusion protein and support our initial hypothesis 
that antigens circulating on red blood cells and bearing danger signals can be used as 
initiators of immune responses in vaccination.    
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Figure 2: TER119-BBOX-OVA retains the adjuvant properties of BBOX. C57BL/6 mice 
were injected with equimolar amounts of BBOX and TER119-BBOX-OVA and the spleens 
were harvested 12 hr later. The cells were stained and analyzed by flow cytometry A,B,C) 
Upregulation of costimulatory molecules A) CD40, B) CD80 and C) CD86  on CD11c+ gate. 
D) Intracellular staining for IL12 expression. Representative plots with positive gate on 
CD11c+, IL12+ cells. E) The graph shows IL12 expression in all groups; gate on CD11c+ cells 
(Analysis with t test, *p<0.05) 
2.4.3. Uptake of TER119-BBOX-OVA by hepatic cells and upregulation of 
antigen presenting cells in the liver.  
The generation of antigen-specific effector T cell responses requires that 
antigens are taken up by APCs and further presented to T cells in the presence of 
costimulatory molecules. We are particularly interested in the liver uptake because it 
hosts different types of antigen presenting cells, which can be immunogenic or 
tolerogenic, depending on the stimulant. Therefore, we explored the hepatic cellular 
uptake targets of the TER119-BBOX-OVA protein and compared it to the equivalent 
erythrocyte-binding antigen TER119-OVA without the BBOX and OVA-only protein. 
All proteins were tested with and without CpG. To show that the injected constructs 
reach the liver, are taken up by APCs and activate them, we treated C57BL/6 mice 
with Alexa-647 fluorophore-labeled proteins. After 17 h, we analyzed the cellular 
distribution of the injected proteins and the presence of co-stimulatory molecules.  
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Flow cytometry analysis revealed preferred uptake of the TER119-BBOX-
OVA with and without CpG by hepatocytes, as seen by CD45- MHCIIlow CD1d- 
staining in all groups (Fig 3A). In particular, there is a 2-fold increase in the uptake of 
TER119-BBOX-OVA compared to TER119-OVA and almost 2-fold compared to 
OVA alone. Similarly, hepatic stellate cells (HSCs), known to express molecules 
required for antigen presentation (MHC I, MHC II and costimulatory molecules), were 
stained with CD45+ MHCII+ CD1d+ CD146- and showed preferential uptake of the 
TER119-BBOX-OVA protein both with and without CpG (Fig 3B). In particular, the 
uptake by TER119-BBOX-OVA was increased by 4-fold compared to TER119-OVA 
and 2-fold compared to OVA, in the presence of CpG. Further processing of the liver 
homogenate allowed the separation of the non-parenchymal liver cells in a 
homogenous solution that included KCs, liver DCs and LSECs. The uptake by the 
different cell types within this layer is represented in pie charts in Figure 3C. TER119-
OVA (Fig. 3C top left) is mostly distributed among KCs (CD45+, F4/80+) with 49.2% 
uptake, a small percentage (4.2%) of liver DCs (CD45+, CD11c+) and the rest (46.6%) 
of the protein is taken up by other unstained populations. The addition of CpG to 
TER119-OVA (Fig. 3C top right) only slightly increased the percentages of KCs and 
DCs that uptake the protein but does not change drastically the uptake distribution 
percentages. Interestingly, in addition to Kupffer cells, TER119-BBOX-OVA (Fig. 3C 
middle left) is taken up also by LSECS (1.3%) labeled as CD45-, CD31-, CD146+ cells 
and higher percentages (7.7%) of liver DCs compared with TER119-OVA. The 
addition of CpG to TER119-BBOX-OVA (Fig. 3C middle right) further increases the 
uptake percentages by LSECs (4%) and DCs (14%). Finally, OVA-only that does not 
bind to erythrocytes has the biggest percentage of KCs uptake (59.9%) as well as some 
uptake by LSECs (1%) and liver DCs (6.1%) (Fig. 3C bottom left). The distribution of 
OVA changes with the addition of CpG (Fig. 3C bottom right) between KCs (39.2%) 
and other unstained populations (51.6%) but no big differences are observed between 
LSECs uptake (0.8%) and DCs (8.2%) in this group.   
 
Finally, we confirmed by flow cytometry the upregulation of costimulatory 
molecules in AF-647 positive cells, which have taken up the antigen (Fig. 3D). We 
found that CD80 is upregulated in LSECs, DCs and HSCs that are positive for uptake 
of TER119-BBOX-OVA or TER119-BBOX-OVA + CpG. This result supports the 
capacity of these cells to activate T cells. In particular, 1.5% and 1% of LSECs positive 
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for TER119-BBOX-OVA and TER119-BBOX-OVA + CpG uptake correspondingly 
are positive for CD80 upregulation compared to no upregulation by OVA, OVA + 
CpG, TER119-OVA and TER119-OVA + CpG with the exception of one mouse in the 
last group (Fig. 3D left). The upregulation of CD80 in liver DCs is present in all 
groups injected with CpG; 6% with TER119-OVA + CpG, 7.5% with TER119-BBOX-
OVA + CpG and 6% with OVA + CpG as well as in TER119-BBOX-OVA (4%) and 
OVA (3%) (Fig. 3D middle). In HSCs 10% of the cells positive for TER119-BBOX-
OVA are positive for CD80 upregulation and more interestingly 20% of TER119-
BBOX-OVA + CpG cells are positive which represents a 3-fold increase compared to 
OVA + CpG (Fig. 3D right).   
 
Taken together, the above data support that TER119-BBOX-OVA mixed with 
CpG can reach the liver, initiate local immune responses and thus be further used as a 
potent vaccine candidate.  
2.4.4. Efficient crosspresentation of TER119-BBOX-OVA + CpG improves the 
proliferation of OVA-specific CD8+ T cells.   
In principle, the design of potent CD8 vaccines, able to kill viruses and tumors, 
requires effective crosspresentation of the antigen to CD8+ T cells and a strong 
adjuvant. We further explored whether TER119-BBOX-OVA can crosspresent OVA 
to CD8+ T cells using an established adoptive transfer model. Carboxyfluorescein 
succinimidyl ester (CFSE)-labeled OTI CD8+ T cells (CD45.2+) were injected into 
CD45.1+ mice, followed 24 h later by i.v. injections of equimolar amounts of TER119-
BBOX-OVA, OVA or TER119-OVA, used as a positive control as shown elsewhere 
[18]. All formulations were injected with or without 10 μg CpG. The proliferation of 
CD45.2+ cells was measured 4 days later in the spleen and liver by the dilution of 
CFSE, using flow cytometry. TER119-BBOX-OVA mixed with CpG crosspresents to 
CD8+ T cells more efficiently than OVA, as it is seen by increased proliferation of OTI 
T cells (Fig.4). Representative gating on proliferating OTI T cells shows enhanced 
dilution of CFSE in TER119-OVA and TER119-BBOX-OVA injected mice in the 
spleen (98.7% and 90.1%, respectively) compared to OVA (76.8%) or saline-injected 
mice (3.17%), in which no proliferation was observed (Fig 4A). The average dilution 
of CFSE-labeled OTI T cells in all groups for both spleen (Fig. 4B left) and liver (Fig. 
4B right) clearly shows that antigens fused to the scFv antibody TER119, with or  
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proliferation in spleen and 80% in liver). We also measured the expansion of the OTI T 
cells by the increase of the CD45.2+ cell population. TER119-BBOX-OVA mixed with 
CpG crosspresents the antigen to OTI T cells, thus promoting their proliferation by 4-
fold in the spleen (Fig. 4C left) and more than 5-fold in the liver (Fig. 4C right), as 
compared to soluble OVA mixed with CpG. Interestingly, the BBOX insertion 
decreased the proliferation capacity of TER119-BBOX-OVA compared to TER119-
OVA, most probably due to the lower binding affinity of the former onto erythrocytes 
related with folding properties of the two molecules. Overall, treatment with TER119-
BBOX-OVA + CpG results in efficient cross presentation to CD8+ T cells as measured 
by proliferation and expansion of OTI cells, as compared to the OVA + CpG control. 
 
?
Figure 4: TER119-BBOX-OVA mixed with CpG crosspresents to CD8+ T cells and 
enhances the proliferation of adoptively transferred OTI T cells. A total of 106 CFSE 
labeled OTI T cells were adoptively transferred into naive Bl6 mice by i.v. injections in 100μl 
solutions. A day later the mice were immunized i.v. with equimolar amounts (0.45nmoles) of 
TER119-OVA, TER119-BBOX-OVA or OVA with or without 10μg CpG and the spleen and 
liver were harvested 4 days later. A) Representative CFSE dilution of OTI proliferating (CD8+ 
CD45.2+) spleen cells injected with TER119-OVA (top left), TER119-BBOX-OVA (top right), 
OVA (bottom left) and saline (bottom right). The numbers display the percentage of 
proliferating cells in CD45.2+ cells. B) Proliferating CFSElow OTI T cells (gate from A) in 
spleen (left) and liver (right) for all groups. C) Quantified expansion of OTI CD8+ CD45+ T 
cells in spleen (left) and liver (right). All data were determined by multiparameter flow 
cytometry and analyzed with Prism 5 ("Bonferroni's Multiple Comparison Test",  ***p value < 
0.0001) 
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2.4.5. Immunization with TER119-BBOX-OVA mixed with CpG leads to 
enhanced cytotoxicity of CD8+ T cells mainly in the liver of vaccinated mice.  
The activation of CD8+ T cells and their differentiation to CTLs is crucial for 
CD8 vaccine development. We next evaluated the induction of cytotoxic CD8+ T cell 
responses in mice immunized on day 0 and 14 with TER119-BBOX-OVA + CpG 
compared to TER119-OVA + CpG and OVA + CpG, as described in Fig. 5A. The 
cytotoxicity of CD8+ T cells was assessed in the spleen and liver of vaccinated mice 6 
days after the boost. Overall, more cytotoxic CD8+ T cells were measured in the group 
of mice vaccinated with TER119-BBOX-OVA + CpG compared with any other group.  
 
A single i.v. injection was sufficient to raise effective CD8+ T cells in all mice 
injected with TER119-BBOX-OVA + CpG, TER119-OVA + CpG and OVA + CpG 
measured by SIINFEKL pentamer staining in the blood of mice 8 days after the 
injection (Fig 5B). It is very interesting that only the mice injected with TER119-
BBOX-OVA+ CpG had an effector phenotype characterized by a CD44+CD62L- 
staining on CD8+ SIINFEKL pentamer+ blood cells, that was 4-fold and 8-fold higher 
compared with TER119-OVA + CpG and OVA + CpG correspondingly on day 8 of 
the experiment (Fig. 5C). On day 20, the spleen and liver of all mice where harvested 
and the lymphocytes were stained ex vivo for OVA specific SIINFEKL pentamer+ 
cells. There were 0.4% of pentamer+ cells in the spleen of TER119-BBOX-OVA + 
CpG mice compared with 0.2% for both TER119-OVA + CpG and OVA + CpG (Fig. 
5D) and 2.1% in the liver of TER119-BBOX-OVA + CpG compared with 1.7% and 
1.5% for TER119-OVA + CpG and OVA + CpG correspondingly (Fig. 5F). The 
crosspresentation efficiency of both TER119-BBOX-OVA + CpG and TER119-OVA 
seen in Fig. 4 explains the close values of OVA specific cells in these two groups. The 
frequency of effector phenotype of the cells in the TER119-BBOX-OVA + CpG group 
remained high (45% effector positive cells both in spleen and liver), as measured by 
CD44+ CD62L- staining (Fig. 5 E&G).  
 
The cytotoxicity of activated CD8+ T cells was further investigated by 
examining the cytokine secretion profile of lymphocytes taken from the spleens and 
livers of vaccinated animals. Consistent with the above data, ex vivo restimulation of 
splenocytes and liver lymphocytes with SIINFEKL for 6 hr led to a significant increase 
in the percentage of cytotoxic IFNγ-secreting cells in the spleen and liver of TER119-
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BBOX-OVA + CpG-vaccinated mice. In particular, 2-fold higher responses, as 
compared to TER119-OVA + CpG and OVA + CpG were seen in the spleen of mice 
vaccinated with TER119-BBOX-OVA + CpG (Fig. 5H). In the liver, TER119-BBOX-
OVA + CpG had 3-fold and 6-fold higher responses in IFNγ secretion compared with 
TER119-OVA + CpG and OVA + CpG, respectively (Fig. 5I). The above observations 
were also confirmed by ex vivo restimulation of the organs for 4 days with SIINFEKL, 
following ELISA measurements in the supernatant (data not shown). 
 
Effective vaccines that elicit simultaneous activation of cytotoxic CD8+ T cells 
and neutralizing antibodies are favored. The humoral responses were assessed by 
antibody titer measurements in all mice after vaccination. All groups of mice 
immunized with CpG displayed antibody titers around 2 with no significant differences 
between them. Interestingly, 2 out of 4 mice in the TER119-BBOX-OVA group 
without CpG and 1 out of 4 in the TER119-OVA group also created antibody titers of 
2, in the absence of strong adjuvant (Fig 5J).  
 
Overall, TER119-BBOX-OVA + CpG was very effective in activating CD8+ T 
cells for the production of cytokines after vaccination with much stronger responses 
than TER119-OVA + CpG or OVA + CpG, especially in the liver of immunized mice.  
2.4.6. Immunization with TER119-BBOX-OVA mixed with CpG creates memory 
CD8+ T cells that can be activated upon recall in the liver.   
A feature of a vaccine that confers long-term immunity is its ability to induce 
long-lasting memory T cells, which can be reactivated upon recall with the same 
antigen. Following the same vaccination protocol as described above, we explored 
whether the induced CD8+ T cells can differentiate into memory cells and expand upon 
recall with the OVA antigen. The mice were vaccinated on day 0 and 14, and the pool 
of CD8+ T cells after immunization was allowed to develop memory for 5 weeks. 
Subsequently, all groups of animals,including one group with naïve non-immunized 
mice, were injected s.c. with 10 μg OVA mixed with 20 μg CpG, and allowed another 
5 days for the cells to become activated (Fig. 6A). We evaluated the cytotoxicity of 
CD8+ T cells in the spleen, liver and pooled LNs (Axillary, Branchial and Inguinal) by 
ex vivo restimulation of the lymphocytes with SIINFEKL peptide and found that only 
TER119-BBOX-OVA + CpG was capable of inducing memory CD8+ T cells with the 
capacity to expand and display cytotoxic activity. In particular, after 6 hr of  
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Figure 5: TER119-BBOX-OVA + CpG differentiates CD8+ T cells into effector cells 
mainly in the liver of immunized mice. A)Immunization schedule ; Female C57BL/6 mice 
were immunized with 20μg OVA + 5μg CpG or equimolar amounts of TER119-
OVA,TER119-OVA + CpG, TER119-BBOX-OVA and TER119-BBOX-OVA + CpG on day 
0 and 14. Induction of effector CD8+ T-cell immune responses was measured in the spleen and 
in the liver on day 20. B)OVA-specific CD8+ T cells were assesed by SIINFEKL pentamer 
stain and flow cytometry in blood 8 days after the prime injection. C)The pentamer+ cell’s 
effector phenotype was assesed by CD44+ CD62L- staining by flowcytometry. D)Spleen 
pentamer stain on day 20 and E) effector phenotype of pentamer+ splenocytes.  F) Liver 
pentamer stain on day 20 and E) effector phenotype of pentamer+ liver lymphocytes. H) 
Spenocytes and I) liver lymphocytes were isolated and restimulated ex vivo for 6 h in the 
presence of SIINFEKL; IFN-γ expression by CD8+ T cells was determined by intracellular 
cytokine staining and flow cytometry. J) Total IgG titers in the serum of all vaccinated mice on 
day 20 of the experiment measured by ELISA  All data were analyzed with Prism 5 
("Bonferroni's Multiple Comparison Test", *p<0.05, **p<0.001, ***p<0.0001) 
restimulation with SIINFEKL, only the liver lymphocytes of mice immunized with 
TER119-BBOX-OVA + CpG responded to the stimulation by a 5-fold increase in 
IFNγ secretion (Fig. 6B) compared to OVA + CpG, whereas no active T cells where 
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found in the spleen or the LNs (data not shown), indicating that the long-lasting CD8+ 
T cell immunity is not systemic but rather localized in the liver. Interestingly, 
restimulation of liver CD4+ T cells with antigen ex vivo did not yield an increase in 
cytokine production. In contrast, we were able to measure IFNγ secretion by CD4+ T 
cells after 4 days of restimulation with the OVA antigen both in the spleen (Fig. 6C 
left) and the LNs (Fig. 6C right) in all groups mixed with CpG as well as the TER119-
BBOX-OVA group without CpG. We also measured the total IgG titers in the serum of 
all mice and found that, in accordance to the IFNγ secretion by CD4 T cells, all the 
groups displayed high antibody titers, without significant differences between them 
(Fig. 6D).   
Figure 6: T cells activated by TER119-BBOX-OVA + CpG differentiate to antigen specific 
memory T cells that survive in the liver and can be reactivated upon challenge with the 
same antigen. A) Experimental timeline; Mice were immunized as in Fig. 4, and 5 weeks after 
the boost injection the mice in all groups, including a control group with non-vaccinated mice, 
were challenged with a s.c. injection of 10μg OVA + 20μg CpG. The presence and the 
cytotoxic capacity of memory cells in the spleen, liver and LNs was assessed 5 days later. B) 
Liver lymphocytes restimulated ex vivo with SIINFEKL for 6hr and stained for IFNγ secretion 
in CD8+ T cells. Gate on live cells, CD3+ CD8+. C) Ex vivo restimulation with OVA of spleen 
and LNs lymphocytes for 4 days. The IFNγ secretion in the supernatant of spleen (left) and 
LNs (right) was determined by ELISA.  D) Total IgG titers in the serum of all vaccinated mice 
on day 54 of the experiment measured by ELISA. Statistical analysis of data with  
“Bonferroni’s Comparison test” *p<0.05, **p<0.001  
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The above results confirm that the cytotoxic CD8+ T cells in the liver generated 
after the prime-boost vaccination develop memory and can be recalled into an  effector 
phenotype, escaping the toerogenic fate of activated CD8+ T cells that is associated 
with activation in the liver without costimulation.  
 
2.4.7. Effector CD8+ T cells induced after TER119-BBOX-OVA + CpG 
immunization kill Listeria monocytogenes-infected cells.  
To evaluate the ability of cytotoxic T cells produced after vaccination to 
recognize and kill infected cells we challenged the mice with the pathogen Listeria 
monocytogenes, more specifically with a recombinant strain that expresses OVA 
antigen (Listeria-OVA). Listeria is a gram positive bacteria that can grow and 
reproduce inside the host's cells and is one of the most virulent food-borne pathogens, 
with 20 to 30 percent of clinical infections resulting in death [27]. In mice it infects the 
liver and spleen, and if it is not cleared, is lethal in high doses. Based on the previous 
vaccination data, we chose to compare the best vaccine approach, the TER119-BBOX-
OVA + CpG to the most relevant control, the OVA + CpG, to reduce the number of 
mice used in the experiment. The mice were vaccinated following the regular 
vaccination protocol and 5 days after the boost they were challenged with an i.v. 
injection of Listeria (Fig. 7A). Three days after challenge, the organs were harvested, 
homogenized and 100 μl of the homogenates were grown on agar plates overnight. No 
or minimum bacteria colonies on the plates was considered as successful clearance of 
the bacteria infection. Overall, mice immunized with TER119-BBOX-OVA+CpG 
were very efficient in clearing the bacteria within 72 hr after infection. In particular, in 
the liver between 0-25 colonies grew in the TER119-BBOX-OVA + CpG agar plate 
compared to 60-280 in the OVA + CpG and over 300 in the non-vaccinated mice. 
Representative images of agar plates with bacteria colonies from liver homogenates are 
shown in Fig. 7B, and the total bacteria counts in all groups for both organs are shown 
in Fig. 7C. Consistent with the earlier vaccine and vaccine-memory data, the cytolytic 
activity of CD8+ T cells is more powerful in the liver of TER119-BBOX-OVA+CpG 
vaccinated mice where the infection was almost eradicated.  
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Taken together, the above data demonstrate that vaccination with TER119-
BBOX-OVA + CpG induces effective cytotoxic CD8+ T cell immunity and raises 
potent CD8+ T cells in the liver that can respond rapidly to an infection and clear the 
organs from the pathogen.  
?
Figure 7: Listeria monocytogenes clearance in the spleen and liver of mice immunized with 
TER119-BBOX-OVA + CpG.  A) Infection timeline; Mice were first immunized as in Fig. 4 
and a week after the last boost all mice including naive untreated mice were infected with 
10000CFU bacteria expressing the OVA antigen. The spleens and livers were harvested 3 days 
later. B) Bacteria growth on agar plates. The organs were homogenized to single cell 
suspensions in PBS and 100μl of the homogenate was plated on Brain Heart Infusion agar 
plates. Representative liver plates from mice immunized with TER119-BBOX-OVA + CpG 
(top) OVA + CpG (middle) and untreated naive mice (bottom) are shown. C) Absolute 
numbers of bacteria in spleen (left) and liver (right) based on the number of colonies on the 
plates calculated by the following formula: CFU total= (number of colonies * 40ml total 
homogenate)/0.1ml homogenate plated. Statistical analysis of data with  “Bonferroni’s 
Comparison test” ***p<0.0001 *p<0.05 
2.5. Discussion  
Targeting hepatic cells and raising local, cytotoxic specific responses that can 
overcome the tolerogenic environment of the liver is challenging. In this study we 
explored the effect of recombinant proteins bound to erythrocytes in liver vaccination. 
We show that a fusion protein composed of an erythrocyte binding domain, a danger 
signal and an antigen co-administered with a strong adjuvant can activate cytotoxic T 
cells in the liver. These cells have a memory phenotype and the capacity to clear 
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intracellular hepatic pathogens. Our results demonstrate that a prime-boost vaccination 
with TER119-BBOX-OVA + CpG significantly improves the IFNγ secretion in the 
liver by 6-fold compared with the non-erythrocyte bound antigen OVA + CpG and by 
3-fold compared with TER119-OVA + CpG without BBOX. The potency of TER119-
BBOX-OVA + CpG in vaccination is further proved by the clearance of the Listeria 
infected cells in the liver within 72 hrs after infection, which precedes the time 
required for infiltration of T cells from other organs. Most importantly, TER119-
BBOX-OVA + CpG induces effective memory cells in the liver that last for at least 5 
weeks and can be reactivated upon recall with the same antigen. Overall, we were able 
to overcome the tolerogenic fate of activated CD8+ T cells and to promote the 
cytotoxic activation of CD8+ T cells with a memory phenotype intrahepatically.   
 
Our technology uses the i.v. route to deliver the antigen directly to the liver. 
Recent studies have shown that the i.v. route of immunization induces a more robust 
response in the liver and the spleen compared to other routes of administration [28]. 
The main challenge with i.v. injections is to prevent the free protein from immediate 
clearance, as it is the case with soluble OVA. Binding the antigen onto erythrocytes 
prolongs its circulation in the blood and in combination with the slow blood flow in the 
liver, increases the exposure time to hepatic immune cells and thus the uptake and the 
activation of the CD8+ T cells locally. To further enhance the cytotoxic CD8+ T cells 
responses and prevent the cells from exhaustion and apoptosis, we gave a subcutaneous 
boost injection that resulted in increased cytokine secretion of the activated CD8+ T 
cells and developed an effector memory phenotype, seen by CD44+ CD62L- 
populations in CD8+ T cells in the spleen and liver. Overcoming the obstacle of liver 
tolerance and the clearance by apoptosis of the activated CD8+ T cells is of great 
importance and adds significant value to our erythrocyte-binding platform.  
 
The choice of BBOX and the co-administration of the protein with the CpG-B 
adjuvant were critical for the immunogenic outcome of the vaccine. HMGB1 and its 
active domain BBOX are endogenous DAMPs released by necrotic cells that can 
induce maturation of DCs. Uptake of BBOX by APCs causes the release of 
proinflammatory cytokines such as TNFα, IL-6, IL-8 and IL-12 in vivo by RAGE 
binding and signaling, leading to activation of the NF-κb pathway [29]. According to 
the literature, HMGB1 triggers a sustained and strong inflammation only when it forms 
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complexes with PAMPs (LPS, TLR9 agonists) or cytokines (IL-1β) [30]. Our results 
confirm the above as TER119-OVA + CpG (a TLR9 ligand) produced 3 times less 
IFNγ in the liver of vaccinated mice than TER119-BBOX-OVA + CpG, and TER119-
BBOX-OVA without the CpG was not sufficient to raise cytotoxic CD8+ T cells both 
in the spleen and the liver. Only the combination of the two danger signals in TER119-
BBOX-OVA + CpG vaccinations activated cytotoxic CD8+ T cells, as seen by the 
vaccine experiment in Fig. 4 and the memory recall in Fig. 5.  
 
One of the limitations in subunit vaccines compared with live vaccines is that 
they are poor activators of CD8+ T cells, mainly due to insufficient crosspresentation 
of the antigen by the appropriate APC type. We overcame this obstacle with our 
erythrocyte-binding platform, which, according to previous studies, enables very 
efficient crosspresentation to CD8+ T cells. In particular, TER119-BBOX-OVA + CpG 
is crosspresented to CD8+ T cells both in the spleen and the liver and enhances the 
proliferation of adoptively transferred OTI T cells by increasing their population by 4 
fold as compared to OVA + CpG. Interestingly, the addition of BBOX within TER119-
BBOX-OVA decreases the proliferation capacity compared to TER119-OVA, most 
probably due to less efficient binding of the first protein to red blood cells related with 
the folding properties of the two proteins. In addition to effective crosspresentation, the 
advantage of the erythrocyte-binding platform is the direct targeting of the antigen to 
the liver and the uptake of the protein by different APC types. Biodistribution studies 
showed that TER119-BBOX-OVA with or without CpG was preferentially taken up by 
the APCs in the liver and upregulated the costimulatory molecule CD80.  
 
Uptake by the appropriate cell type determines the crosspresentation to CD8+ T 
cells and their activation to effector cytotoxic T cells [31]. In particular, hepatocytes 
take up TER119-BBOX-OVA and TER119-BBOX-OVA + CpG better than any other 
treatment. Although the primary role of hepatocytes is in metabolism, there is evidence 
that hepatocytes express MHC I and under inflammatory conditions also MHC II [32, 
33] and as such they can participate in T cell activation[34, 35]. Also, uptake by 
hepatic stellate cells is increased in these two groups. This is particularly interesting 
since the role of HSCs in activating T cells is controversial, but one study has 
demonstrated that HSC can activate CD8+ T cells within the liver [36, 37]. The 
upregulation of CD80 in HSCs by TER119-BBOX-OVA and TER119-BBOX-OVA + 
 47 
CpG further supports their possible role in activation of CD8+ T cells in our studies. 
Interestingly, reduced uptake in the BBOX groups compared to other groups is 
observed by KCs, which represent the biggest phagocytic population in the liver [38] 
and as such they have the potential to be good APCs [39]. Furthermore, we could not 
detect upregulation of costimulatory molecules in this subset. The uptake by liver DCs 
is enhanced in TER119-BBOX-OVA and even more in TER119-BBOX-OVA + CpG 
mice with simultaneous upregulation of costimulatory molecules (CD80). Liver DCs 
can internalize blood-derived pathogens and, depending on the subtype, they can 
stimulate T cells [40]; however, the activation is less efficient compared to DCs from 
other tissues [41, 42]. Finally, we believe that the preferential uptake of TER119-
BBOX-OVA proteins by LSECs is critical for the activation of CD8+ T cells in the 
liver.  LSECs can internalize cellular debris, and they express MHC I and II [43]. As 
such, they can directly present to T cells [44, 45]. Uptake by these cells and 
simultaneous upregulation of the CD80 costimulatory molecule in the TER119-BBOX-
OVA and TER119-BBOX-OVA + CpG groups indicates their possible contribution of 
this cell type in CD8+ T cell activation. 
 
Immunization with TER119-BBOX-OVA + CpG is very efficient in CD8+ T 
cell activation in the liver but less so in CD4+ T cell activation in the liver 
compartment. Ex vivo restimulation with the full OVA protein resulted in minimal 
cytokine secretion by CD4+ T cells indicating their non-effective status in the liver, a 
result that requires further exploration as CD4+ T cells are required to ensure the 
survival of CD8+ T cells [46]. However, CD4+ T cells are activated in other organs 
raising antibodies against OVA in all groups, adding value to the potency of our 
vaccine platform. A vaccine that can raise both humoral and cellular responses has 
great potential in dealing with viruses infecting cells as well as viruses circulating 
systemically. 
  
Other approaches from other groups have been explored to raise CD8+ T cells 
in subunit vaccination. A similar study has used short peptide epitopes, not the full 
protein, and conjugated them to TLR ligands prior to injection to raise immune 
responses in the liver without though the induction of IgGs [15]. Also in malaria 
vaccination trials, the originally raised CD8+ T cells by a CD8 epitope of the CS 
malaria antigen of P.yoelii proliferated but did not survive in the liver without the help 
 48 
of CD4+ T cells [46]. Peptide and protein based therapeutic vaccine formulations have 
also failed in inducing CD8+ T cell responses in patients with chronic hepatitis B 
infection mostly due to the insufficient CD8+ T cell activation [47].  
 
Overall, we have developed a novel vaccine platform that can efficiently target 
the liver, crosspresent the antigen to CD8+ T cells and raise local antigen specific 
immune responses. Furthermore, we have succeeded in retaining the effector 
phenotype of these activated cells and preventing them from clearance; a challenge for 
most CD8 liver vaccines that need to deal with persistent infections. The simplicity in 
recombinant production allows any antigen to be cloned and produced as a fusion 
TER119 protein not only in mice but also in human with a different scFv (TER119 
binds only murine glycophorin A). The erythrocyte binding technique serves as a 
potential approach for the development of hepatic vaccines both for prophylactic and 
therapeutic treatment. Given the fast clearance of listeria-infected cells within 72 hr, 
we believe that this vaccine may find application in malaria, where the mosquito bite 
infection resembles that of listeria. Also, the direct liver targeting and the induction of 
local responses suggests that a TER119-BBOX-Ag immunization may be sufficient to 
deal with established infections, such as chronic hepatitis B, or liver carcinomas in 
therapeutic cancer vaccination.  
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Injection Site 
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3.1. Introduction  
?
The idea that cells of the immune system can suppress tumor development was 
first proposed by Paul Ehrlich in the early 1900s [1] and led to the cancer immune 
surveillance hypothesis of Burnet [2], that the immune system can suppress cancerous 
cells and prevent tumor progression before they cause harm to the body. Since then, 
research in the field has revealed that cytotoxic T lymphocyte (CTL) responses play a 
major role in tumor eradication, and it is widely accepted that CD8+ T cells are 
necessary in dealing with transformed cells [3]. As a result, current research focuses on 
eliciting strong antitumor CD8+ T cell responses for the prevention as well as the 
treatment of malignancies, using different vaccination strategies. A large variety of 
different methodologies has been tried in the past years both in prophylactic and 
therapeutic vaccination, including – but not limited to – immunization with peptides 
and recombinant proteins [4]. Examples of protein vaccines that are prepared based on 
tumor-associated antigens (TAAs) include vaccination with prostatic acid phosphatase 
(PAP) fused to the human cytokine GM-CSF [5, 6], fusion of the MAGE-A3 tumor 
antigen with lipoprotein D from H. influenza [7] and epitope like IgG antibody 
vaccination with the ovarian tumor associated antigen CA-125 [8]. 
 
The mechanisms required to mount effective antitumor responses can be 
described in three steps. First, antigen presenting cells (APCs) must capture and 
present TAAs. Key players in these mechanisms are the dendritic cells (DCs), where 
different cellular subtypes can process the antigen, load on either MHC class I or II and 
display to CD8+ or CD4+ T cells respectively. Studies have shown that the DC 
subtypes have different functional specializations and, in particular, that specific DC 
subtypes can determine the type of immune response generated [9]. Following antigen 
uptake by the appropriate cell type, maturation of DCs in response to stimuli such as 
Toll-like receptors is required for migration to the T cell areas of lymphoid organs and 
presentation of antigen to naïve T cells. Finally, activation and expansion of T cells in 
sufficient numbers is necessary to recognize and eliminate tumor cells. These antigen-
educated T cells must then exit the lymph node (LN), traffic to the tumor and kill the 
malignant cells. Tumor immunotherapy studies aim to induce immune responses 
against TAAs following these mechanisms [10]. 
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Recent advances in CD8+ vaccines focus towards induction of Th1 responses 
by direct cross-presentation of an antigen to CD8+ T cells [11]. A subset of lymphoid 
DCs, called CD8+ DCs, resides in the spleen and LNs and, together with the skin 
migratory CD103+ DCs, excels in cross-presentation and cross-priming of CD8+ T 
cells [12-14]. Studies have shown that these subsets can take up exogenous antigens 
and present them on class I MHC. Through this process, CD8+ DCs directly cross 
prime CD8+ T cells and induce a CTL response. The CD8+ DC subset exists both in 
mice and humans and is distinguished by the specific markers expressed on the surface 
of the cells, namely CD8, DEC205, Clec9A and XCR1 [15].  
 
Elegant strategies in the past have employed methods for targeting CD8+ DCs 
using antibodies against the molecules expressed on the surface of the cross-presenting 
DCs. The first example comes from the Ralph Steinmann group where monoclonal 
antibodies (mAbs) were fused with antigens and were targeted to the DEC205 
endocytosis receptor [16]. Co-administration of the αDEC205:OVA fusion protein 
with an agonistic αCD40 antibody to mature DCs resulted in efficient activation and 
cytokine release of CD8+ T cells after a single s.c. injection. However, DEC205 is not 
only expressed in CD8α+ DCs but also in other conventional DCs (cDCs), Langerhans 
cells, interstitial DCs and thymic epithelial cells, and as such the efficiency of the 
vaccine was not optimal [17]. Similar studies were performed with the surface C-type 
lectin-like molecule Clec9A, which is selectively expressed by mouse CD8+ cDCs. In 
particular, it was first shown that targeted delivery of antigen fused mAbs against 
mClec9A raised antigen-specific antibodies and resulted in proliferation of adoptively 
transferred OTI (transgenic CD8+ T cells with a T cell receptor specific for an 
ovalbumin epitope SIINFEKL) and OTII (transgenic CD4+ T cells with a T cell 
receptor specific for an ovalbumin epitope ISQAVHAAHAEINEAGR) cells, without 
the normal activation of DCs [18]. Similar studies targeting short peptides to the same 
molecule (called by them DNGR-1 that is also expressed in humans) showed enhanced 
cytotoxicity of CD8+ T cells and tumor regression after vaccination [19]. While Clec9a 
is mainly expressed on CD8α+ DCs, it is also found at low levels on plasmacytoid DCs 
(pDCs) [20, 21]. 
More recent studies have focused on targeting the chemokine receptor XCR1 
receptor that is exclusively expressed on lymphoid tissue (LT) derived resident CD8+ 
DCs and migratory CD103+ DCs of mice (and the expression is conserved on the 
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CD141+ DCs in humans [22, 23]); all known to excel in cross-presentation of antigen 
to CD8+ T cells. XCL1, the specific chemokine ligand for XCR1, is a chemoattractant 
of CD8+ DCs [24, 25] and has been used by several groups as a target molecule for 
direct delivery to cross-presenting DCs in tumor regression experiments and influenza 
virus protection. In a recent study, XCL1-OVA fusion proteins were used to target 
CD8+ DCs in the spleen and LNs of C57BL/6 mice, in a prophylactic vaccine [26]. 
Together with the co-administration of lipopolysaccharide (LPS), potent cytotoxic 
CD8+ T cells responses resulted in IFNγ secretion and prevention of EL4 tumor (a 
murine T cell lymphoma) growth in a prophylactic vaccine context. In another study, 
dimeric fusions of XCL1 and the PR8 influenza virus antigen were used in DNA 
vaccination [27]. A single intradermal injection resulted in effective IFNγ cytokine 
production and protection after challenge with the influenza virus. Overall, these recent 
studies have shown very promising results for CD8+ T cell-targeted vaccination by 
targeting the cross-presenting CD8+ DCs.  
 
Given the positive results presented in the literature with the XCL1 fusion 
proteins, we aimed to further improve the efficacy of the XCR1-targeting vaccines by 
increasing the number of CD8+ DCs at the injection site and thus enhance the uptake of 
antigen. In particular, we fused XCL1 to the placenta growth factor-2 (PlGF-2) growth 
factor (GF) domain (PlGF-2123-144) that binds the extracellular matrix (ECM) with high 
affinity [28]. Our hypothesis was based on previous studies that showed prolonged 
retention of the fusion proteins comprising this PlGF-2 domain in the ECM by non-
covalent binding with dissociation constants in the 1-10 nM range [29, 30]. Fusion of 
XCL1 to this PlGF-2 domain promoted the chemotaxis of crossprestning DCs at the 
skin site following an intradermal injection. Direct targeting of the antigen to the cross-
presenting DCs was then accomplished by co-administration of XCL1-PlGF-2123-144 
(referred to hereinafter simply as XCL1-PlGF) with a fusuion protein of XCL1 and the 
model protein antigen ovalbumin (XCL1-OVA). Following two intradermal 
immunizations of XCL1-OVA + XCL1-PlGF with the adjuvant polyI:C (an agonist for 
Toll-like receptor 3, TLR3), CD8+ T cells were activated in the secondary immune 
organs of C57BL/6 mice and cytolytic antigen-specific immune responses were raised. 
We evaluated our platform by a prophylactic and therapeutic B16-OVA (the murine 
melanoma line B16F10 expressing OVA as a model TAA) treatment, and we found 
prolonged survival of tumor-bearing mice in both cases. Overall, attraction of CD8+ 
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DCs to the injection site and simultaneous targeting of the antigen to the cross-
presenting DCs enhanced the cytolytic activity of CD8+ T cells and raised potent 
immune responses in a vaccination context, showing promising results for tumor 
treatment.    
 
3.2. Materials and Methods 
 
Animals. Female C57BL/6J mice were purchased from Harlan and female Balb/c and 
Ly5.1 (CD45.1) mice were purchased from Charles River Laboratories. All mice were 
aged between 8-12 weeks and kept under pathogen free conditions at the animal 
facility of Ecole Polythechnic Fédéral de Lausanne. Female C57BL/6-Tg(TcraTcrb) 
1100Mjb (OTI) mice between 8-15 weeks that were used for isolation of splenocytes 
were bred under specific pathogen-free conditions (SPF). The Veterinary Authority of 
the Canton de Vaud has approved all procedures and experiments. 
 
Proteins and Recombinant protein production. Murine XCL1 was purchased from 
SinoBiological. The DNA sequences coding for XCL1-OVA and XCL1-PlGF were 
purchased from Mircrosynth DNA. The PlGF sequence includes the amino acids in 
positions 123-144 described by Martino et. al. [28] and is the following:   
“RRRPKGRGKRRREKQRPTDCHL”. Both XCL1-OVA and XCL1-PlGF sequences 
were introduced into the pXLG plasmid for mammalian expression. A 6 histidine tag 
sequence was inserted to the 3’ end of XCL1-OVA to facilitate purification. No tags 
were inserted in the XCL1-PlGF sequence. HEK cells were transfected with either 
XCL1-OVA or XCL1-PlGF constructs under serum free conditions with 3.75 mM 
valproic acid (Sigma-Aldrich), and after 7 days the proteins in suspension were 
purified with immobilized metal affinity chromatography. XCL1-OVA was processed 
using a HiTrap HP His-tag column (GE Healthcare) and XCL1-PlGF was purified with 
a heparin-binding column (GE Healthcare) using 1 M NaCl for elution. The purified 
proteins were analyzed for purity using SDS/PAGE, endotoxin levels were assessed in 
THP-1 x Blue cells (InvivoGen), and concentration was measured using bicinchoninic 
acid assays (Thermo Scientific). The final product was sterile-filtered, and stored at -80 
°C in working aliquots. 
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XCL1-PlGF binding to ECM in vitro and in vivo. For in vitro binding, ELISA plates 
(Nunc Max- iSorp; Thermo Fisher Scientific) were coated with 50 nM of XCL1-PlGF 
or XCL1 overnight at 4 oC and subsequently blocked with 2% (wt/vol) BSA (Enzyme 
Research Laboratories) in PBS-Tween 20 (PBS-T, 0.05%) for 1 h at room temperature. 
Wells were washed with PBS-T and further incubated with 100 nM fibrinogen in PBS-
T with 0.1% BSA for 45 min at room temperature. After three washes with PBS-T, 
wells were incubated with anti-fibrinogen antibody conjugated to HRP (ab7539; 
Abcam) for 45 min. The binding was detected with tetramethylbenzidine substrate 
(Thermo Scientific) and the absorbance was measured at 450 nm. For in vivo binding, 
XCL1-PlGF and XCL1 were labeled with an Alexa 750 fluorophore (Dyomics) in a 
protein:dye molar ratio of 1:10, and incubated for 1hr at room temperature. The free 
dye was removed by centrifugation with Zeba columns (Thermo Scientific). All 
reactions were performed under sterile conditions to protect from endotoxin 
contamination. The Balb/c mice were injected with 3 μg of XCL1-A750 on one 
footpad and 3,3 μg of XCL1-PlGF-A750 on the opposite. Live imaging with the IVIS 
sprectrum was performed at different timepoints, namely 0, 4, 12, 24, 48 hr post 
injection. The emission and excitation wavelengths were set at 800 and 745nm 
respectively and the exposure time at 0.5 s. The images were analyzed with the IVIS 
software.   
 
CD8+ DCs skin count and antigen uptake. C57BL/6 mice were injected in all 4 
footpads with 3 μg XCL1 or 3.3 μg XCL1-PlGF and were sacrificed 4 and 12 hr after 
the injection. The skin around the injection site was cut and digested for further 
processing. Briefly, the skin tissues were incubated at 37 oC for 1 hr with 105 units/ml 
of Liberase DH mixed with 10% FBS and 1% penicillin, streptomycin (Invitrogen) in 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco). The tissue was smashed with a 
syringe plunge and was passed through a 70 μm strainer for a final resuspension in 
DMEM medium and preparation for staining. The draining LNs were collected and 
processed for staining as described in the tissue preparation section. For the uptake 
experiment, XCL1-OVA, XCL1-PlGF and OVA were labelled with the Alexa 488 
fluorophore (Dyomics) as described above. The mice were injected with 20 μg OVA + 
20 μg CpG-B, 23 μg XCL1-OVA + 20 μg CpG-B or 23 μg XCL1-OVA + 3.3 μg 
XCL1-PlGF + 20 μg CpG-B and the LNs (axillary, branchial and inguinal) and spleen 
were collected for processing and staining 48 hr later, as described in other sections. 
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Briefly, skin DCs were labeled with CD103 (1:200), CD11c (1:200), CD11b (1:200) 
and CD3 (1:100) antibodies purchased from eBioscience. Similarly, LNs were labelled 
with CD8 (1:200), CD11c (1:200), CD11b (1:200) and CD3 (1:100) antibodies. 
 
Adoptive transfer experiment. OTI T cells were isolated from splenocytes of female 
CD45.2+ mice, between 12-16 weeks old, using a CD8 magnetic bead negative 
selection kit (Miltenyi Biotec). The isolated CD8+ OTI cells were incubated with 1 μM 
CFSE (Invitrogen) for 6 min at room temperature, and the reaction was quenched with 
an equal volume of Iscove’s modified Dulbecco’s medium (IMDM) with 10% 
(vol/vol) FBS (Gibco). Before injection, cells were resuspended in pure IMDM to a 
final concentration of 107 cells/ml. A total of 100 μl were injected i.v. into the tail vein 
of recipient female Ly5/ CD45.1+ mice, 8 weeks old. The following day the mice 
received an i.d. injection of 20 μg OVA, 23 μg XCL1- OVA or 23 μg XCL1-OVA + 
3.3 μg XCL1-PlGF all mixed with 10 μg polyI:C, and were sacrificed 4 days later. The 
axillary, branchial and inguinal LNs and spleen were collected, processed and stained 
with CD45.2 (1:200), CD8 (1:200) and CD3 (1:300) for flow cytometry as described in 
other sections. 
 
Immunizations. 8 week old female C57BL/6 mice were immunized under isofluorane 
anesthesia (5% for induction and 2% for maintenance) on day 0 and 14 with an 
intradermal injection of 20 μg OVA + 20 μg polyI:C, 23 μg XCL1-OVA + 20 μg 
polyI:C, 20 μg OVA + 3 μg XCL1 + 20 μg polyI:C, 20 μg OVA + 3.3 μg XCL1-PlGF 
+ 20 μg polyI:C or 23 μg XCL1-OVA + 3.3 μg XCL1-PlGF + 20 μg polyI:C or just 
saline. 5 days after the boost mice were euthanized, and the axillary, branchial and 
inguinal LNs and spleen were collected for ex vivo restimulation and staining as 
described in other sections. 
 
Tissue and cell preparation for ex vivo restimulation of lymphocytes. Splenocytes 
were obtained by disruption of the spleen through a 70-μm cell sieve and subsequent 
red blood cell lysis with 0.155 M NH4Cl. The lymph nodes were digested for 30 min 
with 2 mg/mL Collagenase D (Roche) in IMDM, and passed through a 70-μm cell 
sieve to obtain single cell suspensions. All organs were kept in Dulbecco’s Modified 
Eagle Medium (DMEM) (Gibco) supplemented with 10% FBS and 1% penicillin, 
streptomycin (Invitrogen). For CD8+ T cell-specific restimulation and intracellular 
cytokine staining, cells were first cultured for 3 hr at 37 °C in the presence of 1 μg/mL 
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SIINFEKL, 104 U/ml IL2, and 0.5 μg anti-CD28 (eBioscience), and subsequently for 3 
hr with the addition of 250 μg/mL brefeldin A (SigmaAldrich). For CD4+ T cell 
restimulation, 104 U/ml IL2, 0.5 μg anti-CD28 and 100 μg/mL OVA VI (Sigma-
Aldrich) protein were added to the cells for 3 h, followed by incubation with 50 μg/mL 
brefeldin A for another 12 hr.  
 
Flow cytometry staining. For the detection of live cells, cells were suspended at a 
concentration of 106 cells in 200μl, washed with PBS, and labeled with live/dead 
fixable cell viability reagent (Invitrogen). Subsequently, the cells were incubated for 20 
min on ice with PBS/2% FBS solutions of the surface markers CD3 (1:100) and CD8 
(1:200) or CD4 (1:200). For intracellular cytokine staining, cells were fixed in 2% 
paraformaldehyde solution, washed with 0.5% saponin (SigmaAldrich) in PBS/2% 
FBS, and incubated with the IFNγ (1:200) or TNFα (1:200) antibody diluted in saponin 
solution for 30 min on ice. Finally, the cells were resuspended in PBS/2% FBS for 
analysis. Samples were processed on CyAn ADP Analyzer (Beckman Coulter) and 
data were analyzed with FlowJo software (Tree Star). The antibodies against mouse 
CD3, CD4, CD8, IFNγ and TNFα were purchased from eBioscience.   
 
Tumor inoculations. Mice were anesthetized with isoflurane (5% for induction and 
2% for maintenance) and their backs were shaved. For the therapeutic treatment, 2.5 x 
105 B16-OVA melanoma cells were injected i.d. on the back of each mouse followed 
by 7 consecutive injections every 4 days of 20 μg OVA + 20 μg polyI:C, 23 μg XCL1-
OVA + 20 μg polyI:C or 23 μg XCL1-OVA + 3.3 μg XCL1-PlGF + 20 μg polyI:C. 
For the prophylactic treatment mice were vaccinated with 20 μg OVA + 20 μg polyI:C, 
23 μg XCL1-OVA + 20 μg polyI:C or 23 μg XCL1-OVA + 3.3 μg XCL1-PlGF + 20 
μg polyI:C on day 0 and 14 and 5 days later 2.5 x 105 B16-OVA melanoma cells were 
injected i.d. on the back of each mouse. Tumors were measured every 2 days with a 
digital caliper starting 4 d post-inoculation, and volumes (V) were calculated as 
ellipsoids (V = π/6 x length x width x height). Mice were sacrificed when tumor 
volumes reached 1 cm3 as required by Swiss law. 
 
Data Analysis. All flow cytometry data were analyzed using FlowJo (v8.8.6). Graphs 
and statistical analyses of data were performed using Prism (v5, GraphPad). The 
statistical significance was determined by one way ANOVA – Bonferoni test or t-test 
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with Welch correction, as indicated in each figure separately. The asterisks indicate the 
significance as follows: *p<0.05, **p < 0.01, ***p < 0.001. 
 
3.3 Results and Figures 
?
3.3.1. PlGF-2123-144 fusion prolongs XCL1 retention at injection site through ECM 
binding.  
The heparin-binding sequence of placenta growth factor-2, PlGF-2123-144, binds 
strongly to the ECM with an equilibrium dissociation constant Kd of 1.9nM, as shown 
in previous studies [28]. We hypothesized that we could form a reservoir for attracting 
CD8+ DCs by maintaining the presence of the XCL1 chemokine ligand at the site of 
injection through ECM binding. Thus, we engineered a fusion of PlGF-2123-144 with 
XCL1 and expressed the recombinant protein, XCL1-PlGF, in HEK cells. To assess in 
vivo ECM binding, XCL1-PlGF was conjugated with Alexa 750 fluorophore and 
injected i.d. into the footpad of Balb/c mice. As a control, XCL1 alone was conjugated 
with Alexa 750 fluorophore and injected i.d. into the opposite footpad of the same 
Balb/c mouse, as seen in Figure 1A. The fluorescence intensity of both proteins was 
measured using an IVIS Spectrum imaging system at various time points over 48 hours 
(Fig 1B). XCL1-PlGF binds to the ECM and remains at the injection site for at least 2 
days, whereas the fluorophore intensity of XCL1 diffuses during time, indicating 
limited binding to the site of the injection. Imaging of the footpad draining LNs with 
the IVIS Spectrum 48 hr after the injection confirmed the diffusion of XCL1 towards 
the LNs as seen by the fluorescent XCL1-LNs versus fluorescence-absent XCL1-PlGF 
LNs (Fig. 1C). In vitro, XCL1-PlGF binds to an example ECM molecule, fibrinogen, 3 
times better than XCL1 alone as confirmed by ELISA measurements (Fig. 1D).  The 
above data suggest that XCL1-PlGF can remain at the site of the injection for at least 
48 hr and potentially allow XCR1+ DCs to sense and migrate locally.  
 
62 
Figure 1: XCL1-PlGF binds to the extracellular matrix in vitro and in vivo and remains 
bound at the injection site for at least 48 hr. A) Live imaging by IVIS spectrum of Balb/c 
mice injected with 3μg XCL1 on the right footpad and equimolar amount of XCL1-PlGF on 
the left footpad, both conjugated to Alexa 750 fluorophore. Images at injection time t=0 (left 
mouse) and t=48 hr (right mouse) show the fluorescence intensity of XCL1-PlGF (left footpad) 
and XCL1 (right footpad). B) Median fluorescence intensity calculated at different time points 
by the IVIS spectrum software. C) XCL1-A750 drainage to the popliteal lymph node (right 
tube). XCL1-PlGF remains at the injection site (left tube) 48 hr after injection (fluorescent free 
LN). D) In vitro binding of XCL1-PlGF to the ECM protein fibrinogen, measured by an 
ELISA assay. 
3.3.2. XCL1-PlGF recruits cross-presenting DCs to the site of injection.  
The cross-presenting DCs of the epidermis that express the CD11c and CD103 
surface markers represent 1% of the total skin DC population of naïve C57BL/6 mice 
[14]. Therefore, the competition for antigen uptake by other APCs is a limiting factor 
for the CD8+ T cell-targeting vaccine efficacy. We hypothesized that the prolonged 
presence of the XCL1 chemokine ligand bound to the ECM would allow skin CD8+ 
DCs to sense and migrate towards the XCL1 location and that this would enhance the 
preferred uptake of the antigen by the concentrated cross presenting DCs. We tested 
our hypothesis by measuring the skin DC populations at different time points after 
injection of either XCL1-PlGF or XCL1 alone. We found that 4 and 12 hr after the 
injection of XCL1-PlGF, the percentage of CD103+ cross-presenting skin DCs 
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increased by 2 and 5-fold, respectively, compared to the naïve C57BL/6 untreated 
mice. Fewer cells accumulated at the site of XCL1 injection (Fig. 2A). Similar 
measurements of CD8+ DCs in the LNs of the same mice revealed no differences 
among the populations at any time point indicating migration of DCs only at the skin 
site and not towards the LNs. (Fig. 2B).  
 
Figure 2: XCL1-PlGF attracts crosspresenting DCs to the site of injection. Naive C57BL/6 
mice where injected i.d. with equimolar XCL1 or XCL1-PlGF. 12 and 4 hr post injection, skin 
and skin draining LNs were stained for cross-presenting DCs. A. Skin samples were cut around 
the injection site and stained for CD11c+ CD103+ live cells. B. Skin draining LNs from all 4 
footpads were harvested and stained for CD3- CD11c+ CD8+ live cells. 
3.3.3. XCL1-PlGF mixed with XCL1-OVA enhances antigen uptake by cross-
presenting DCs and promotes cross-priming of CD8+ T cells.  
Given the positive results for attraction of CD8+ DCs at the skin site, we further 
investigated whether the increased number of DCs capable for cross-presentation at the 
site of injection would lead to enhanced uptake of the antigen and further promote the 
cross-presentation to CD8+ T cells. In order to target the antigen directly to the cross-
presenting DCs, OVA was fused to the XCL1 ligand and the XCL1-OVA fusion 
protein was expressed in HEK cells. XCL1-OVA was labeled with Alexa 488 
fluorophore and injected i.d. with or without XCL1-PlGF. As control, OVA alone was 
conjugated with Alexa Fluor 488 and injected as above. Consistent with previous 
studies, the XCL1-OVA fusion protein increased the uptake of the antigen by 3.5-fold 
compared with OVA. Co-administration of XCL1-PlGF with XCL1-OVA further 
enhanced the uptake by CD8+ DCs in the LNs resulting in a 4-fold increase compared 
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to OVA (Fig. 3A) but without significant difference compared to the XCL1-OVA 
group .  
 
It has been previously demonstrated that uptake of an antigen by cross-
presnting DCs promotes cross-priming of CD8+ T cells [24, 31]. Given the effective 
uptake of the OVA antigen by the XCL1-OVA and XCL1-OVA + XCL1-PlGF 
administration, we evaluated the cross-presentation efficiency of our fusion proteins 
following an adoptive transfer experiment with OTI CD8+ T cells. In particular, we 
adoptively transferred OTI T cells into Ly5 CD45.2 mice and 24 hr later we 
immunized the mice with 23 μg XCL1-OVA, 23 μg XCL1-OVA mixed with 3.3 μg 
XCL1-PlGF or 20 μg OVA alone; all groups were co-administered with 20 μg polyI:C. 
The increase in the OTI population in the spleen and LNs of all mice 4 days after the 
immunization was measured as an indicator of effective cross-presentation to CD8+ T 
cells. OTI populations in both the XCL1-OVA and the XCL1-OVA + XCL1-PlGF 
groups had quadrupled in the spleen (Fig. 3B) and tripled in the LNs (Fig. 3C), 
compared with the OVA-injected mice. However, no differences in OTI population 
were observed between XCL1-OVA and XCL1-OVA + XCL1-PlGF immunizations. 
Collectively, the above results suggest that immunization with XCL1-PlGF mixed with 
XCL1-OVA may lead to enhanced uptake of the antigen and promote cross-
presentation to CD8+ T cells; a desirable effect for CD8+ T cell-targeted vaccination. 
3.3.4. Enhanced cytolytic activity of CD8+ T cells in the LNs of mice vaccinated 
with XCL1-OVA + XCL1-PlGF.  
Effective vaccination for the prevention or therapeutic treatment of viral 
infections and tumors requires potent activation of cytolytic responses from CD8+ T 
cells. XCL1-OVA mixed or not with XCL1-PlGF is effectively taken up by CD8+ DCs 
and promotes cross-prentation to CD8+ T cells. We evaluated whether the addition of 
XCL1-PlGF to XCL1-OVA immunizations would further increase the cytotoxicity of 
the activated CD8+ T cells compared to XCL1-OVA alone that has been shown by 
others to excel in CD8+ T cell-targeted vaccines. Female C57BL/6 mice were 
immunized with a prime-boost vaccination on day 0 and 14 with 20 μg OVA, 23 μg 
XCL1-OVA, 20 μg OVA + 2 μg XCL1, 20 μg OVA + 3 μg XCL1-PlGF or  23 μg 
XCL1-OVA + 3 μg XCL1-PlGF all mixed with 20 μg polyI:C (Fig. 4A). A single i.d. 
immunization increased by 3-fold the population of SIINFEKL pentamer+ cells in the  
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Figure 3: XCL1-PlGF + XCL1-OVA  enhances the uptake of antigen by CD8+ DCs and 
cross-primes to CD8+ T cells. A) OVA and XCL1-OVA were conjugated with an Alexa 488 
fluorophore. The mice were injected i.d. with 20μg OVA or equimolar amounts of XCL1-OVA 
or XCL1-OVA + XCL1-PlGF and all groups were mixed with 20μg CpG. The uptake of the 
antigen by CD8+ DCs in the LNs was measured by flow cytometry 48hrs later. Gate on live 
cells, CD11c+ CD8+ (*P<0.05). B and C) 106 OTI splenocytes were adoptively transfered to 
naive Ly5 C57Bl/6 mice and 24 hours later the mice were injected  i.d. with 20μg OVA or 
equimolar amounts of XCL1-OVA or XCL1-OVA + XCL1-PlGF. The proliferation of OTI T 
cells was measured by flow cytometry as a percentage of CD45.2+ cells (gate on CD3+ CD8+ 
live cells) in the (B) spleen and (C) LNs (***P<0.0001) 
circulation of mice injected with XCL1-OVA + XCL1-PlGF compared with XCL1-
OVA 7 days after the injection (Fig. 4B). Furthermore, the activated SIINFEKL 
pentamer+ cells displayed an effector phenotype, as measured by CD44+ CD62L- 
staining of pentamer+ cells and flow cytometry (Fig. 4C). These results show an 
advantage in cross-presentation to CD8+ T cells in the presence of XCL1-PlGF. 
Processing of the LNs 6 days after the boost injection revealed enhanced 
cytotoxicity of the CD8+ T cells in the mice vaccinated with XCL1-OVA + XCL1-
PlGF. In particular, the axillary, branchial, popliteal and inguinal LNs of the mice were 
collected and restimulated ex vivo with SIINFEKL for 6 hr followed by staining for 
IFNγ and TNFα CD8+ T cells. Vaccination with XCL1-OVA + XCL1-PlGF caused a 
significant increase in the cytolytic activity of CD8+ T cells in the LNs as indicated by 
the 1.5- and 2-fold enhanced secretion of IFNγ (Fig, 4D) and TNFα (Fig, 4E) 
populations, respectively, compared with XCL1-OVA immunization. Overall, XCL1-
OVA + XCL1-PlGF had a clear benefit in stimulation of cytotoxic CD8+ T cell 
responses, making it an appealing platform for CD8 vaccines.  
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The activation of CD4+ T cells was further evaluated, as humoral responses and 
antibody production largely depends on this subset. The pool of LNs was restimulated 
with the full OVA protein for 12 hr and stained for IFNγ+ and TNFα+ CD4+ T 
lymphocytes. Interestingly, we found that the OVA restimulation failed to activate 
CD4+ T cells as displayed by no differences in cytokine secretion among the groups. 
More importantly, all the groups vaccinated with XCL1 alone or an XCL1 fusion 
protein had lower cytotoxicity than the OVA + polyI:C group showing no benefit of 
the XCL1 ligand in CD4+ T cell activation (Fig. 4F). Finally, the OVA specific 
antibodies were measured in the serum of vaccinated mice at the end of the 
experiment. No differences were observed among the groups, consistent with the equal 
CD4+ T cell activation (Fig. 4G). This result emphasizes the clear specificity of the 
XCL1 fusion proteins in activation of CD8+ T cells. Taken together, the above suggest 
that XCL1-PlGF mixed with XCL1-OVA is very effective in raising cytolytic T cell 
responses by cross-presenting the antigen directly to CD8+ DCs and not by the 
classical MHC II antigen presentation pathway for extracellular antigens.  
 
3.3.5. XCL1-PlGF enhances the efficacy of XCL1-OVA tumor vaccines in both a 
prophylactic and a therapeutic manner.  
In current cancer research for vaccines that can either prevent or treat tumors, 
targeting and activating CD8+ T cells is crucial for the development of effective 
antitumor therapies. Having demonstrated the clear superiority in cytotoxicity of the 
XCL1-PlGF + XCL1-OVA vaccine, we further evaluated its potency in tumor 
regression. In particular, we tested the XCL1-OVA + XCL1-PlGF vaccine formulation 
in a therapeutic and a prophylactic model of B16-OVA tumor treatment and found that 
it shows a benefit in tumor regression and overall survival compared to other groups.  
 
Following an established protocol for therapeutic vaccine treatment [32] naïve 
C57BL/6 mice were inoculated with 2x105 tumor cells and 4 days later the mice 
received consecutive i.d injections of OVA, XCL1-OVA or XCL1-OVA + XCL1-
PlGF, all mixed with 20 μg polyI:C at frequent time points; namely day 4, 7, 11, 15, 19 
and 23 (Fig. 5A). Tumor growth was followed for over a month and the volume was 
measure by a caliper using an ellipsoid formula every other day. Delay of growth (Fig. 
5B) and improved overall survival by 4 days (Fig. 5C) was observed in the XCL1-
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OVA + XCL1-PlGF group compared to the other groups, indicating the benefit of 
XCL1-PlGF in therapeutic treatment. 
 
Figure 4: XCL1-PlGF mixed with XCL1-OVA significantly increases the cytotoxicity of 
CD8+ T cells. A) Immunization schedule; Female C57BL/6 mice were injected i.d. with 20μg 
OVA + 20μg pI:C, 23μg XCL1-OVA + 20μg pI:C, 20μg OVA + 3μg XCL1 + 20μg pI:C, 20μg 
OVA + 3μg XCL1-PlGF + 20μg pI:C or 20μg XCL1-OVA + 3μg XCL1-PlGF + 20μg pI:C on 
day 0 and 14 and were sacrificed 6 days after the last boost. Blood samples were collected on 
day 7 after the first immunization. B) Activation of OVA-specific CD8+ T cells in the blood 7 
days after the prime injection, assesed by SIINFEKL pentamer stain and flow 
cytometry(**p<0.001). C) Activation phenotype of pentamer+ cells measured by CD44+, 
CD62L- staining in flow cytometry. D) LN lymphocytes were isolated and restimulated ex vivo 
for 6 h in the presence of SIINFEKL; IFN-γ and E) TNFa expression by CD8+ T cells was 
measured by intracellular cytokine staining and flow cytometry ( *p<0.01, ***p<0.0001). F) 
Ex vivo restimulation of lymphocytes with OVA for 12 hr followed by intacellular cytokine 
stain and flow cytometry, Representative data of IFNγ secretion by CD4+ T cells. G) Antibody 
titers in the serum of mice at the end of the experiment, measured by ELISA 
In prophylactic treatment, the mice were vaccinated first on day 0 and 14 with 
the same groups as in the therapeutic model, and on day 19 2x105 tumor cells were 
inoculated in the back of all groups, including an untreated naïve group (Fig. 5D). 
Consistent with the vaccination data and the therapeutic treatment, the tumor growth in 
the XCL1-OVA + XCL1-PlGF group was significantly delayed compared to XCL1-
OVA vaccination, as it remain almost at the same volume for 30 days post inoculation  
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(Fig. 5E).  Consequently, the survival of the mice in this group was prolonged by 7 and 
16 days compared to the XCL1-OVA and OVA, respectively (Fig. 5F).
Overall co-administration of XCL1-PlGF with XCL1-OVA has a beneficial 
effect in tumor treatment both therapeutically and prophylactically compared to XCL1-
OVA immunization alone and can potentially serve as a useful platform in improving 
the current CD8+ T cell-targeting vaccine design  
 
Figure 5: XCL1-OVA +XCL1-PlGF prolongs tumor growth both in therapeutic and 
prophylactic treatments. A) Therapeutic vaccination schedule; B16-OVA melanoma tumor 
cells were inoculated on day 0 and after 4 days the mice were vaccinated with 20μg OVA + 
20μg pI:C, 23μg XCL1-OVA + 20μg pI:C or 23μg XCL1-OVA + 3μg XCL1-PlGF + 20μg 
pI:C, following 5 consecutive boosts every 4 days. B) Tumor volumes calculated as ellipsoids 
(V = π/6 x length x width x height)  and C) survival curves in all groups. D) Prophylactic 
vaccination schedule; Mice were vaccinated with the same groups as in A on day 0 and 14 and 
on day 19 B16-OVA tumors cells were inoculated in mice. E) Tumor volume and H) survival 
curves. (*p<0.01, **p<0.001)    
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3.4. Discussion  
?
The aim of cancer immunotherapy is to elicit strong CTL responses against 
tumor infected cells. This has been challenging and one of the main reasons is due to 
the limited frequency of cross presenting DCs that will activate the CD8+ T cells. 
Therefore, the general aim of this study was to explore a novel platform for antigen 
targeting to cross-presenting DCs. Novel vaccines that target the antigen directly to 
cross-presenting DCs to promote cross-priming of CD8+ T cells have shown promising 
results in tumor treatment with potential application in humans. In this study we 
improved the current methodology by providing a platform for sustained attraction of 
XCR1-expressing DCs to the site of antigen administration. In particular, we fused the 
XCL1 chemokine ligand to the PlGF-2123-144 ECM-binding domain and succeeded in 
prolonging the presence of XCL1 at the injection site. Intradermal administration of 
XCL1-PlGF resulted in migration of skin cross-presenting DCs (CD103+) locally and 
promoted the targeted take up of the antigen when co-administered with XCL1-OVA 
fusion proteins. The enhanced cross-presentation and activation of CD8+ T cells 
resulted in improved cytokine release following a prime-boost vaccination study. 
Furthermore, the XCL1-OVA mixed with XCL1-PlGF significantly increased the 
survival of tumor bearing mice both in a prophylactic and a therapeutic approach, 
supporting further use of the PlGF platform as a standard approach for enhancement of 
antigen uptake in vaccination.     
 
The implementation of XCL1-PlGF in the vaccine platform aimed at creating a 
sustained reservoir of cross-presenting DCs at the injection site that would allow 
enhanced uptake of the antigen directly targeted to this DC subtype. The physiological 
role of XCL1 secreted by activated NK cells and CD8+ T cells in vivo is to 
chemoattract DCs that express XCR1 on their surface [33]. Following previous studies 
from our laboratory, we used the PlGF-2 engineered domain, which displayed the 
strongest binding to the ECM, in order to maintain XCL1 at the injection site. We took 
advantage of the prolonged retention of the molecule at the injection site and used it in 
a fusion protein with XCL1 (XCL1-PlGF) to attract the cross-presenting DCs locally. 
As seen by the fluorescent images in Fig. 1, XCL1-PLGF can maintain its presence at 
the injection site for longer than 48 hr, whereas XCL1 alone did not bind adequately 
and rapidly diffused to the draining LNs. The prolonged presence of the fusion protein 
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resulted in attraction of cross-presenting DCs at the injection site, as compared with the 
naïve CD103+ population. Interestingly, as seen in Fig. 2A, XCL1 alone also attracted 
cross-presenting DCs to the injection site, although at a slower rate than PlGF-fused 
XCL1. This could be explained by studies showing binding of XCL1 to heparin [34] 
and in particular that XCL1 (also called lymphotactin) exists in two different forms in 
physiological conditions, that interconvert between each other. One conformation that 
binds to glycosaminoglyacans (heparin) and one that activates the XCR1 [35]. These 
studies refer to human XCL1, but it is possible that this is also the case in mice, where 
heparan sulfate proteoglycan is present at the skin epidermis.  
 
Our initial hypothesis was that the prolonged presence of the chemokine and 
the increased recruiting of the DCs locally would result in enhanced uptake of the 
antigen by cross-presenting DCs and improved cross-priming of CD8+ T cells. As seen 
by the uptake experiment in Fig. 3, 48 hr after the injection of XCL1-OVA, XCL1-
OVA + XCL1-PlGF or OVA enhanced uptake is observed only in the groups 
containing XCL1-OVA, as expected. The addition of XCL1-PlGF only slightly 
improves the uptake compared with XCL1-OVA alone although the difference 
between the two groups is not statistically significant. This can possibly be explained 
by the timing of the experiment, as 48 hr exceed the time required for an antigen to 
drain to the LNs and be processed by the APCs locally [36]. According to Fig. 2, 4 hr 
after the injection the XCL1-PlGF injected mice had significantly higher numbers of 
cross-presenting DCs concentrated at the injection site and as such we believe that 
administration of XCL1-OVA 4 hr after the XCL1-PlGF injection and processing of 
the LNs 8-16 hr later would help in observing better differences between the groups 
containing XCL1-PlGF or not. Injecting the antigen after the local migration of cross-
presenting DCs would also improve the activation of OTI transferred CD8+ T cells. 
Similar to the uptake experiment, better differences among the groups including or not 
the XCL1-PlGF could have been observed at different time points in the adoptive 
transfer experiment. In particular, 2-3 days after the immunization should be adequate 
to develop an OTI proliferated pool of cells in the LNs and 5 days should allow for a 
detectable population in the spleen. Considering the above, future studies should be 
performed using a different timeline that would allow better observation of the 
differences among the groups.    
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Although the enhanced uptake and cross-presentation are not confirmed by our 
experiments with XCL1-PlGF immunization, we still observe enhanced cytotoxicity of 
CD8+ T cells and improved cytokine secretion in our vaccination studies. Following a 
prime-boost vaccination, the cytokine secretion in the LNs of mice injected with 
XCL1-OVA + XCL1-PlGF was significantly enhanced compared to XCL1-OVA 
vaccination, implying an improved mechanism in CD8+ T cell activation by XCL1-
PlGF. This advantage is preserved also in tumor treatment, as seen by slower rate of 
tumor growth both in the therapeutic and the prophylactic setting. Prolonged survival 
of mice immunized with XCL1-OVA + XCL1-PlGF implies that our approach is of 
biological relevance in vaccines, since the XCR1 expression is preserved in human 
cross-presenting DCs [22] and can be a target in vaccination using this methodology. 
Overall, these result suggests that our initial hypothesis for local skin attraction and 
enhanced cross-presentation may not be the explanation for the positive outcome in 
vaccination, using the XCL1-PlGF protein, and further mechanism studies should be 
conducted. 
 
The Kroczek group has used a similar strategy in targeting the antigen directly 
to the CD8+ T cells with an XCL1-OVA fusion protein [26]. In our studies we could 
observe the same trend as the Kroczek group of enhanced XCL1-OVA activity 
compared to OVA alone after the adoptive transfer and the vaccination experiments. 
Direct comparison between the two methods though is not possible, as different dosing 
and immunization approaches have been used. In particular, the Kroczek group used 
LPS as an adjuvant in vaccination, that is a TLR4 agonist not adequately expressed on 
CD8+ DCs. Instead, we used polyI:C, which is a TLR3 agonist abundantly expressed 
on cross-presenting DCs together with TLR9. We believe that this approach is 
advantageous, as we limited the diffusion of the danger signals to other cell types ???
????????????? ??????? the activation of the CD8+ DCs. The drawback in our 
experiments is loss in the classical pathway of CD4+ T cell activation as seen by 
limited cytotoxicity in this cell type and low antigen specific antibody titers. Overall, 
we believe that our contribution by the addition of XCL1-PlGF to the XCL1-OVA 
platform adds value to the current methodologies as it significantly improves the 
cytotoxic efficacy in vaccination compared to XCL1-OVA alone group. To further 
improve the immune responses raised by the XCL1-PlGF platform mixed with XCL1-
OVA and polyI:C, we can proceed with double adjuvant treatments and, more 
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specifically, use together with polyI:C a TLR9 agonist such as CpG to vaccinate mice. 
This could have an additive effect in activation and cytokine secretion of CD8+ T cells 
and at the same time also contribute in humoral responses, since CpG has been used by 
us and by others for inducing humoral responses.  
?
Targeting the XCR1 surface molecule of cross-presenting DCs is a very 
promising approach in CD8+ DC vaccination so far, ????????? ??? failures of similar 
methodologies targeting other surface markers of CD8+ DCs. The DEC205 approach 
has been challenging, as this receptor is also expressed on other cell lineages, such as 
conventional DCs (cDCs), Langerhans cells, interstitial DCs and thymic epithelial cells 
resulting in loss of the desired specificity. Also, the specificity of the Clec9A molecule 
is questioned by one study [21] as its presence has been reported in other cell types. In 
contrast, XCR1 is uniquely expressed on cross-presenting CD8+ DCs of the secondary 
immune organs and the CD103+ DCs of skin. Targeting the antigen directly to these 
DCs by binding the XCR1 receptor has shown very promising results in CD8+ T cell 
activation by recent studies [26, 27, 37]. We succeeded in further improving the 
already existing platforms for direct targeting of an antigen to XCR1 bearing cross-
presenting DCs by implementing new strategies to enhance the cytotoxicity of CD8+  T 
cell inducing vaccines. Our platform can be translated to human vaccination and, to our 
knowledge, the PlGF protein is not immunogenic and does not have side effects. Thus, 
we believe that our improved platform has biological relevance in human vaccines and 
can enhance the efficacy of existing methodologies.  
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4.1. Introduction  
?
A goal in vaccination is to induce strong immune responses that can protect the 
host against infectious diseases in the long-term. An effective vaccine must support the 
recognition of an antigen and the consequent activation of the immune system to 
induce antigen-specific immunity. Different mechanisms, including the efficient 
uptake and delivery of antigen to appropriate sites, are responsible for inducing 
immune responses in secondary immune organs. Several immunostimulators are used 
in vaccination, along with antigens, to facilitate initiation of the appropriate 
mechanisms for development of immunity, the most common being adjuvants[1]. In 
most cases, and mainly in the non-live vaccines, different adjuvants are included in 
vaccine formulations to induce a more robust immune response. Although different 
roles of adjuvants have been proposed by several groups [2], their exact mechanisms of 
action and roles in stimulating innate, and later adaptive immunity, is still unclear; 
some function by stimulating particular molecular pathways for activation of dendritic 
cells (DCs), whereas others are less direct in their mode of action. .  
 
The oldest, and probably the most popular theory for the role of adjuvants, is 
the depot effect, first described by Glenny [3]. According to this theory, antigens are 
trapped and slowly released at the site of injection, when co-administered with an 
adjuvant. It was later shown that this ensures the constant stimulation of the immune 
system, and allows enhanced uptake and maturation of antigen presenting cells (APCs) 
to further elicit an immune response [4]. In one study, it was shown that antigen 
remained at the site of injection for at least 2-3 weeks, and resulted in activation of the 
immune system when co-administered with an alum adjuvant [5]. Similarly, in a 
different antigen-adjuvant formulation, Hebert showed that the model antigen OVA 
can result in antibody production that is forty times higher when administered in water-
in-oil emulsions [6]. Since then, many adjuvant formulations, such as complete 
Freund's adjuvant (CFA) [7] or AS04 – an adjuvant combination of monophosphoryl 
lipid A (MPLA) and alum – were shown to have a depot effect on the release of 
antigen [8].  
 
In order to explore further improvement of current vaccine strategies and also 
avoid complications such as severe local and systemic side-effects, including sterile 
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abscesses, eosinophilia and myofascitis [9], which strong adjuvants can cause, different 
approaches to enhance immunogenicity and support the sustained release of antigen  in 
vaccines have been tried. Delivery of antigen in a sustained manner has been shown to 
be advantageous in vaccination, as the prolonged presence and interaction of an 
antigen with cells of the immune system increases the efficiency of uptake, and thus 
promotes an effective immune response [10]. In addition, the sustained release of 
antigen may allow a reduction in the number of immunizations required, as the 
presence of the antigen is maintained locally [11]. Towards this end, significant effort 
has been made to provide novel vaccine platforms for sustained antigen release. Aside 
from synthetic materials such as virus-like particles, nanoparticles, liposomes and 
biodegradable polymers [12-14] that have been vastly used for antigen delivery, 
methods that trap antigen at the site of injection, allowing for sustained release, and 
thus enhanced uptake by APCs, are of particular interest. The skin and, in particular, 
the epidermis have a large number of epidermal Langerhans cells (skin-resident 
dendritic cells) that can capture antigens and transport them to draining lymph nodes.  
Therefore, the skin is an attractive immunological site for vaccination [15].  
 
There are several examples in the literature with skin-based vaccination 
approaches. Vaccine-loaded microneedles on skin patches have been used in 
vaccination against influenza to enhance protection against the virus, with positive 
results when compared to free, soluble antigen [16]. Also, the use of antigen-loaded 
depot technologies have shown positive results for the sustained release of antigen at 
the site of injection [17]. The use of hydrogels is another means of trapping antigen for 
enhanced immunogenicity in skin vaccination. For example, it has been shown that a 
liquid solution of chitosan can form a hydrogel in vivo, after injection, and can support 
the sustained release of OVA antigen for > 24 days. This resulted in enhanced 
activation of CD4+ and CD8+ T cells, compared to the results of activation with soluble 
OVA. There was also greater antibody production, with titers equal to those produced 
by OVA vaccination with an alum adjuvant [18].  
 
While the technologies described above have shown positive results in 
sustaining the release of antigen and immunogenicity, these methods, however, require 
manufacturing that is costly and could potentially damage the antigen. To overcome 
these complications we evaluated and present here an alternative approach to trap 
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antigen at the site of injection. Specifically, we engineered a recombinant protein 
consisting of antigen fused to the extracellular matrix binding (ECM) domain of the 
growth factor placenta growth factor-2 (PlGF-2), specifically the domain PlGF-2123-144 
[19], using ovalbumin (OVA) as a model antigen, thus creating the fusion protein 
OVA-PlGF-2123-144 (abbreviated hereinafter as OVA-PlGF). It was hypothesized that 
the presence of OVA-PlGF could be maintained at the site of  injection by direct 
binding of PlGF to the ECM of the skin. This would allow more APCs to approach the 
site of injection and take up the antigen. Furthermore, in the presence of a potent 
adjuvant, the APCs would mature and drain to the lymph nodes LNs to elicit antigen-
specific immune responses. The OVA-PlGF fusion protein was produced in HEK293 
cells and was used in a prime-boost vaccine experiment with female C57BL/6 mice. 
Both the humoral and cellular responses were assessed in the spleens and LNs of 
vaccinated animals, and these were compared to responses elicited by immunizations 
with free OVA. Contrary to the hypothesis of our design, no significant benefit from 
binding to the ECM could be observed with OVA-PlGF vaccinations when compared 
to vaccinations with free OVA antigen.   
 
4.2. Materials and Methods 
?
Animals Female C57BL/6J mice were purchased from Harlan and female Balb/c and 
Ly5.1 (CD45.1) mice were purchased from Charles River laboratories. All mice were 
aged between 8-12 weeks and kept under pathogen free conditions at the animal 
facility of Ecole Polytechnique Fédérale de Lausanne. The Veterinary Authority of the 
Canton de Vaud approved all procedures and experiments. 
 
OVA-PlGF recombinant production. OVA-PlGF was produced as previously 
described for the engineering of other growth factors [20]. Briefly, the sequence 
encoding for PlGF-2(123-144) was subcloned in a pSecTagA mammalian vector 
engineered to express the OVA protein. The PlGF sequence was added at the C-
terminus together with a 6 histidine tag for purification at the N-terminus. The 
sequence for the OVA-PlGF was as follows: “HHHHHH – OVA – 
RRRPKGRGKRRREKQRPTDCHL”. The protein was expressed in a HEK293 cells 
under serum free conditions with 3.75 mM valproic acid (Sigma-Aldrich), and after 7 
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days the protein in suspension was purified using a HisTrap HP column (GE 
Healthcare) with immobilized metal affinity chromatography. The purified protein was 
analyzed for purity using SDS/PAGE, endotoxin levels were assessed in THP-1 x Blue 
cells (InvivoGen), and concentration was measured using bicinchoninic acid assays 
(Thermo Scientific). The final product was sterile-filtered, and stored at -80 °C in 
working aliquots. 
 
Immunizations. 8-week old female C57BL/6 mice were immunized under isofluorane 
anesthesia (5% for induction and 2% for maintenance) on day 0 and 14 with an 
intradermal injection of 20 μg OVA, 20 μg OVA + 20 μg CpG-B, 20 μg OVA-PlGF, 
20 μg OVA-PlGF + 20 μg CpG-B or just saline. 7 days after the boost mice were 
euthanized, and the axillary, branchial and inguinal LNs and spleen were collected for 
ex vivo restimulation and staining as described in other sections. 
 
Pentamer staining. While mice were under anesthesia, 50 μl of blood was collected 
from their facial vein and stored in EDTA containing tubes. Blood was spun at 2000xg 
for 5 min and the serum was collected from the supernatant. The remaining cells were 
lysed for 5 min at room temperature with 0.155M NH4Cl and were further processed in 
preparation for analysis by flow cytometry as described in other sections. Following 
the live dead staining, the cells were incubated at room temperature for 12 min with 
1:10 dilution of SIINFEKL pentamer (Bioscience). The cells were further stained for 
CD3 (1:100), CD8 (1:200), CD44 (1:200), CD62L (1:200), CD19 (1:800) and acquired 
by flow cytometry. For the pentamer stain of LNs and spleen, 106 cells from both 
organs were stained as described above.    
 
Tissue and cell preparation for ex vivo restimulation of lymphocytes. Splenocytes 
were obtained by disruption of the spleen through a 70-μm cell sieve and subsequent 
red blood cell lysis with 0.155M NH4Cl. The lymph nodes were digested for 30 min 
with 2 mg/mL Collagenase D (Roche) in IMDM, and passed through a 70-μm cell 
sieve to obtain single cell suspensions. All organs were kept in Dulbecco’s Modified 
Eagle Medium (DMEM) (Gibco) supplemented with 10% FBS and 1% penicillin, 
streptomycin (Invitrogen). For CD8+ T cell–specific restimulation and intracellular 
cytokine staining, cells were first cultured for 3 hr at 37 °C in the presence of 1 μg/mL 
SIINFEKL, 104 U/ml IL2, and 0.5 μg anti-CD28 (eBioscience), and subsequently for 3 
 80 
hr with the addition of 250 μg/mL brefeldin A (SigmaAldrich). For CD4+ T cell 
restimulation, 104 U/ml IL2, 0.5 μg anti-CD28 and 100 μg/mL OVA grade VI (Sigma-
Aldrich) protein were added to the cells for 3 h, followed by incubation with 50 μg/mL 
brefeldin A for another 12 hr.  
 
Flow cytometry staining. For the detection of live cells, cells were suspended at a 
concentration of 106 cells in 200μl, washed with PBS, and labeled with live/dead 
fixable cell viability reagent (Invitrogen). Subsequently, the cells were incubated for 20 
min on ice with PBS/2% FBS solutions of the surface markers CD3 (1:100) and CD8 
(1:200) or CD4 (1:200). For intracellular cytokine staining, cells were fixed in 2% 
paraformaldehyde solution, washed with 0.5% saponin (SigmaAldrich) in PBS/2% 
FBS, and incubated with the IFNγ (1:200) or TNFα (1:200) antibody diluted in saponin 
solution for 30 min on ice. Finally, the cells were resuspended in PBS/2% FBS for 
analysis. Samples were processed on CyAn ADP Analyzer (Beckman Coulter) and 
data were analyzed with FlowJo software (Tree Star). The antibodies against mouse 
CD3, CD4, CD8, IFNγ and TNFα used were purchased from eBioscience.   
 
Antibody titers measurement. Blood was collected from the facial vein of all mice 
and was spun at 2000xg for 10 min. The serum was collected from the supernatant and 
was stored at -20 0C for later analysis. ELISA plates (Nunc MaxiSorp, Thermo Fisher 
Scientific) were coated with 10 μg/ml OVA antigen in phosphate buffer saline (PBS) 
and were incubated at 4 oC over night. Next, the plates were blocked with 2% bovine 
serum albumin (BSA) in PBS with 0.05% Tween 20 (PBS-T) for 2 h at room 
temperature (RT). Wells were then washed with PBS-T and further incubated with the 
following dilution of the serum: 1:100, 1:200, 1:300, 1:400 in BSA for 2 hr at RT. 
After washes, the anti-IgG antibody was added in a 1:8000 dilution in BSA for 1hr at 
RT and was detected with tetramethylbenzidine substrate by measurement of the 
absorbance at 450 nm. 
 
Data Analysis. All flow cytometry data were analyzed using FlowJo (v8.8.6). Graphs 
and statistical analyses of data were performed using GraphPad® Prism (v5). Statistical 
significance was determined by pair-wise Student’s t-test with Welch correction. The 
asterisks indicate the significance as follows: * implies p<0.05, *** implies p < 0.001. 
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4.3. Results and Figures 
A potent vaccine elicits antigen-specific antibodies through CD4+ T cells and 
activates cytolytic CD8+ T cells. We evaluated the immune responses raised after a 
prime-boost intradermal vaccination with OVA, OVA + CpG-B, OVA-PlGF and 
OVA-PlGF + CpG-B, measuring responses in the circulation as well as in the spleens 
and LNs of vaccinated mice. First, the activated CD8+ T cells circulating in the blood 
14 days after the first injection were measured. SIINFEKL pentamer staining was 
performed on blood samples of all mice, followed by flow cytometry analysis. A 1.3-
fold increase in the pentamer+ cells circulating in the blood was observed in the group 
of mice vaccinated with OVA-PlGF + CpG-B compared to free OVA + CpG-B. (Fig.1 
A).  However, the activation phenotype of the pentamer+ cells in the OVA-PlGF + 
CpG-B group, determined by staining with CD44 and CD62L surface markers, was 
lower than for immunizations with OVA + CpG, but there were no significant 
differences between the two groups. Also, from the measurement of antibody titers 
circulating in the serum of all mice, as measured by ELISA 14 days after the prime 
injection (Fig. 1C), no differences were observed between the groups that included 
CpG-B in their vaccine formulations, although with OVA + CpG there was an order of 
magnitude increase in antigen-specific titers. Together, these results, from samples 
obtained 14 days after the first immunization, did not show a clear advantage of OVA-
PlGF + CpG immunization over OVA + CpG-B.  
Figure 1: Activation of CD8+ T cells after a single intradermal injection. Mice were 
vaccinated intradermal with OVA, OVA + CpG-B, OVA-PlGF and OVA-PlGF + CpG-B and 
14 days later blood samples were collected from the facial vein to evaluate the activation of 
CD8+ T cells and antibody induction in circulation. A. Blood samples were stained with 
SIINFEKL pentamer and measured by flow cytometry; gate on live, CD3+ CD8+ cells. B. 
Evaluation of activation phenotype by flow cytometry measurements of CD44+ CD62L- cells; 
gate on pentamer+ cells. C. IgG OVA specific antibody titers measured by ELISA in the serum 
of all mice. (*p<0.05) 
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The spleen and LNs were harvested 7 days after the boost injection and the 
organs were processed for further analysis. Similar to the measurements made with 
pentamer on blood samples, the splenocytes and LN lymphocytes were stained for 
SIINFEKL pentamer+ cells and their activation phenotype was determined by CD44 
and CD62L  staining. No differences were observed between the OVA + CpG-B and 
the OVA-PlGF + CpG-B groups in the pentamer+ cells of the spleen (Fig. 2A) whereas 
in the LNs, the OVA-PlGF + CpG-B group showed preferred activation, although this 
difference was not statistically significant. The activation phenotypes in the different 
organs were very similar, with no significant differences observed between the 
different vaccination groups.   
Figure 2: OVA-PlGF + CpG-B does not activate CD8+ T cells better than OVA + CpG-B.  
Mice were vaccinated intradermal with OVA, OVA + CpG-B, OVA-PlGF and OVA-PlGF + 
CpG-B on day 0 and 14 and the spleen and LNs were collected and processed a week after the 
boost. Lymphocytes from spleen and LNs were stained for SIINFEKL pentamer and measured 
by flow cytometry on day 21. A. Spleen SIINFEKL pentamer+ cells; gate on CD3+ CD8+ cells. 
B. Activation phenotype of pentamer+ splenocytes measured on CD44+ CD62L- cells; C. LN 
pentamer+ stain and D. activation phenotype.*p<0.05 
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Next, the cytolytic activity of recovered CD8+ T cells was evaluated. The 
activation of CD8+ T cells in vaccination is a prerequisite for the elimination of tumor 
cells and virus-infected cells. The induction of cytokine secretion a week after the 
boost injection was measured in samples obtained from the spleens and LNs of all 
mice. The organs were harvested, processed and restimulated for 6 hr with the 
SIINFEKL peptide, and then the cells were stained for the presence of IFNγ and TNFα. 
No significant differences were observed in the levels of cytokine production between 
OVA + CpG-B and OVA-PlGF + CpG-B as seen in Fig. 3, suggesting that vaccination 
with OVA-PIGF has no benefit over vaccination with OVA alone, for activation or 
cross-presentation of antigen to CD8+ T cells. More specifically, identical percentages 
of IFNγ (Fig. 3A) and TNFα (Fig. 3B) were observed in the spleens of OVA + CpG-B 
and OVA-PlGF + CpG-B vaccinated mice, while in the LNs of the same mice there 
was a trend towards increased production of both cytokines in the OVA-PlGF + CpG-
B group, although not statistically significant  when compared to OVA + CpG-B (Fig. 
3C. and 3D). 
 
Traditional strategies for immunization attempt to also induce activation of 
CD4+ T cells. Activation of this subtype helps in the induction of CD8+ T cell and 
facilitates the production of antibodies by B cells. Evaluation of the CD4+ T cell 
activation was performed by restimulation of both spleen and LNs with OVA antigen 
overnight followed by staining for intracellular IFNγ and TNFα. Minimal production 
of IFNγ was observed in the spleen of each mouse (Fig. 4A), but the production of 
TNFα in OVA-PlGF + CpG-B samples improved 4-fold when compared to the OVA + 
CpG-B samples (Fig. 4B). In contrast, in the LNs, the percentage of IFNγ-producing 
CD4+ T cells in the OVA + CpG-B group was four times higher than the OVA-PlGF + 
CpG-B group (Fig. 4C), and no differences were observed in the frequencies of TNFα-
producing CD4+ T cells (Fig. 4D).  
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Figure 3: OVA-PlGF mixed with CpG-B does not promote the cross-priming of CD8+ T 
cells. Lymphocytes from spleens and LNs were collected a week after the boost injection and 
evaluated for the cytolytic activity of CD8+ T cells after restimulation for 6 hr with SIINFEKL 
peptide. Cells were labeled for intracellular expression of IFNγ and TNFα and measured by 
flow cytometry.  A. IFNγ+ and B. TNFα+ splenocytes (gate on live, CD3+CD8+ T cells). C. 
IFNγ+ and D. TNFα+ CD8+ T cell of LNs, as in spleen. 
Finally, antibody titers were measured by ELISA in all groups at the end of the 
experiment. As expected, high antibody titers were measured in the groups immunized 
with vaccine formulations containing an adjuvant, however, there were no significant 
differences in titers when comparing the formulations of the OVA and OVA-PlGF 
antigens (Fig. 5).  
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Figure 4: OVA-PlGF mixed with CpG-B does not enhance the activation of CD4+ T cells. 
Lymphocytes from spleens and LNs a week after the boost injection were evaluated for the 
activation of CD4+ T cells after restimulation overnight with the OVA protein. Cells were 
labeled for intracellular expression of IFNγ and TNFα and measured by flow cytometry.  A. 
IFNγ+ and B. TNFα+ secreting CD4+ T cells in spleen (gate on live, CD3+ CD8+ T cells). C. 
IFNγ+ and D. TNFα+ CD4+ T cell of LNs 
Figure 5: IgG OVA specific antibody titers measured by ELISA in the serum of mice on day 
21 of the experiment. 
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4.4. Discussion 
?
It is widely known that non-live vaccines have lower immunogenicity than live 
vaccines, and as such, current technologies are focused on enhancing the immune 
responses primed by these types of vaccines. A common approach to improve the 
antigen-specific immune responses in subunit vaccination, for instance, is to maintain 
the sustained release of the drug-protein or subunit by creating a depot effect. In this 
study we evaluated antigen trapping at the site of injection as a method for enhancing 
the immunogenicity of protein-based vaccines. The method was designed to trap 
antigen within the skin, at the point of injection, and prolong its presence locally, 
aiming for enhanced uptake by APCs. OVA was chosen as a model antigen, and it was 
fused to the ECM-binding domain of the PlGF-2 growth factor, namely PlGF-2123-144, 
which binds strongly to ECM proteins present in the skin. The immunogenicity was 
measured in vivo by vaccinating female C57BL/6 mice with OVA-PlGF and OVA, 
with or without the addition of the CpG-B adjuvant. Following two intradermal 
injections, on days 0 and 14, the humoral and cellular responses were evaluated. 
Contrary to the hypothesis of our design, no striking differences were observed 
between fused OVA-PlGF and free OVA groups when CD4+ and CD8+ T cell 
activation, and antibody production were considered.  
 
A single intradermal injection of OVA-PlGF + CpG-B resulted in an increase 
in the number of CD8+ T cells with antigen-specific T cell receptors compared to 
injection with OVA + CpG-B, based on data from pentamer staining of blood samples. 
However, the benefit of immunizing with OVA-PlGF observed in circulation seemed 
to be absent in the spleen, after the boost injection, while in the LN, a similar trend 
with the blood staining was observed, but this increase was no longer statistically 
significant. The positive results in the LNs are encouraging as these are the first organs 
to take up antigen, and are key for activation of the adaptive immune system. 
Moreover, it was expected that there would be a retention of the increased level of 
OVA-specific CD8+ T cells, and possibly an enhancement of the response with the 
boost injection when OVA-PIGF was used, however, this was not observed. A 
potential explanation for this discrepancy is the early time chosen for evaluation of the 
responses. Standard protocols from our laboratory [21] and other research groups 
suggest that the peaks of the responses are observed 7 days after the boost injection. 
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However, the kinetics regarding the transport of the OVA-PlGF molecule to the APCs 
in vivo could be different from the kinetics of free OVA, as antigen trapping at the site 
of injection might slow trafficking to the LNs. Future studies must involve 
characterization of these properties for the OVA-PlGF molecule.  
 
Ex vivo restimulation of spleen and the skin draining LNs with OVA and the 
SIINFEKL peptide revealed that there was similar immunogenicity between the OVA 
and OVA-PlGF proteins. No significant differences were observed in the levels of 
IFNγ and TNFα cytokines produced by CD8+ T cells after vaccination with either 
OVA + CpG-B or OVA-PlGF + CpG-B, indicating that there may be no improvement 
in cross-presentation of antigen to CD8+ T cells with the platform. Furthermore, 
restimulation with OVA did not result in a clear outcome with regards to the activation 
of CD4+ T cells. In the spleen, no IFNγ secreting cells were measured whereas the 
TNFα+ CD4+ T cells were 7-fold higher in the OVA-PlGF + CpG-B group than in the 
OVA + CpG-B group. In contrast, in the LNs there was a clear benefit of OVA + CpG-
B in IFNγ production, which was not seen in the TNFα+ CD4+ T cells. A manifestation 
of the mixed results in the CD4+ T cell compartment is seen by the equal IgG titers 
raised against the OVA antigen in both groups. Thus, in perhaps the most basic of 
vaccine read-outs, the OVA-PlGF variant of the wild-type OVA antigen was not 
beneficial.  
 
One expected outcome of the vaccination was the rather negligible 
immunogenicity of the OVA-PlGF platform in the absence of CpG-B. Very little 
activation, mainly in the LNs, was observed in the group of mice vaccinated with 
OVA-PlGF only. This is in agreement with the general observation that subunit 
vaccines require the support of strong adjuvants in order to raise potent immune 
responses, unlike with live vaccines, and that the depot effect is not sufficient to 
activate the immune system when immunizing with only an antigen. Therefore, new 
technologies for subunit protein vaccination focus on simultaneous injection of antigen 
and adjuvant.  
 
Considering the lack of increased efficacy of the OVA-PlGF vaccine in this 
study, a re-evaluation of the platform is required. With a better understanding of the 
release kinetics of the OVA-PIGF, it may be possible to improve the immunogenicity 
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of the vaccine. Combining the PIGF platform with multiple adjuvant administration or 
with other platforms, such as fibrin-based implanted gels [22, 23], which can stabilize 
the antigen and also promote its sustained release, could lead to enhancements in 
efficacy of the vaccine. Overall, improving the immunogenicity of subunit vaccines, 
and more specifically in protein based vaccines based, is very challenging, and a 
substantial amount of work is still required to make progress in the field.    
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5.1. Abstract 
Nanoscale carrier platforms promote immune responses to vaccination by facilitating 
delivery of vaccine components to immunologically relevant sites. The technique is 
particularly valuable for subunit vaccination, in which co-administration of 
immunostimulatory adjuvant is known to enhance immune responses to protein 
antigen. The fabrication of polymer-based nanoparticle vaccines commonly requires 
covalent attachment of vaccine components to the carrier surface. In contrast, we here 
describe a cationic micelle vaccination platform in which antigen and adjuvant loading 
is mediated by non-covalent molecular encapsulation and electrostatic complexation. 
Cationic micelles were generated through self-assembly of a polyarginine-conjugated 
diblock copolymer amphiphile, with or without encapsulation of monophosphoryl lipid 
A, an amphiphilic experimental vaccine adjuvant. Micelle complexes were 
subsequently formed by complexation of ovalbumin (OVA) and CpG-B 
oligodeoxynucleotide (a second experimental adjuvant) to the cationic micelles. In a 
35-day study in mouse, micelle-mediated co-delivery of OVA antigen and CpG-B 
enhanced cellular and humoral responses to vaccination. These outcomes were 
highlighted in spleen and lymph node CD8+ T cells, with significantly increased 
populations of IFNγ+, TNFα+, and polyfunctional IFNγ+ TNFα+ cells. Elevated 
cytokine production is a hallmark of robust cytotoxic T lymphocyte (CTL) responses 
sought in next-generation vaccine technologies. Increased production of OVA-specific 
IgG1, IgG2c, and IgG3 also confirmed micelle enhancement of humoral responses. In 
a subsequent 35-day study, we explored micelle-mediated vaccination against OVA 
antigen co-administered with MPLA and CpG-B adjuvants. A synergistic effect of 
adjuvant co-administration was observed in micelle-free vaccination but not in groups 
immunized with micelle complexes. This outcome underlines the advantage of the 
micelle carrier: we achieved optimal cellular and humoral responses to vaccination by 
use of this nanoparticle platform with a single adjuvant. In particular, enhanced CTL 
responses support future development of the cationic micelle platform in experimental 
cancer vaccines and for vaccination against reticent viral pathogens. 
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5.2. Introduction  
  
Vaccination represents one of the most successful medical interventions against 
infectious pathogens. Since Edward Jenner published the first vaccination against 
smallpox in 1798, vaccines have been used for prevention of infectious disease and 
more recently, the United States Food and Drug Administration approved the first 
therapeutic vaccine for prostate cancer.1 Vaccination strategies promote humoral 
immunity (antibody production for neutralization of circulating antigens) and/or 
cellular immunity (cytotoxic T cell responses for disease attenuation and elimination of 
intracellular pathogens via cell killing and secretion of inflammatory cytokines). Most 
vaccines in clinical use mediate protection through induction of neutralizing, antigen-
specific antibodies. However, this humoral response is insufficient for eradication of 
intracellular infection or tumor-transformed cells, for which the activity of cytotoxic 
CD8+ T lymphocytes (CTLs) is necessary to eliminate diseased cell populations. As 
such, recent vaccine design approaches have sought to promote cellular immunity 
along with induction of humoral responses.2, 3  
 
In the past, vaccines utilized live or attenuated cells or viruses to mimic natural 
infections, providing more potent immunogenicity compared to non-living vaccines.4 
However, the risk of harmful side effects associated with overt toxicity of pathogenic 
components has shifted interest towards methods utilizing whole proteins in subunit 
vaccination.5 Superior safety is a significant advantage of protein-based subunit 
vaccines, but costly manufacturing procedures and limited immunogenicity remain 
challenges in current vaccine design. Improvements to subunit vaccination focus on 
enhancing immunogenicity by co-administration of immunostimulatory adjuvants and 
by carrier-mediated delivery that controls the presence and sustained release of 
antigen.  
 
Adjuvants are immune potentiators that bind to pattern recognition receptors (PPRs) 
of antigen presenting cells (APCs) to augment immune responses to the antigen with 
which they are administered.6 The most thoroughly characterized class of PRRs is the 
Toll-like receptors (TLRs), which represent an important binding target of natural and 
synthetic TLR agonists developed as experimental adjuvants. TLRs are expressed in a 
variety of immune cells including macrophages, dendritic cells (DCs), and monocytes.7 
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Upon adjuvant binding, activated signaling pathways downstream of the TLRs initiate 
secretion of proinflammatory cytokines and upregulate expression of costimulatory 
molecules on the APC surface.8 TLRs are associated with the cell surface or 
intracellular compartments, based on their detection of pathogen-associated cell wall 
components (TLR1, 2, 4-6) or intracellular nucleotide-based molecules (TLR3, 7-9).9 
CpG oligodeoxynucleotide constructs are a family of experimental adjuvants 
frequently explored in vaccination. Presenting repeated unmethylated CpG 
dinucleotide motifs, these molecules are well-characterized TLR9 agonists that induce 
Th1 responses and elevate antibody production.10 Similarly utilized is monophosphoryl 
lipid A (MPLA), a low-toxicity derivative of bacterial lipopolysaccharide and TLR4 
agonist with potent immunostimulatory properties.11 
 
As engineering principles are more fully adopted in the field of vaccinology,12 the 
use of nanoparticulate platforms has evolved into a desirable and experimentally 
validated approach in vaccine design. The broad variety of nanoparticle preparations, 
their capable delivery of antigen and adjuvant, and their interactions with 
immunologically relevant tissues and cells has been the subject of recent reviews.13-15 
Significant benefits of nanoparticulate vaccine delivery are now recognized. For 
example, these platforms enhance delivery of protein-based subunit vaccine antigen to 
target immune cells, in part by protecting antigen from proteolytic degradation 
following administration. The platform thereby increases bioavailability, and with it, 
the likelihood of antigen delivery to secondary lymphoid compartments implicated in 
immune response to vaccination. Nanoparticle-mediated delivery also permits 
incorporation of multiple vaccine components in a single construct. In this biomimetic 
approach, the introduction of protein-based antigen and immunostimulatory adjuvant 
via nanoscale carrier closely resembles natural pathogenic infection and provokes a 
more robust immunological response than any of these elements presented alone.16, 17 
Nanoparticle vaccines capably traffic to injection site-draining lymph nodes (LN) 
independent of cellular uptake; previous efforts within our group have demonstrated 
that particles of ~20 nm diameter permit most efficient transport.18 Both solid-core 
nanoparticles and watery-core polymersomes have subsequently been examined in our 
group, for antigen and/or adjuvant delivery in the context of vaccination.19-22 Similarly, 
sub-50 nm self-assembled spherical micelles were applied for antigen delivery 
following covalent conjugation of ovalbumin (OVA) to the micelle surface.23 The 
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present work expands on these studies, by defining a role for poly(ethylene glycol)-b-
poly(propylene sulfide) (PEG-PPS) micelles as a complete vaccination platform. 
Through non-covalent molecular loading and charge-mediated interactions, PEG-PPS 
micelles act as a nanoscale carrier for two distinct adjuvants (MPLA and CpG-B) as 
well as model whole protein OVA antigen, without requiring the complexity of 
covalent attachment  of the antigen to the carrier. 
 
Here we introduce a self-contained, micelle-based nanoparticle vaccine in which 
neither OVA antigen nor adjuvant have been covalently modified. The cationic micelle 
carrier was obtained by self-assembly of a novel polymer-peptide construct defined by 
polyarginine-conjugated PEG-PPS, with or without MPLA encapsulation during 
micelle formation. Electrostatic interactions between the positively charged micelle 
and negatively charged OVA and CpG-B drove formation of the particulate vaccines. 
The performance of these nanoparticle vaccines was subsequently explored in a 35-day 
OVA vaccination study in mouse. We determined that the cationic micelle carrier 
facilitated robust, OVA-specific humoral responses desired from an adjuvanted subunit 
vaccine. Furthermore, cationic micelle-mediated vaccination displayed enhanced 
cellular responses in inflammatory cytokine-producing CD8+ T cell populations 
derived from lymph node and spleen. Taken together, these outcomes demonstrate the 
ease of preparation of a self-contained, micelle-based nanoparticle vaccine, coupled 
with improved vaccination outcomes via humoral as well as cellular immune 
responses. 
 
5.3 Materials and Methods 
?
Synthesis of PEG-PPS-R13 conjugate. All reagents were from Sigma-Aldrich unless 
otherwise noted. Preparation of poly(ethylene glycol) (PEG)-based macroinitiator was 
achieved by thioacetate modification of methoxyPEG-OH (MW 2000) according to 
previously published methods.39, 40 PEG-thioacetate initiator (300 mg, 1 equiv) was 
transferred to Schlenk tube under flowing argon and dissolved in air-free 
tetrahydrofuran (8 mL). Sodium methoxide (0.5 M solution in methanol, 1.1 equiv) 
was added via syringe, for macroinitiator activation during 30 min incubation. 
Subsequently, propylene sulfide monomer (15 equiv) was added to initiate ring-
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opening polymerization of the monomer. After 1.5 hr, the reaction was terminated by 
addition of excess 2,2’-dipyridyl disulfide (10 equiv) solution in tetrahydrofuran. This 
copolymer end-capping reaction stirred overnight under ambient conditions. Excess 
tetrahydrofuran was removed, and the PEG-PPS block copolymer product was 
obtained in >85% yield following double precipitation in diethyl ether and vacuum 
drying. 1H NMR spectroscopy was performed in CDCl3 on the Bruker AVANCE (400 
MHz) platform with Topspin software: δ = 1.38 (d, CH3, PPS side group); 2.63 (m, 
CH in PPS backbone); 2.91 (CH2 in PPS backbone); 3.38 (s, OCH3); 3.6-3.7 (s, broad, 
PEG backbone OCH2CH2); 7.10, 7.65, 7.75, 8.46 (CH, pyridine group). The reference 
peak integration of PEG methoxy hydrogens was compared to peak integrations of PPS 
backbone hydrogens, to confirm PPS degree of polymerization = 15. 
 
PEG-PPS (20-40 mg) was reacted for 2 hr with R13 peptide (NH2-Cys-Gly-Trp-
(Arg)13, PolyPeptide Laboratories, 1.4 equiv) in DMF/trace triethylamine (0.5-1 mL). 
In this reaction, peptide conjugation to PEG-PPS was achieved by disulfide exchange, 
a by-product of which is 2-pyridinethione. Release of this molecule imparted a 
distinctive yellow tone to the reaction solution and confirmed efficient conjugation. 
The polymer-peptide conjugate was repeatedly precipitated in diethyl ether to remove 
2-pyridienthione and vacuum dried. With gentle pipetting, addition of endotoxin-free 
water (B. Braun Medical AG, 10 mg conjugate/mL) to the dried product drove 
formation of cationic micelle assemblies, as confirmed by zeta potential analysis and 
dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments) of the resulting 
aqueous dispersion. This dispersion was exhaustively diafiltered (10,000 MWCO) 
against endotoxin-free water to remove unreacted peptide. Following purification, 
PEG-PPS-R13 was lyophilized to obtain the final product, a viscous solid, in >70% 
yield. 
 
Preparation of the cationic micelle vaccination platform. Self-assembly of PEG-
PPS-R13 micelles was performed by solvent evaporation. PEG-PPS-R13 was 
dissolved in dichloromethane (1 w/v%) with gentle agitation. For preparation of 
MPLA-loaded assemblies, MPLA (Monophosphoryl Lipid A from S. Minnesota R595, 
InvivoGen) in 3:1 dichloromethane:methanol was added with Hamilton syringe to 
PEG-PPS-R13 solution. The conjugate solution was added dropwise to endotoxin-free 
water and allowed to stir under ambient conditions until complete evaporation of 
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organic solvent. The remaining aqueous phase contained formed micelles at a final 
concentration of 10 mg PEG-PPS-R13 per mL. MPLA-loaded micelles contained 
MPLA at a final concentration of 0.5 mg MPLA per mL, and their pro-inflammatory 
behavior was confirmed by endotoxin assay performed with InvivoGen HEK-Blue 
hTLR4 cell system using LPS standard. This assay confirmed no endotoxic 
contaminants in samples not containing MPLA. Micelles as well as complexes 
(described below) were characterized by dynamic light scattering for mean particle 
diameter and by zeta potential measurement for charge character. 
 
Injection samples containing complexed micelles were prepared by mixing a given 
volume of the previously prepared micelle dispersion with sterile solutions of OVA 
(endograde, Hyglos, 10 mg/mL in water) and/or CpG-B (Microsynth, 3.18 mg/mL in 
water). Sterile normal saline was added to bring sample solutions to volume. The 
following final reagent concentrations were maintained across sample formulations: 
2.5 mg/mL PEG-PPS-R13 conjugate, 0.5 mg/mL OVA, 0.125 mg/mL MPLA, 0.5 
mg/mL CpG-B. Reagent concentrations were identical in control groups not containing 
micelles; these were prepared by simple mixing of antigen and adjuvant solutions. 
Here, MPLA was used at a concentration of 500 ug/mL (in 10 v/v % biotechnology 
grade dimethylsulfoxide in water). All samples were prepared under sterile conditions 
immediately prior to injection. 
 
Cryo Transmission Electron Microscopy. 5 μL micelle sample solution was applied 
to electron microscopy grid (Agar Scientific) with holey carbon film. Sample grids 
were blotted and flash vitrified in liquid ethane using an automatic plunge freezing 
apparatus (Vitrobot, FEI) to control humidity (100%) and temperature (23 °C). 
Analysis was performed at -170 °C on a Tecnai F20 electron microscope operating at 
200 kV, using the Gatan 626 cryo-specimen holder (20,000-50,000× magnification; -3 
to -5 μm defocus). Digital images were recorded on in-line Eagle CCD camera. 
 
Animals. Female C57BL/6J mice (8-12 weeks) were purchased from Harlan 
Laboratories and housed under pathogen-free conditions at the animal facility of Ecole 
Polytechnique Fédérale de Lausanne. All experiments were performed in accordance 
with Swiss law and with approval from the Cantonal Veterinary Office of Canton de 
Vaud, Switzerland. 
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Immunizations. Mice were immunized via intradermal injection at each limb hock, 
under isofluorane anesthesia (5% for induction and 2% for maintenance) on day 0, 14, 
and 28 of the studies. For the singly- and doubly-adjuvanted vaccination studies, 
samples groups utilizing micelle carriers are described in Table 1. Micelle-free controls 
included OVA + CpG-B or MPLA (singly-adjuvanted study), and uncomplexed OVA 
+ MPLA + CpG-B and OVA alone (doubly-adjuvanted study). Injection control groups 
received normal saline. Mice were treated according to reagent concentrations 
normalized across all groups and studies; depending on sample group, mice received 
100 μg PEG-PPS-R13 conjugate / 20 μg OVA / 5 μg MPLA / 20 μg CpG-B per 
injection. Mice were euthanized 7 days following second boost (day 35). The axillary, 
brachial, inguinal, and popliteal LNs and spleen were collected for ex vivo 
restimulation and staining as described below. 
 
Tissue and cell preparation for ex vivo restimulation of lymphocytes. Splenocytes 
were obtained by disruption of the spleen through 70-μm cell sieve and subsequent red 
blood cell lysis with 0.155M NH4Cl. Lymph nodes were digested for 30 min with 2 
mg/mL Collagenase D (Roche) in Iscove's Modified Dulbecco's Medium (IMDM), and 
passed through 70-μm cell sieve to obtain single cell suspensions. All organs were kept 
in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% 
FBS and 1% penicillin/streptomycin (Invitrogen). For CD8+ T cell restimulation and 
intracellular cytokine staining, cells were first cultured for 3 hr at 37 °C in the presence 
of 1 μg/mL SIINFEKL, 104 U/ml IL-2, and 0.5 μg anti-CD28 (eBioscience). 
Thereafter, cells were cultured an additional 3 hr following addition of 250 μg/mL 
brefeldin A (Sigma-Aldrich). For CD4+ T cell restimulation, 104 U/ml IL-2, 0.5 μg 
anti-CD28 and 100 μg/mL OVA grade VI (Sigma-Aldrich) were added to the cells for 
3 hr incubation, followed by incubation with 50 μg/mL brefeldin A for an additional 12 
hr. Alternatively, cells were restimulated for 4 days in the presence of 100 μg/mL 
OVA grade VI or 1 μg/mL SIINFEKL for analysis of supernatant cytokines.  
 
Flow cytometry staining and ELISA. Cells were suspended at a concentration of 106 
cells per 200 μl, washed with PBS, and labeled with live/dead fixable cell viability 
reagent (Invitrogen). Subsequently, cells were incubated for 20 min on ice with 
antibodies to the T cell surface markers CD3 (1:100) and CD8 (1:200) or CD4 (1:200) 
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in 2% FBS in PBS (labeling buffer). For intracellular cytokine staining, cells were 
fixed with 2% paraformaldehyde solution, washed with 0.5% saponin (Sigma-Aldrich) 
in labeling buffer, and incubated with IFNγ (1:200) or TNFα (1:200) antibody diluted 
in saponin solution for 30 min on ice. Finally, the cells were resuspended in labeling 
buffer for analysis. Samples were processed on CyAn ADP Analyzer (Beckman 
Coulter) and data were analyzed with FlowJo software (Tree Star). Antibodies against 
mouse CD3, CD4, CD8, IFNγ and TNFα were purchased from eBioscience. Following 
4-day restimulations, supernatant cytokines were quantified using Ready-SET-Go! 
ELISA kits  (eBioscience) according to manufacturer guidelines.  
 
Measurement of antibody titers. Blood was collected from the facial vein of all mice 
and spun at 2000 × g for 10 min. Serum was removed and stored at -20 °C prior to 
analysis. ELISA plates (Nunc MaxiSorp, Thermo Fisher Scientific) were coated with 
10 μg/ml OVA grade VI in PBS and incubated at 4 °C overnight. The plates were 
blocked with 2% bovine serum albumin (BSA) in PBS + 0.05% Tween 20 (PBS-T) for 
2 hr at room temperature. The plates were washed with PBS-T and incubated for 2 hr 
at RT with serial serum dilutions (1:100 to 1:700) in 2% BSA in PBS-T. After 
sequential plate washes, plates were incubated 1 hr at RT with horseradish peroxidase-
conjugated anti-IgG or -IgG subtype in 2% BSA in PBS-T, according to the following 
dilutions: total IgG (1:8000), IgG1 (1:8000), IgG2a (1:5000), IgG2b (1:5000), IgG2c 
(1:8000), and IgG3 (1:8000). All antibodies were provided by Southern Biotech. 
Conversion of tetramethylbenzidine substrate was detected by absorbance 
measurement at 450 nm. 
 
Data Analysis. Graphs and statistical analyses were executed in Prism 5 (GraphPad). 
Statistical significance was determined by one-way ANOVA with Bonferroni post-test. 
 
5.4. Results and Discussion 
?
5.4.1. Preparation and characterization of cationic micelles and micellar 
aggregates.  
As shown in Figure 1A, PEG-PPS diblock copolymer (1) was obtained by ring opening 
polymerization of propylene sulfide from a thioacetate-terminated poly(ethylene 
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glycol) macroinitiator, followed by PPS end-capping with pyridyl disulfide. Purity of 
the PEG-PPS diblock copolymer was verified by gel permeation chromatography 
(Supporting Information Figure S1). A simple disulfide exchange reaction with 
cysteine-containing polyarginine  (degree of polymerization = 13) yielded the cationic 
peptide-conjugated copolymer PEG-PPS-R13 (2) utilized in these studies. The 
conjugate was insoluble in tetrahydrofuran, rendering impossible analysis by gel 
permeation chromatography. PEG-PPS-R13 molecular weight was assessed by 
MALDI mass spectrometry (Supporting Information Figure S2) and peptide 
conjugation to the copolymer was confirmed by FTIR spectroscopy (Supporting Figure 
S3). PEG-PPS-R13 self-assembly into stable micelles was mediated by water-
excluding hydrophobic interactions of the PPS domain; the charged R13 peptide 
domain partitions into the hydrophilic PEG corona upon micelle formation (Figure 
1B). Naked micelles displayed the anticipated size, charge, and topological 
characteristics; they are nanoscale spherical particles of significant positive charge 
(Figure 1B,C). Addition of MPLA to PEG-PPS-R13 during micelle formation yielded 
adjuvant-loaded constructs in which amphiphilic MPLA partitions between the 
hydrophilic corona and the hydrophobic core. Electrostatic interactions between 
cationic PEG-PPS-R13 and anionic MPLA promoted tighter molecular packing within 
the formed micelle, as confirmed by slightly decreased particle diameter (Figure 1D). 
As anticipated, MPLA incorporation did not interfere with self-assembly of spherical 
micelles (Figure 1E). 
 
Following physical characterization of PEG-PPS-R13 micelle and MPLA-loaded 
PEG-PPS-R13 micelle populations, we prepared the ensemble of aggregate species 
designed for vaccination studies. In addition to acting as an encapsulation platform for 
MPLA, the cationic micelle drove electrostatic association of anionic whole protein 
antigen OVA and anionic CpG-B adjuvant. The assemblies were generated by simple 
mixing of previously prepared micelle or MPLA-loaded micelle dispersions with 
aqueous solutions of OVA and/or CpG-B. This highlights one of the benefits of our 
assembly-driven approach; once formed, the unmodified or MPLA-loaded cationic 
micelles represent a modular platform to which multiple vaccine components may be 
added, for easy, rapid, and sterile preparation of treatment samples and control groups. 
The basic structure, particle size, and zeta potential of the formed aggregates are 
presented in Table 1. Notably, the diameters of the micelle aggregates are 
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approximately one order of magnitude smaller than cationic PEG-polypeptide micelles 
examined elsewhere for OVA vaccination,24 and we anticipated that this decreased size 
would facilitate particle trafficking. Upon association of OVA and/or CpG-B, the 
spherical particle increased only slightly in diameter; similarly, association of these 
negatively charged molecules decreased particle zeta potential. Nevertheless, charge 
behavior in these assemblies remained distinctly cationic. By promoting interaction 
with negatively charged cell surfaces, this biophysical characteristic may benefit 
particle uptake by APCs following administration. The ensemble of assembly species 
was divided for use in two in vivo vaccination studies, to characterize micelle 
performance in the context of vaccination with a single adjuvant (either MPLA or 
CpG-B) and vaccination with two adjuvants (both MPLA and CpG-B). 
 
 
Figure 1. A polyarginine peptide-conjugated poly(ethylene glycol)-b-poly(propylene sulfide) 
(PEG-PPS) block copolymer forms cationic micelles following self-assembly. (A) Synthetic 
methodology for preparation of the peptide-conjugated copolymer PEG-PPS-R13. (B) 
Emulsion solvent evaporation promotes self-assembly of cationic PEG-PPS-R13 micelles. (C) 
Cryo transmission electron microscopy (cryoTEM) of PEG-PPS-R13 micelles. (D) Emulsion 
solvent evaporation of PEG-PPS-R13 in the presence of amphiphilic monophosphoryl lipid A 
(MPLA) yields MPLA-loaded micelles. (E) CryoTEM confirmed that MPLA incorporation 
does not interfere with formation of micelle populations. Scale bars, 200 nm. 
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Table 1. Physical characteristics of cationic micelle complexes used in vaccination  
 
5.4.2. Singly-adjuvanted vaccination utilizing cationic micelles enhances cytotoxic 
responses in spleen- and lymph node-resident CD8+ T cells.  
The design of effective vaccine platforms requires that antigen reaches the secondary 
lymphoid organs for local presentation to lymphocytes by APCs. Induction of immune 
responses was evaluated in the spleen and LNs of mice vaccinated with a 
prime/boost/boost immunization scheme (Fig. 2A). Mice were vaccinated with cationic 
micelle assemblies presenting whole OVA antigen and CpG-B or MPLA (Table 1). 
The following groups were utilized as controls: micelle assemblies with OVA and 
without CpG-B, and free OVA antigen mixed with either CpG-B or MPLA. The 
negative (injection) control group received saline. Spleen and LNs were harvested one 
week after second boost and evaluated for activation within the CD8+ and CD4+ T cell 
compartments.   
The cytotoxic activity of spleen- and LN-resident CD8+ T cells (i.e., CTLs) was 
evaluated after 6 hr ex vivo SIINFEKL restimulation, as defined by intracellular 
staining of IFNγ- and TNFα-secreting CD8+ T cells. As seen in representative 
splenocyte flow cytometry analysis, immunization with micelle + OVA + CpG-B 
raised the largest population of IFNγ+ (Figure 2B, top row) and TNFα+ (Figure 2B, 
bottom row) CD8+ T cells. Notably, vaccination with micelle + OVA + CpG-B 
resulted in a population of splenic IFNγ+ CD8+ T cells 3-fold larger than that derived 
from mice vaccinated with micelle / MPLA + OVA. This demonstrates a clear 
advantage of the CpG-B adjuvant compared to MPLA in the single-adjuvant study. 
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Furthermore, the use of micelles is necessary for enhanced induction of cytotoxic 
responses, as observed by minimal cytokine expression in the OVA + CpG-B and 
OVA + MPLA groups lacking micelle carriers. Our findings indicate that maximum 
stimulation of CD8+ T cell cytotoxicity is achieved by micelles bearing the adsorbed 
OVA antigen and CpG-B. These conclusions are supported by recent vaccination 
studies that characterized improved CD8+ T cell responses following dual delivery of 
polymer micelle-conjugated OVA with electrostatically complexed CpG-B.25 We 
achieve similar results without the need for covalent conjugation of the OVA antigen. 
 
Expanding from this representative data, IFNg and TNFa secretion from spleen-
resident CD8+ T cells in all groups are presented in Figure 2C and 2D, respectively. 
Vaccination with micelle + OVA + CpG-B generated an 8-fold increase in CD8+ T cell 
IFNγ secretion and a 6-fold increase in CD8+ T cell TNFα secretion, compared to the 
micelle-free OVA + CpG group. The remaining groups yielded negligible cytokine 
secretion in splenic CD8+ T cells. Of particular interest in vaccine design are 
polyfunctional T cells, those positive for simultaneous secretion of multiple cytokines. 
The population of polyfunctional splenic CD8+ T cells secreting both IFNγ and TNFα 
was 6-fold greater in mice immunized with micelle + OVA + CpG-B compared with 
OVA + CpG-B (Figure 2E). 
 
We similarly analyzed the profile of activated LN-resident CD8+ T cells from all 
vaccinated mice; these data were consistent with observations from splenic 
populations. Compared with the micelle-free OVA + CpG-B group, vaccination with 
micelle + OVA + CpG-B promoted a 3-fold increase in the percentage of IFNγ+ 
(Figure 2F) and TNFα+ (Figure 2G) CD8+ T cells. Following trends observed in 
splenocyte populations, the remaining groups displayed minimal CD8+ T cell 
cytotoxicity. Furthermore, in mice vaccinated with micelles + OVA + CpG-B, 
polyfunctional CD8+ T cells were increased 3-fold compared to OVA + CpG-B-
vaccinated mice and 5-fold compared with mice vaccinated with either micelle / 
MPLA + OVA or OVA + MPLA (Figure 2H).  
 
Induction of cytotoxic CD8+ T cells is particularly desirable in the context of protein-
based subunit vaccination. Furthermore, CTLs play a major role in tumor eradication 
and clearance of pathogen-infected cells.2 As a result, current vaccine design seeks to 
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elicit strong CD8+ T cell responses for the prevention or treatment of tumor 
malignancies, and for elimination of cellular infection characterized by solely 
intracellular presentation of pathogen-derived antigen, which cannot be influenced by 
circulating antibodies. To be effective, these vaccines must induce activation and 
expansion of antigen-specific CD8+ T cells, by promoting antigen loading onto MHC 
class I molecules and antigen cross-presentation to CD8+ T cells by APCs.26 In support 
of such desirable outcomes, our results show that the cationic micelle-based vaccine 
platform promotes efficient CD8+ T cell cross-priming and activity. These findings 
underline the significant advantage of the nanoscale micelle carrier over micelle-free 
subunit vaccination. Indeed, in the context of cancer vaccine technologies27 and 
vaccination against clinically challenging viral infections,28 the benefits of nanoparticle 
carriers are already recognized. 
 
Based on the requirement of CD4+ T cell help in CD8+ T cell activation and 
promotion of humoral responses, we evaluated the capacity of our micelle platform to 
activate CD4+ T cells obtained from the spleen and LNs of vaccinated mice. 
Lymphocytes from both organs underwent overnight ex vivo restimulation with OVA 
antigen, and IFNγ and TNFα cytokine secretion was determined by flow cytometry. As 
in CD8+ T cell responses, combined IFNγ and TNFα secretion in the micelles + OVA 
+ CpG-B group was significantly higher than any other group (Figure 2I). However, 
the overall percentage of these double-positive cells was lower in the CD4+ population 
(Figure 2I) versus the CD8+ population (Figure 2E). In further analysis, harvested 
splenocytes were restimulated for 4 days with OVA, for ELISA measurement of 
cytokine secretion in the supernatant. Only the groups vaccinated with micelle + OVA 
+ CpG-B and OVA + CpG-B secreted IFNγ after restimulation, but no significant 
differences were measured between the two groups (Figure 2J). Similar results were 
observed in TNFα secretion (Figure 2K) and in LN restimulation (data not shown). 
Although present, the activation of CD4+ T cells by the micelle platform is less 
efficient when compared to strong activation of CD8+ T cells, suggesting significant 
cross-presentation of processed OVA antigen to CD8+ T cells. 
 
?
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Figure 2. Cationic micelles electrostatically complex whole protein antigen ovalbumin (OVA) 
and CpG-B adjuvant to enhance cytotoxic T lymphocyte (CTL) responses in mouse spleen and 
lymph nodes (LNs) following singly-adjuvanted vaccination. (A) Immunization schedule; 
female C57BL/6 mice were immunized on day 0, 14, and 28 by intradermal injection. Spleen 
and LNs were harvested for processing one week after second boost. (B) The cellular 
cytotoxicity in all groups restimulated for 6 hrs with SIINFEKL peptide was determined by 
intracellular staining of IFNγ and TNFα and measured by flow cytometry. Representative plots 
with positive gating on IFNγ (top) or TNFα (bottom) populations of splenic CD8+ cells. (C, D, 
and E) Average cytokine secretion of splenocytes following 6 hr SIINFEKL restimulation and 
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intracellular staining for (C) IFNγ+ (D) TNFα+ and (E) polyfunctional IFNγ+ TNFα+ cells, as 
determined by flow cytometry. This analysis was performed on live populations gated on CD3+ 
CD8+ cells. (F, G, and H) Average cytokine secretion in LN lymphocytes following 6 hr 
SIINFEKL restimulation. This analysis was performed on live populations gated on CD3+ 
CD8+ cells, with staining for (F) IFNγ+, (G) TNFα+ and (H) polyfunctional IFNγ+ TNFα+ cells. 
(I) Splenocytes were restimulated with OVA antigen overnight and cytokine secretion was 
measured by flow cytometry. Polyfunctional IFNγ+ TNFα+ cells were gated on live CD3+ 
CD4+ populations. (J and K) Splenocytes were cultured ex vivo with OVA antigen for 4 days 
and (J) IFNγ and (K) TNFα secretion in supernatant was determined by ELISA. *p < 0.05, 
***p < 0.0001. Additional statistical relationships removed for clarity. 
?
5.4.3. Singly-adjuvanted vaccination with cationic micelles induces humoral 
responses.  
The protective efficacy of a vaccine for infectious disease is substantially conferred by 
antigen-specific antibody production. By examining IgG subclasses, we evaluated the 
character of OVA-specific antibody production mediated by use of micelle assemblies. 
At the conclusion of the experiment, analysis of antibody titers identified equivalent 
levels of OVA-specific total IgG in the sera of mice vaccinated with either CpG-B or 
MPLA adjuvant (Fig. 3A). In contrast, analysis of IgG subtype distribution revealed 
significantly increased IgG1 (Fig. 3B) and IgG3 (Fig. 3C) secretion in the micelle + 
OVA + CpG-B group, compared to free OVA + CpG-B. When comparing groups 
vaccinated with micelle / MPLA + OVA versus free OVA + MPLA, we observed 
similarly elevated IgG1 titers (Fig. 3B), while IgG3 responses were similarly limited 
(Fig. 3C). These findings are in agreement with proposed temporal models of antibody 
class switching in response to protein antigen, in which early IgG3 production is 
subsequently replaced by higher affinity IgG1.29, 30 Both IgG3 and IgG1 are implicated 
in immune response to viral infection,31 and together our results suggest a beneficial 
role of the cationic micelle platform in future viral vaccination applications.  
 
Subtype analysis revealed robust antibody secretion in the micelle + OVA + CpG-B 
group in IgG2a (Fig. 3D), IgG2b (Fig. 3E) and IgG2c (Fig. 3F) subtypes. In IgG2a and 
IgG2b, no significant differences were observed upon comparison to titers in the 
micelle-free OVA + CpG-B group; however, these differences were significant in the 
IgG2c subtype. Vaccination with micelle / MPLA + OVA produced limited IgG2 class 
antibody secretion, with titers lower than the micelle-free MPLA + OVA group for all 
subtypes. These results indicate an advantage of the micelle + OVA + CpG-B platform 
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in antigen-specific antibody production, when compared to both the MPLA-presenting 
micelle platform and the free antigen mixed with either adjuvant. In a previous study, 
CpG-B incorporated into PLGA nanospheres was found to stimulate IgG1, IgG2b, and 
IgG3 production following vaccination against tetanus toxoid.32 In the context of 
micelle-mediated OVA vaccination using CpG-B adjuvant, we achieved similar IgG1, 
IgG2b, and IgG3 expression profiles, along with enhanced IgG2c. 
 
Figure 3. Post-vaccination IgG titers highlight strong humoral responses in mice injected with 
CpG-B. Total IgG and subtype titers in the serum of all vaccinated mice as measured by 
ELISA on day 35 of the experiment. (A) Total IgG titers of all mice in all groups. (B) IgG1, 
(C) IgG3, (D) IgG2a, (E) IgG2b, and (F) IgG2c subtypes in all groups. **p < 0.001, ***p < 
0.0001. Additional statistical relationships removed for clarity. 
 
5.4.4. Doubly-adjuvanted vaccination does not provide additive effect of the two 
adjuvants.  
We hypothesized that vaccination with two adjuvants in combination would provide an 
additive effect, resulting in improved humoral and cellular responses compared to 
vaccination with a single adjuvant. Following the same immunization schedule, mice 
were vaccinated with micelle / MPLA + OVA + CpG-B or the corresponding micelle-
free group, OVA + MPLA + CpG-B. Cytokine secretion from lymphocytes was 
?
?
?
?
? ????????????
??????? ?????
????
???
???
??
?? ?? ??
???? ????
?
?
?
?
?
??
?????
????
???
???
??
??
?. ?. ?.
?. ?. ?.
? ?
????
???
???
???
???
???
???
????
???
???
????
??
??
???
???
???
??
???
? ?
?? ???
??
???
????
???
???
?
? ?
????
???
???
???
???
???
???
????
???
???
????
??
??
???
???
???
??
???
? ?
?? ???
??
???
????
???
???
?
? ?
????
???
???
???
???
???
???
????
???
???
????
??
??
???
???
???
??
???
? ?
?? ???
??
???
????
???
???
?
???
 108 
assessed following ex vivo restimulation with SIINFEKL or OVA. This assessment 
showed that use of the CpG-B- and MPLA-presenting micelle platform retains the 
advantage of enhanced cytotoxicity when compared to a micelle-free treatment. 
However, an additive effect was only observed in the micelle-free OVA + MLPA + 
CpG-B group, and not in the doubly-adjuvanted, OVA-presenting group utilizing the 
micelle carrier (Figure 4). The strong response provided by micelle-associated CpG 
seems to render any additional benefit due to incorporated MPLA comparatively small.  
 
As a main readout for cytotoxic activity, we measured IFNγ and TNFα cytokine 
secretion of CD8+ T cells obtained from the spleen and LNs of vaccinated mice, 
following 6 hr restimulation with SIINFEKL peptide. Enhanced populations of IFNγ+ 
(Figure 4A) and TNFα+ (Figure 4B) CD8+ T cells were observed in the micelle / 
MPLA + OVA + CpG-B group, however these lacked significant improvement over 
the micelle-free OVA + MPLA + CpG-B group. Interestingly, cytotoxicity of the 
micelle-free group is improved compared with the singly-adjuvanted groups of OVA + 
CpG-B and OVA + MPLA described in Figure 3. This indicates additive benefit of 
double adjuvants only in micelle-free vaccination, and not in micelle-antigen-adjuvant 
aggregates. Moreover, polyfunctional IFNγ+ TNFα+ splenic CD8+ T cell populations 
remained higher but without significant differences compared to the OVA + MPLA + 
CpG-B group  (Figure 4C).  However, significantly enhanced cytokine production in 
micelle versus micelle-free doubly-adjuvanted groups was observed in lymph node-
derived CD8+ T cells of vaccinated mice, in which a 2-fold increase of IFNγ+ (Fig. 
4D), TNFα+ (Fig. 4E) and IFNγ+ TNFα+ (Fig. 4F) CD8+ T cells was measured between 
the two groups. The additive effect of two adjuvants remained absent in LNs following 
micelle-mediated vaccination. 
 
Following overnight restimulation with OVA, minimal cytokine production was 
observed in CD4+ T cells derived from spleen and LNs of vaccinated mice. The 
percentage of IFNγ+ TNFα+ spleen CD4+ T cells was identical between the micelle, the 
micelle-free and OVA-only groups, indicating inefficient activation of this cell type 
(Figure 4G). Higher percentages of activated CD4+ T cells were measured in the LNs 
of mice vaccinated with micelle / MPLA + OVA + CpG-B, but the comparison with 
the OVA + MPLA + CpG-B group was not significant (Figure 4H). To further evaluate 
the systemic responses raised by micelle-mediated vaccination, we measured serum 
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antibody titers: equally high total IgG titers were measured in both micelle and 
micelle-free groups (Figure 4I), consistent with results obtained from cytokine analysis 
within CD4+ T cell populations. The same IgG subtypes analyzed in the singly 
adjuvanted study were examined here; although antibody levels were high in groups 
immunized with CpG-B- and MPLA- adjuvanted OVA antigen, no significant 
differences were observed between groups immunized in the presence or absence of 
the micelle carrier (Supporting Information Figure S4). We conclude that adjuvant co-
administration does not have an additive effect in the context of the micelle platform; 
as such, singly-adjuvanted micelle-antigen aggregates are sufficient to raise potent 
cytotoxic CD8+ T cells and support induction of humoral responses. Previously, in a 
non-vaccination model, collaborative efforts by our group have shown that co-
administration of MPLA and CpG-B in mouse increases inflammatory cytokine 
concentrations in bronchoalveolar lavage and blood serum.33 Yet in vaccination studies 
elsewhere, MPLA was determined to have no additive effect when used in conjunction 
with alum.34 Thus the role of adjuvant synergistic effect in vaccination remains poorly 
defined, and may depend on unaccounted factors such as variable immunization 
timelines or route of administration.  
 
 
 
?
?
?
?
?
?
?
?
?
?
?
?
 110 
 
Figure 4. Cationic micelle-mediated co-administration of ovalbumin, CpG-B, and MPLA 
promotes cellular responses to doubly-adjuvanted vaccination against the whole protein 
antigen. Mice were vaccinated according to the same immunization schedule, with spleen and 
LNs harvested on day 35. Cells were restimulated with SIINFEKL peptide or OVA antigen. 
Cytokine secretion was measured by flow cytometry. (A) IFNγ+, (B) TNFα+ and (C) 
polyfunctional IFNγ+ TNFα+ splenocytes gated on live CD3+ CD8+ cells after 6 hr SIINFEKL 
restimulation. (D) IFNγ+, (E) TNFα+ and (F) polyfunctional IFNγ+ TNFα+ lymph node isolates, 
gated on live CD3+ CD8+ populations after 6 hr SIINFEKL restimulation. (G) Spleen and (H) 
LNs were restimulated overnight with OVA antigen and polyfunctional IFNγ+ TNFα+ cells 
were gated on live CD3+ CD4+ populations. (I) Total IgG serum titers of all vaccinated mice on 
day 35 of the experiment measured by ELISA. **p < 0.001, ***p < 0.0001. Additional 
statistical relationships were removed for clarity. 
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5.6. Conclusions 
?
Here we have undertaken a simplified approach to nanoparticle vaccine formulation, 
utilizing molecular encapsulation and complexation to eliminate the need for covalent 
modification of vaccine components. Once assembled, unloaded and MPLA-loaded 
PEG-PPS-R13 micelles provide a modular platform for streamlined vaccine 
preparation. The application of PEG-PPS-R13 micelles for co-administration of OVA 
and CpG-B achieves meaningful vaccination outcomes through both humoral 
responses (enhanced production of multiple, OVA-specific IgG subtypes) and cellular 
responses (increased populations of cytokine-producing CTLs). Micelle-mediated 
delivery also eliminates the need for double adjuvants, simplifying platform 
preparation and reducing cost. The cationic micelle complex joins a family of 
nanoparticle vaccine platforms including virus-like particles,35 polymer-based 
nanoparticles,36, 37 and liposomal vesicles38 characterized by notable enhancement of 
CD8+ T cell responses. Along with the quality of humoral responses desired of a 
subunit vaccine, this characteristic promotes future examination of the PEG-PPS-R13 
micelle carrier in cancer vaccine development and in prophylactic vaccination against 
viral infection. 
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Supporting Information 
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Figure S1. Gel permeation chromatography of 
PEG-PPS diblock copolymer, performed in 
tetrahydrofuran at 40°C with 1 mL/min flow rate. 
Figure S2. MALDI mass spectrometry of PEG-PPS-R13 polymer-peptide 
conjugate, performed in positive linear mode with CHCA matrix. Elevated laser 
power was necessary to induce molecular flight, resulting in fragmentation. 
Molecular weight of the resulting PEG-PPS-R13 fragments are indicated above. 
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Figure S3. FTIR spectra of methoxyPEG-OH starting material (narrow black line), PEG-PPS 
(narrow red line), and PEG-PPS-R13 (bold blue line). The PEG-PPS-R13 spectrum shows the two 
characteristic amide I (1654 cm-1) and amide II (1544 cm-1) bands contributed by the R13 domain. 
N-H stretching vibrations in this domain also generate a broad band centered at 3300 cm-1. 
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Figure S4. Post-vaccination IgG titers show no differences in subtype expression levels 
following micelle-mediated and micelle-free immunization in doubly-adjuvanted vaccination. 
Total IgG and subtype titers in serum of all vaccinated mice was measured by ELISA on day 
35 of the doubly-adjuvanted experiment. (A) Total IgG titers, and titers of the (B) IgG1, (C) 
IgG3, (D) IgG2a, (E) IgG2b, and (F) IgG2c subtypes. 
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Chapter 6: 
 
Conclusions and Future Directions  
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6.1 Conclusions 
?
CD8+ T cells are capable of recognizing and eliminating infected or 
transformed cells. Consequently, their activation is a primary goal of vaccine 
development for both infectious disease and cancer. Advances in our understanding of 
CD8+ T cells, and in particular the cues that promote their activity, are revealing new 
pathways toward improved vaccine outcomes. Several studies in the past have resulted 
in important vaccine improvement technologies with promising results for CD8+ T cell 
stimulation in vaccination [1-3]. However, despite these advances, effective vaccines 
against many pathogens, such as HIV and hepatitis C, and cancers, such as melanoma, 
remain significant unmet global health needs. 
 
The generation of a robust CD8+ T cell response requires the cross-priming of 
these cells by specialized cell types, to which the vaccine platform must efficiently 
deliver the antigen(s) of interest for processing and cross-presentation. Moreover, 
antigen delivery must occur under immunostimulatory conditions, in order to result in 
the activation, as opposed to tolerization, of relevant CD8+ T cells [4]. The use of 
protein antigens in subunit vaccination poses fewer health risks than the use of live 
attenuated microbes. However, these antigens generally lack inherent immunogenicity 
and cell targeting properties. As such, effective design of subunit vaccines must 
incorporate additional means for efficient antigen delivery and immunostimulation. In 
this thesis, we have explored four different vaccine platforms for the activation of 
CD8+ T cells and evaluated their efficacy in mouse models of liver infection and 
melanoma.  
 
The first challenge was to develop a novel vaccine platform that can efficiently 
target the liver, cross-present the antigen to CD8+ T cells and raise local antigen-
specific immune responses with long-lasting memory. A tri-domain fusion protein was 
produced consisting of the erythrocyte-binding antibody TER119, OVA as a model 
antigen, and the BBOX domain of HMGB1 as an adjuvant (TER119-BBOX-OVA). 
TER119-BBOX-OVA co-administered with CpG-B elicited strong CTL responses 
intrahepatically. In particular, following a prime-boost vaccine schedule, TER119-
BBOX-OVA + CpG-B resulted in a 6-fold higher level of IFN-γ secretion in the liver 
of vaccinated mice compared with OVA + CpG vaccinations and in the clearance of 
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Listeria infected cells within 72 hr. More importantly, the activated CD8+ T cells in the 
liver acquired a memory phenotype that lasted for at least 5 weeks. We hypothesized 
that the modular construction of this vaccine design, consisting of an erythrocyte-
binding domain, an antigen of interest, and a BBOX adjuvant domain, will enable 
generation of recombinant vaccines for a variety of diseases of clinical relevance. For 
example, this vaccine may find application in malaria, where the mosquito bite 
infection resembles that of Listeria [5, 6]. Also, the direct activation of local hepatic 
responses against the antigen suggests that a TER119-BBOX-Ag immunization may be 
sufficient to deal with established liver infections, such as chronic hepatitis B, or liver 
carcinomas in therapeutic cancer vaccination.  
 
A second approach for direct antigen targeting to cross-prime CD8+ T cells is 
via delivery to a specific DC subset know to excel in cross-presentation, called CD8+ 
DC. Cross-presenting DCs have been targeted by other groups via the XCL1 
chemokine ligand that uniquely binds on their surface, as discussed earlier in Chapter 
3. We improved the efficacy of the existing XCL1-targeting vaccine by introducing a 
novel molecule that attracted CD8+ DCs at the injection site and promoted the uptake 
of the antigen. In particular, XCL1 was fused to a domain of PlGF-2 growth factor that 
binds the ECM with high affinity and was co-delivered with the XCL1-OVA fusion 
protein, used to activate CTLs in previous studies. The XCL1-OVA mixed with XCL1-
PlGF vaccination improved by 1.5-fold the cytokine release compared to XCL1-OVA 
alone following a prime-boost immunization study and more importantly, significantly 
prolonged the survival of tumor bearing mice both in a prophylactic and a therapeutic 
approach. This last result is of particular interest since the main challenge with tumor 
vaccines is to find novel ways to vaccinate therapeutically and deal with established 
tumors [7]; without though underestimating the importance of prophylactic 
vaccination. Moreover, the results we observed in the aggressive and poorly 
immunogenic B16-F10 mouse tumor model further emphasize the effectiveness of this 
vaccine design [8]. 
 
We also examined the effect of forming a depot for antigen release as a 
possible inducer of T cell responses in vaccination. Slow release of an antigen has been 
a common approach mostly with biodegradable materials. In this thesis we attempted 
to create a depot effect by fusing the antigen to the PlGF-2 domain following the 
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hypothesis that retaining the antigen at the injection site would allow enhanced uptake 
by local DCs and would result in improved immunogenicity in the draining LNs. We 
evaluated our hypothesis by fusing OVA to PlGF-2 (OVA-PlGF) and measured the 
humoral and cellular responses following a regular vaccination protocol. Contrary to 
the hypothesis of our design, no significant benefit from binding to the ECM could be 
observed with OVA-PlGF vaccinations when compared to vaccinations with free OVA 
antigen. Possible improvement of this vaccine platform would require better 
understanding of the depot creation and the release kinetics of OVA-PlGF that possibly 
affect the peak timing of immune responses compared to free OVA. 
 
Delivery vehicles are very commonly used for transportation of antigen to 
relevant immune organs. Of particular interest are nanocarriers that facilitate cross-
priming and activation of CD8+ T cells such as virus-like particles, polymer-based 
nanoparticles, and liposomes reviewed in the introduction and chapter 5. Here we 
explored a simplified approach to co-deliver unmodified antigen with adjuvants in a 
micelle-based vaccine platform. The micelle complexes were either loaded or not with 
encapsulated MPLA and co-administered with CpG-B and OVA in a single or double 
adjuvant vaccine platform. Following three consecutive intradermal injections, both 
humoral (enhanced production of multiple OVA-specific IgG subtypes) and cellular 
(increased populations of cytokine-producing CTLs) responses were observed in the 
group treated with micelles containing OVA and co-administered with a single CpG-B 
adjuvant, abolishing the need for double adjuvant administration for improved 
vaccination. This design achieves the highly desirable vaccination outcome of eliciting 
both CTL responses and neutralizing antibodies, which has been especially challenging 
for subunit vaccines. Furthermore, the use of unmodified antigens in this design will 
enable facile extension to other diseases. These characteristics promote future 
examination of the micelle carrier in cancer vaccine development and in prophylactic 
vaccination against viral infections.  
 
Designing effective vaccine platforms is challenging and requires the collective 
effort of different fields in immunology and bioengineering. Improving the 
immunogenicity of a subunit vaccine by co-administering adjuvants and targeting the 
antigen to the appropriate cell type does not guarantee effective CTL responses or 
antibody production. One example of a commonly faced challenge in modern vaccine 
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design technology is related to lack of knowledge regarding the type of immune 
response that would result in the best long-term protection in several diseases. 
Moreover, searching the appropriate cell receptor for direct targeting of antigens to 
relevant immune cells is not always a straightforward approach. Finally, appropriate 
animal models that would accelerate the translation from the laboratory to the clinic are 
not widely available and more research needs to be focused towards this direction. We 
believe that the improvement of subunit vaccines will be a result of collective effort 
among different fields involved in vaccine design including optimal epitope and cell 
receptor selection [9, 10], characterization of the immunological pathways that follow 
a viral infection or tumor progress [11-13] and engineering of appropriate materials 
and molecules that will facilitate the initiation of an immune response [14-16]. 
References 
1.  Speiser DE, Lienard D, Pittet MJ, et al. In vivo activation of melanoma-specific 
cd8(+) t cells by endogenous tumor antigen and peptide vaccines. A comparison to 
virus-specific t cells. European Journal of Immunology 2002;32(3): 731-41. 
2.  Mudd PA, Martins MA, Ericsen AJ, et al. Vaccine-induced cd8(+) t cells control 
aids virus replication. Nature 2012;491(7422): 129-U52. 
3. Koup RA, Douek DC. Vaccine design for cd8 t lymphocyte responses. Cold Spring 
Harbor Perspectives in Medicine 2011;1(1). 
4. Chen LP, Flies DB. Molecular mechanisms of t cell co-stimulation and co-inhibition 
(vol 13, pg 27, 2013). Nature Reviews Immunology 2013;13(7). 
5. Pope C, Kim SK, Marzo A, et al. Organ-specific regulation of the cd8 t cell response 
to listeria monocytogenes infection. (vol 166, pg 3402, 2001). Journal of Immunology 
2001;166(9): 5840-. 
6. Schmidt NW, Butler NS, Badovinac VP, et al. Extreme cd8 t cell requirements for 
anti-malarial liver-stage immunity following immunization with radiation attenuated 
sporozoites. Plos Pathogens 2010;6(7). 
7. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, 
and protective t cell immunity. Seminars in Immunology 2010;22(3): 144-54. 
8. Wang JL, Saffold S, Cao XT, et al. Eliciting t cell immunity against poorly 
immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. 
Journal of Immunology 1998;161(10): 5516-24. 
9. Correia BE, Bates JT, Loomis RJ, et al. Proof of principle for epitope-focused 
vaccine design. Nature 2014;507(7491): 201-6. 
10. Reddy ST, Georgiou G. Systems analysis of adaptive immunity by utilization of 
high-throughput technologies. Current Opinion in Biotechnology 2011;22(4): 584-9. 
11. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of 
human dendritic cell subsets. Immunity 2010;33(4): 464-78. 
12. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 
2011;480(7378): 480-9. 
13. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 
2011;144(5): 646-74. 
 122 
14. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for 
immunomodulation. Nature 2009;462(7272): 449-60. 
15. Irvine DJ, Hanson MC, Rakhra K, et al. Synthetic nanoparticles for vaccines and 
immunotherapy. Chemical reviews. 
16. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from 
natural immunity. Nature Materials 2013;12(11): 978-90. 
 
  
123 
Curriculum Vitae 
VASILIKI PANAGIOTOU  
vasilikipana@gmail.com  (+41) 0788408942               Pre du Marche 38, 1004 Lausanne  
 
Ecole Polythechnic Federal Lausanne (EPFL), January 2011-November 2015                   Lausanne, Switzerland 
Doctor of Philosophy in Biotechnology and Bioengineering. 
Laboratory of Prof. Jeffrey Hubbell. Thesis title: Protein Engineering approaches for direct antigen targeting in 
CD8+ T cell inducing vaccines 
 
Massachusetts Institute of Technology (MIT), September 2008 - June 2010                        Cambridge, MA, USA 
Master of Science in Chemical Engineering 
Laboratory of Prof.Chistopher Love. Thesis title: Clonal Selection and Characterization of Epigenetic Variation in 
Pichia Pastoris 
 
Aristotle University of Thessaloniki, September 2006 - June 2008                                         Thessaloniki, Greece 
Master of Science in Applied Genetics and Biotechnology 
Laboratory of Prof. George Georgiou Thesis title: Engineering a Humanized Catalytic Drug as  
a Cancer Therapeutic Agent                                                                                                          Austin, TX, USA 
 
Aristotle University of Thessaloniki (AUTH), September 2001 - June 2006                          Thessaloniki, Greece 
D.Eng., Department of Chemical Engineering. 
Laboratory of Prof. Prodromos Daoutidis. Thesis title:Oscillation Behaviour of Dictyostelium Cells:Modelling & 
Robustness Analysis 
 
 
 
• EPFL, Switzerland:
1. Independently designed 2 different vaccine platforms for effective tumor and virus killing in mice models 
2. Collaborated in the immunological characterization of a micelle based vaccine platform 
3. Search of posttranslational modifications of insulin in the islets of diabetic mice as a potential initiator 
mechanism in type 1 diabetes 
• MIT, USA:  
Chemical mutagenesis of Pichia pastoris yeast and advanced single-cell screening looking for high 
secretion and top producing clones. Produced a 2.65-fold greater clone than those of the parental strain and 
the technology was patented by the MIT Technology Licensing Office (No14803). 
• University of Texas, Austin: 
Use of recombinant DNA techniques to mutagenize a humanized catalytic enzyme that hydrolyzes L-
Arginine in the blood and leads to death of hepatocellular carcinomas and melanomas.  
• AUTH, Greece: 
Use of Matlab tools to predict the robustness of a Dictyostelium cell model undergoing chemotaxis. The 
model consisted of 7 variables and 14 kinetic parameters and the analysis was based on the bifurcation 
theory.  
 
• ????? ????????????????????? ??????????????????????????????????????????? ??????? ??????
Drug discovery process and tools, Target selection, Regulatory responsibilities for drug discovery, Design 
of clinical protocols, Market access, IP files 
 
• Product and Process Quality in Manufacturing, November 2014                                EPFL, Switzerland 
Theory of quality, Market-informed quality, Quality and innovation in product and process design, Just-in-
time manufacturing, Methods of inspection and quality appraisal, Quality control circles, Quality control 
assessment tools 
 
      EDUCATION 
   RESEARCH EXPERIENCE 
    CONTINUING EDUCATION 
124 
 
• APIVITA Natural cosmetics, September 2010 - November 2010                              Athens, Greece 
1.Extraction and characterization of the physical properties of plants used in cosmetics. (R&D department) 
2. Production of cosmetics and stability tests of new products. (Chemical laboratory) 
 
• Technical University of Harburg-Hamburg,  July 2005 -August 2005)                    Hamburg, Germany                              
Supercritical fluid extraction of the plant Artemisia Annua for the production of Artemisin that is used as a 
drug in cancer.  
 
 
 
• Recombinant protein production: cloning, expression and purification with affinity chromatography 
• Laboratory techniques: Design of vaccine formulations, Pharmacodynamic/ pharmacokinetic measurements, 
flow cytometry, immunohistochemistry, microscopy imaging, protein labeling, ELISA, Western Blots, 
PCR, MALDI TOF 
• Animal handling: all types of injections, perfusion, skin surgery, in vivo imaging, organ harvesting, islets 
isolation 
• Cell biology: primary cells culture, different cell types isolation, MACS technology 
• IT: MATLAB, flowjo, Prism graphs and analysis, statistical analysis with SPSS, excellent use of MS office 
1. Love, K. R., Politano, T. J., Panagiotou, V., Jiang, B., Stadheim, T. A. & Love, J. C. Systematic single-cell 
analysis of Pichia pastoris reveals secretory capacity limits productivity. PLoS One 7, e37915, 
doi:10.1371/journal.pone.0037915 (2012). 
2. Jason R. Cantor, Vasiliki Panayiotou, Giulia Agnello, George Georgiou and Everett M. Stone. Engineering 
reduced-immunogenicity enzymes for amino acid depletion therapy in cancer. Methods Enzymol.;502:291-319 
(2012) 
3. Pazaitou-Panayiotou K1, Papapetrou PD, Chrisoulidou A, Konstantinidou S, Doumala E, Georgiou 
E, Panagiotou V, Sotiriadou E, Mavroudi E, Apostolaki-Christopoulou M. Height, whole Body Surface Area, 
gender, working outdoors, and sunbathing in previous summer are important determinants of serum 25-
hydroxyvitamin D levels. Exp Clin Endocrinol Diabetes. (2012)  
4. Vasiliki Panagiotiou, Kerry Routenberg Love, Bo Jiang, Terrance Stadheim,and J. Christopher Love,. 
Generation and Screening of Pichia pastoris Strains with Enhanced Protein Production by Use of 
Microengraving. Applied and Environmental Microbiology, ,p. 3154-3156, Vol. 77, No. 9 (2011) 
5. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, 
Kyttaris V, Panagiotou V, Mylvaganam G, Tseleni-Balafouta S, Mantzoros CS. Circulating adiponectin is 
inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol
Metab.96(12):E2023-8 (2011) 
6.Kerry Routenberg Love, Vasiliki Panagiotou, Bo Jiang, Terrance Stadheim, &J. Christopher Love. 
Identification and selection of supersecretors in Pichia pastoris populations by microengraving. 
Biotechnology&Bioengineering Vol.106, Issue 2, (319–325), (2010) 
 
2008: The Presidential Fellowship at MIT, USA 
2007: Honor award for excellence in studies, Technological Institution of Greece (TEE), Athens, Greece 
Greek: Mother language 
English: Excellent (Proficiency in English from University of Michigan)  
German: Good (Zertifikat Deutsch als Fremdsprache from Goethe Institut) 
French: Basic 
Traveling and getting to know people and cultures Sports: Sailing (skipper license), running (participated in half 
marathon races) and swimming (1st place in freestyle in many Greek tournaments)  
WORK EXPERIENCE
    TECHNICAL AND IT SKILLS 
??????LANGUAGES 
PUBLICATIONS
??????AWARDS / SCHOLARSHIPS 
     EXTRACURRICULAR INTERESTS 

 125 
 
 
